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Abstract 
There is an epidemic of Type 2 diabetes. It is predicted that by 2030 that the number of 
those with Type 2 diabetes will rise to over 350 million globally. There has been much 
debate regarding the cost effectiveness of early intervention in Type 2 diabetes. Studies 
have shown that despite ' intensively' treated patients serious complications still occur. 
Research indicates there is demonstrable and quantifiable insulin resistance and either 
impaired fasting glucose or impaired glucose tolerance for 5 to 10 years before the onset of 
Type 2 diabetes. It is in this state of a glucose metabolism disorder there is an opportunity 
to prevent or delay the onset of diabetes. 
This project provides a comprehensive review of the contemporary research literature to 
answer the question "What is the best test to screen adults for glucose metabolism 
disorders, for earliest possible detection in a primary care setting in Canada". A review of 
71 studies identified strengths and weaknesses of a variety of screening modalities. The 
key fmding was that the Oral Glucose Tolerance test (OGTT) is the most sensitive test in 
all populations for identification of glucose metabolism disorders. It is also clear that 
despite recommendations by contemporary clinical guidelines, the use ofHbA1c is ill 
suited to identification of glucose metabolism disorders. It is therefore recommended that 
the OGTT be used were feasible in testing for glucose metabolism disorders, preferably 
with plasma insulin levels being done at the same time to facilitate the use of an 
insulinogenic index. If this is not possible, consideration should be given for using glucose 
challenge testing or Hba1c and fasting plasma glucose in combination. 
The Nurse Practitioner, along with other primary health care practitioners, is in an ideal 
position to intervene in the disease trajectory through effective screening and patient 
education. Interventions have the promise of improving patient and health system 
outcomes and reducing the future personal and financial burden of Type 2 diabetes. 
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GLUCOSE METABOLISM DISORDERS 
Chapter 1 
Type 2 diabetes is a rapidly growing epidemic in Canada and the rest of the world 
(Public Health Agency of Canada, 2011 ). There were approximately 2.4 million people 
with Type 2 diabetes in Canada in 2008/2009 (Public Health Agency of Canada, 2011), and 
another 5 million Canadians over the age of 20 with prediabetes in 2004 (Public Health 
Agency of Canada, 2011 ). Diabetes plays a significant part in the deaths of 41 ,500 
Canadians per year (Public Health Agency of Canada, 2011). The lifespan of Canadians 
adults without diabetes is longer than that of those with diabetes by about 10 years 
(Canadian Diabetes Association, 2009). It is estimated that at the current rates, diabetes 
will cost the Canadian healthcare system $16.9 billion per year (Canadian Diabetes 
Association, 2009; Public Health Agency of Canada, 2011). Early diagnoses, aimed at both 
prevention of development to diabetes and control of hyperglycemia can reduce the 
morbidity and mortality frequently associated with glucose metabolism disorders (The 
United Kingdom Prospective Diabetes Study Group, 1998). Glucose metabolism disorders 
have also been known as prediabetes, impaired fasting glucose, and impaired glucose 
tolerance. For the purpose of this paper and ease of comprehension, the term glucose 
metabolism disorder will be used. 
Nurse practitioners (NPs) have a long history of forging therapeutic relationships 
with clients and involvement in partnerships working to manage chronic disease (Hayes, 
McCahon, Reeve Panahi, Hamre, & Pohlman, 2008; Ohman-Strickland et al. , 2008; Seale, 
Anderson, & Kinnersley, 2006; Watts et al. , 2009). Nurse practitioners are well suited to 
offer affected clients, a mix of lifestyle coaching and pharmaceutical interventions that have 
been shown to prevent or slow the progression of this disease (Lindstrom et al. , 2003; 
Ramachandan, Snehalatha, & Mary, 2006; The Diabetes Prevention Program Research 
Group, 2012). In the treatment of chronic diseases, NPs have been shown to provide 
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quality care, high rates of patient satisfaction, improved patients outcomes, and a slight 
reduction in costs to the health care system (Litaker et al., 2003). 
The present project offers a comprehensive review of literature reporting on the 
outpatient-setting screening tests that uncover glucose metabolism abnormalities. The 
question this project seeks to answer is: "What is the best test to screen adults for glucose 
metabolism disorders, for earliest possible detection in a primary care setting in Canada" . 
The following section will provide a background to glucose metabolism disorders and 
screening tests, and will include a brief discussion of the pathophysiology and identify 
patients at risk. This will be followed by an overview of the methods used, after which a 
critical appraisal of the literature will be presented. 
Understanding the need for and the mechanism to detect glucose metabolism 
abnormalities is crucial in stemming the tide of the sequelae of glucose metabolism 
disorders. Early detection provides time to conduct interventions aimed at prevention of 
progression to diabetes if possible, and or reducing the affects of the disease if prevention is 
not possible. The fmdings of this project will be presented and discussed in general and 
with specific reference to the role the Family Nurse Practitioners (FNPs) play in screening 
processes, as well as the choice of tests and intervention strategies. Thus, a comprehensive 
review of different testing methods in the context of the role of the FNP can offer a 
valuable insight into means by which patient outcomes can be improved. Early recognition 
and intervention is the mechanism by which much pain and suffering for both the affected 
patients and their family can be prevented. 
Background and Context 
There were approximately 2.4 million people with Type 2 diabetes in Canada in 
2008/2009 (Public Health Agency of Canada, 2011), and another 5 million Canadians over 
the age of 20 with prediabetes in 2004 (Public Health Agency of Canada, 2011 ). The 
population this paper focuses on are non-pregnant adults undiagnosed with a glucose 
2 
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metabolism disorder. For the purposes of this paper, adults are persons who are 18 years or 
older with no symptoms or evidence of possible glucose metabolism abnormality 
complications. Efforts at detection of diabetes can be justified if the disease represents an 
important health problem, is prevalent enough, has a reasonably long asymptomatic phase, 
and clinically meaningful interventions are available (American Diabetes Association, 
2003). This project offers a comprehensive review ofliterature reporting on the outpatient-
setting screening tests that uncover glucose metabolism disorders at their earliest 
presentation. The following sections will review glucose metabolism disorders, normal 
physiology and biochemistry, pathophysiology, population at risk, sequelae of the disorder, 
affect of interventions, screening tests, clinical practice guidelines and the role of the nurse 
practitioner. These sections will demonstrate the importance of this health problem, its 
prevalence, and the long asymptomatic phase as well as the effect of interventions. 
Glucose Metabolism Disorders 
Glucose metabolism disorders are also known as prediabetes, impaired fasting 
glucose, or impaired glucose tolerance. Therefore, a glucose metabolism abnormality is the 
state that lies between normal values and those that meet the criterion of a diagnosis of 
diabetes. This state of abnormal glucose metabolism can precede Type 2 diabetes itself by 
years. Research indicates there is demonstrable and quantifiable insulin resistance and 
either impaired fasting glucose or impaired glucose tolerance for 5 to 10 years before the 
onset of Type 2 diabetes (National Institute of Diabetes & Digestive & Kidney Diseases, 
2008). Newer research also indicates there is a loss of beta cell capacity to respond to 
glucose load in even the earliest stages of glucose metabolism dysfunction (Armato, 
Defronzo, Abdul-Ghani, & Ruby, 2012). This disordered metabolic state is not a benign 
one; it is one that confers a doubling of risk of cardiovascular disease and stroke (Ryden et 
a!., 2007). Studies have demonstrated that at least 21% of newly diagnosed Type 2 
diabetics have retinopathy (Fong eta!., 2003) and 17.34% nephropathy (Agarwal, Sengar, 
3 
GLU COSE METABOLISM DISORDERS 
Jain, & Khare, 2011). This indicates that damage occurs prior to the existence of diabetes. 
There is general agreement (Lindstrom et al., 2003; Norris et al. , 2005; Pan et al., 1997) 
that it is in this stage of the disease that Type 2 diabetes may be averted. Multiple studies 
have demonstrated the reversal of a disordered glucose metabolism to a normoglycemic 
state (Norris et al. , 2005). Therefore, there is both personal and societal value in diagnosing 
glucose metabolism abnormalities at their earliest appearance. This is especially important 
in raciaVethnic groups who bear an increased burden of type 2 diabetes due to a 
combination of genetic predisposition and poverty. It is in this role of early detection and 
intervention that primary health care providers such as nurse practitioners have a key role to 
play. 
Normal Physiology and Biochemistry in Glucose Metabolism 
In order to conduct an informed discussion of the mechanism of glucose 
metabolism disorders, it is necessary to understand the normal glucose metabolism process. 
The following review, while by no means exhaustive, aims to set the stage for a discussion 
of the pathophysiology of glucose abnormalities. 
Normal physiology for glucose involves a number of functions that include 
endocrine, exocrine, receptor, and cell function . Plasma glucose concentrations are a 
function of the rate of glucose entering the circulatory system balanced by the rate of 
glucose removal from circulation. Glucose in circulation is obtained from three sources: 
absorption through the small intestine after eating; glycogenolysis, which is the 
breakdown of glycogen that is the storage form of glucose, and gluconeogenesis, which is 
the formation of glucose mainly from lactate and amino acids (Guyton & Hall, 201 0). 
The primary supplier of circulating endogenous glucose is the liver, which provides 85%; 
the remaining 15% is produced by the kidneys (DeFronzo, 2004 ). The regulation of the 
level of glucose in the circulating blood, termed glucoregulation, is in large part achieved 
through the affects of insulin. 
4 
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Insulin is a hormone released by the pancreas. The pancreas has both endocrine 
and exocrine functions. Pancreatic innervation comes from the parasympathetic fibers of 
the vagus nerve. These activate postganglionic fibers that stimulate enzymatic and 
hormonal secretion (McCance, Huether, Brashers & Rote, 2010). 
The smell, sight, and first taste of food trigger a cephalic insulin reaction and is 
mediated by the vagus nerve through sensors in the hypothalamus. This cephalic phase 
of insulin release is in response to sensory stimuli; this produces a rapid but small 
increase in arterial plasma insulin (Cherrington, Sindelar, Edgerton, Steiner, & 
McGuinness, 2002). When the meal reaches the intestine, several peptides (called 
in cretins) are released. There are many in cretins and the functions of some of them are 
not completely understood. The gastric inhibitory peptide, glicentin, and glucagon-like 
peptides, which are all in cretins, strongly increase the amount of insulin secretion. Thus, 
incretins cause a greater increase in insulin secretion when a meal is eaten than if glucose 
is administered intravenously (Guyton & Hall, 201 0). Pancreatic amylase released by the 
pancreas in its exocrine function facilitates the breakdown of complex sugars into the 
simple sugars of galactose, glucose, and fructose. Simple sugars are transported across 
the intestinal lumen by a number of glucose transporter carrier proteins, some of which 
are sugar-specific. Transporters are required for glucose as it is hydrophilic and, 
therefore, cannot easily cross the lipid bilayers that constitute cell membranes. The 
glucose transporter proteins transport glucose through facilitated diffusion down a 
concentration gradient (Guyton & Hall, 2010). 
The glucose transporter proteins have distinct mechanisms of action, properties, 
and tissue distribution (Guyton & Hall, 201 0). Of interest for the purposes of this paper 
is the glucose transporter that is regulated by insulin, Glucose transport 4 (GLUT -4). 
Glut-4 is found in adipose tissue, cardiac and skeletal muscle; it is thought to be the most 
prevalent glucose transporter throughout the body and, therefore, has a major function in 
5 
GLUCOSE METABOLISM DISORDERS 
controlling levels of glucose in the circulating blood (McCance et al., 201 0). Of these 
tissues, muscle is the site of the majority of insulin stimulated glucose disposal, with up 
to 80% of glucose uptake occurring in skeletal muscle (DeFronzo, 2004). Glut-4 is 
translocated from intracellular storage vesicles to the plasma membrane. The affect of 
insulin on the insulin receptor and its effect on the cell contents are key to this process. 
The presence of insulin or muscle contractions increases the movement of GLUT -4 from 
its intracellular position to the plasma membrane (where it can facilitate entrance of 
glucose into cells). 
Insulin is secreted by~ cells that are located in the portion ofthe pancreas known 
as the Islets of Langerhans. The Islets of Langer hans contain several types of cells that 
produce the polypeptide hormones (glucagon, insulin, somatostatin, and pancreatic 
polypeptide) (Guyton & Hall, 201 0). Insulin is synthesized by the~ cells of the pancreas 
from its precursor proinsulin. Proinsulin is made up of an A peptide and a B peptide 
connected by a C peptide and two disulfide bonds. During synthesis, the C peptide is 
separated leaving insulin, which is the A and B peptide chains connected by the disulfide 
bonds. Insulin is an anabolic hormone that increases the storage of glucose, fatty acids, 
and amino acids in cells and tissues (McCance et al., 2010). 
Insulin is pulsatile in its secretion and regulated primarily by glucose metabolism. 
Insulin concentration pulses at three different times. A pre-burst occurs in anticipation of 
food triggered by the sight and smell and first taste of food. A rapid burst of insulin 
occurs about every 5-15 minutes, which is a contributing factor to maintaining a basal 
level of insulin and thus glucose. The other pulses of insulin occur with a range of 50-
140 minutes after the first burst, and are believed to be the result of glucose in the plasma, 
usually because of eating. It is thought that this intermittent pulsation takes place to 
allow for uptake by the liver and by the brain of glucose and to alleviate some of the 
down regulation of insulin receptors (Guyton & Hall, 2010). 
6 
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Insulin has five major functions: facilitation of glucose transportation across 
certain cell membranes, stimulation of the enzymatic conversation of glucose to 
glycogen, the retardation of gluconeogenesis, regulation of lipogenesis, and promotion of 
protein synthesis and growth (Guyton & Hall , 2010). All of these actions are mediated 
by the binding of insulin to insulin receptor sites on the cell membrane. The major effect 
of these functions is a reduction in blood glucose levels, by transportation of glucose into 
cells (McCance et al., 2010). 
Insulin receptors are embedded in the plasma membranes ofhepatocytes and 
myocytes. The insulin receptor, once activated by insulin, causes phosphorylation of 
adenosine triphosphate (ATP) to several proteins in the cytoplasm. These proteins 
include insulin receptor substrates containing signalling molecules, which activates 
Phosphatidylinositol 3-kinase and leads to an increase at the cell membrane of GLUT -4 
(Guyton & Hall, 2010). The presence ofGLUT-4 on the cell membrane is associated 
with a ten-to-twenty fold increase in the uptake of glucose into the cell (McCance et al. , 
201 0). Nevertheless, the presence of insulin receptors has an inverse relationship with 
the amount of circulating insulin. 
The number of insulin receptors in a cell changes depending on the amount of 
insulin in the circulating blood. The higher the level of insulin in circulation, the lower 
the number of insulin receptors per cell. Conversely, the lower the amount of circulating 
insulin, the greater the number of insulin receptors on each cell (Sesti, 2006). An 
increase in circulating insulin not only has an effect on insulin receptors but also on the 
liver to promote glycogenesis. 
Glycogenesis is the attachment of glucose molecules to glycogen for storage. 
The effect is that 25% of glucose absorbed from the small intestine is immediately taken 
up by hepatocytes for storage as glycogen (Aronoff, Berkowitz, Shreiner, & Want, 2004). 
Glycogenesis is a more complex mechanism and will not be discussed fully for the 
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purposes of this paper. In summary when there is a surplus of glucose, insulin signals the 
liver to store as much as possible in the form of glycogen for later use (Sesti, 2006). 
Insulin also affects the liver by reducing the release of glucose from glycogen, 
thereby reducing gluconeogenesis. Glycogen in many ways is the opposite of insulin: 
when blood glucose levels are low, glucagon, which is a catabolic hormone, mobilises 
glucose, fatty acids, and amino acids from storage into the blood, thereby increasing 
glucose levels in the blood. This is the opposite function of insulin, which is activated by 
high glucose levels, and facilitates the storage of glucose, fatty acids, and amino acids, 
thus reducing the level of glucose in the blood (McCance et al., 2010). 
The maintenance of a normoglycemic state requires that all of the mechanisms 
involved in normal glucose homeostasis are functioning. There are a number of causes of 
dysfunction of glucose homeostasis; however, for the purposes of the present project, 
only those that can lead to glucose metabolism disorders and can be screened for will be 
examined. Not everyone who has a dysfunction in glucose homeostasis develops a 
glucose metabolism disorder, and not everyone is at equal risk of developing glucose 
metabolic dysfunction. The pathophysiology of glucose metabolism disorders will be 
reviewed in the next section. 
Pathophysiology 
Diabetes and glucose metabolism disorders do not appear separately in 
pathophysiology texts. They are considered for the study of pathophysiology as different 
points on a continuum of disease and are therefore studied and written about as a single 
entity. While glucose metabolism disorders and diabetes has been studied for a long 
time, there are still elements of the pathophysiology that are not fully understood. The 
role of amylin is argued to be either a beta cell protectant or destructive of beta cells. 
There continues to be disagreement as to the role that fatty acid metabolism plays in 
insulin resistance and, ultimately, in diabetes. There is also disagreement as to the role of 
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insulin signalling pathways and insulin receptors in the creation of insulin resistance, as 
well as disputes, whether type 2 diabetes is really a reduction of insulin secretion or an 
inability of insulin production to overcome the degree of insulin resistance (DeFronzo, 
2004). Nevertheless, the purpose of this paper is a comparison of available tests to 
identify glucose metabolism disorders at the earliest possible presentation. Thus, 
although a detailed examination of the pathogeneses of glucose metabolism disorders is 
not necessary, a brief discussion of general pathophysiology of glucose metabolism 
disorders is required to frame the analysis. 
Glucose metabolism disorders are a composition of several disorders of 
metabolism, which, in combination, lead to type 2 diabetes. One of the earliest 
manifestations of glucose metabolism abnormalities is insulin resistance. Insulin resistance 
is a state of decreased responsiveness of the target tissues to normal levels of circulating 
insulin (Sesti, 2006). Once insulin resistance is present, the body attempts to maintain 
homeostasis by producing more insulin in an attempt to overcome the resistance. 
Hyperinsulinemia is one of the first discernible indicators of a glucose metabolism 
abnormality (DeFronzo, 2004). This is an important consideration in deciding which 
testing modality is best suited to uncovering the disorder in its earliest stages. 
Insulin is secreted in response to the presence of glucose: the more glucose in the 
system the more insulin is secreted, to a point. The relationship, when graphed, in diabetics 
between fasting plasma glucose and insulin a concentration is an inverted U shape. As the 
level of fasting glucose rises to between 4.43mmol/l to 7.77mmol/l, the fasting plasma 
insulin level increases until it reaches a peak value ofbetween two to two and a halftimes 
that found in a non-diabetic who is a weight and age matched control (DeFronzo, 2004). In 
diabetics, once the fasting plasma level exceeds 7.77mmol/l, the fasting insulin level 
declines precipitously. This has a dual effect, as not only is insulin not facilitating entry of 
glucose into muscle cells, it is also no longer suppressing hepatic glucose production 
9 
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(DeFronzo, 2004). The relationship between plasma glucose and insulin levels is similar 
during an oral glucose tolerance test (OGTT), except the curve is shifted to the left when 
compared to the basal insulin secretion rate (DeFronzo, 2004). This means that the level of 
insulin production drops at a lower level of blood glucose in those with glucose metabolism 
abnormalities, than those who are not affected by the disorder. This helps to explain why 
insulin resistance and the OGTT are earlier markers of glucose metabolism disorders. The 
presence of persistent hyperglycaemia indicates a reduction in insulin production that 
occurs once the level of insulin can no longer produce normoglycemic levels. 
A normal insulin level does not necessarily signify that p cell function is normal. 
While there is still much debate whether p cell dysfunction causes hyperinsulinemia or vice 
versa, there is agreement on some of the findings. There is agreement that there is 
considerable loss of p cell function before the state of diabetes is reached. It appears that 
the first burst or pulsation of insulin is blunted early on in the development of diabetes, 
which leads to post prandial hyperglycaemia, while the second stage of insulin secretion, 
which is triggered by sustained hyperglycaemia, may be maintained much longer (Scheen, 
2003). It is for this reason that those with a diagnosis of impaired glucose tolerance on 
OGTT have suffered a loss of60-70% ofp cell function (DeFronzo, 2004). Even those 
who have normal glucose tolerance but whose glucose level on OGTT is at the top third of 
the range (6.56-7.77mmol/l) have already lost 50% of their p cell function (DeFronzo, 
2004). While there is agreement that insulin resistance and the decline in p cell function do 
occur, there is not agreement as to how insulin resistance occurs at the molecular level, or 
what causes the decline in p cell function. There are a number of mechanisms by which the 
response of cells to insulin appears to occur, and whether they are simultaneous or linear in 
appearance is not known. 
Insulin receptors, insulin signal transduction pathways, defects in the insulin-
signalling cascade, GLUT -4 expression and function, as well as free fatty acids are all 
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thought to play a part in the creation of insulin resistance (Sesti, 2006). Insulin binds to 
receptors on the outside of the cell membrane, which causes phosphorylation of 
intracellular enzymes. Phosphorylation of these enzymes causes an increase in growth, 
gene expression, and fat, protein, and glucose synthesis. Insulin also causes cell 
membranes to become more permeable to glucose, especially in adipose and skeletal 
muscle cells (Guyton, & Hall, 2011). The increased permeability of the cell membranes is 
due to the translocation of vesicles within the cell, which release glucose transport proteins 
at the cell membrane. These glucose transport proteins bind with the cell membrane and 
facilitate uptake into the cell (Guyton & Hall, 2011). Insulin resistance is the lack of 
expression of the receptors and reduction of intracellular transport proteins (Guyton, & 
Hall, 2011). Whether the change in receptors is due to a different type of receptor being 
expressed, a defect in the expression of transporters, or both remains to be determined 
(Sesti, 2006). There is another mechanism that affects the amount of glucose that is 
transported into cells. Glucose metabolism disorders have long been associated with 
obesity, which is an insulin resistant state. 
Glucose metabolism disorders are associated with obesity, in which adipose tissue 
is distributed intra abdominally. Obese individuals, who have most of their fat deposited 
intra abdominally, generally suffer more adverse metabolic consequences than those who 
store their fat subcutaneously (Scheen, 2003). Excess abdominal fat is associated with an 
increase in release of non-esterfied fatty acids. As these fatty acids compete for substrate 
oxidation, they are associated with insulin resistance in myocytes and hepatocytes. 
Associated with this insulin resistance is lipid accumulation within the myocytes and 
hepatocytes. In the liver, this increased insulin resistance reduces the suppressive effect of 
insulin on hepatic glucose output. In the muscles, it results in reduced glucose oxidation 
and storage as glycogen. As the levels of free fatty acids continue, excess triglycerides are 
stored not only in the adipose tissue but also in ectopic storage areas. This, in part, 
11 
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accounts for the increase in non-alcoholic liver disease in those with insulin resistance 
(DeFronzo, 2004; Scheen, 2003; Sesti, 2006). Elevated levels of fatty acids also affect the 
p cells by competing with glucose for oxidation. There is a higher level of the by-products 
of oxidation, which increases the amount of nitric oxide, which raises the amount of 
inflammatory cytokines including interleukin-1 and tumor necrosis factor a, which impair P 
cell function and cause p cell death (DeFronzo, 2004). This inflammatory response is not 
restricted to the p cells; when the amount of glycogen synthesis is reduced, there are 
increased levels of the acute phase inflammatory marker C - reactive protein (CRP), 
suggesting a role for chronic low-grade inflammation in chronic hyperglycemia (Florez et 
al., 2006). It is these by-products of oxidation that are tested for using the Ezscan, which is 
reviewed, in the findings section. 
This inflammatory response also, in part, explains what has been termed "glycaemic 
memory" or why a person who has instituted a tight glucose control after diagnosis with 
diabetes might still suffer the consequences of diabetes, such as nephropathy, neuropathy, 
and retinopathy as well as cardiovascular disorders (Lachin et al. , 2008). One of the main 
features of insulin resistance is a reduction in the capacity of the muscle to normally oxidise 
substrates, glucose, and lipids both in a fasting and in a fed state. Ordinarily, there is an 
ability to switch between glucose and lipid oxidation depending on fuel availability and 
requirements; this flexibility is lost in those with glucose metabolism abnormalities. 
Those with glucose metabolism abnormalities have a higher capacity to oxidise 
lipids rather than switching to glucose oxidation. Mitochondria are involved in the 
oxidation of fuels and in several cellular functions. Mitochondrial function is also 
associated with insulin resistance. The number and size of mitochondria are reduced in the 
skeletal muscle of obese and diabetic patients. This impairment of mitochondrial function 
leads to an overproduction of superoxide by the mitochondrial electron transport chain. 
Superoxide is the initial oxygen free radial that the mitochondria produce. Superoxide is 
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subsequently converted into other more reactive free radicals that can damage cells in 
numerous ways (Brownlee, 2001). One of the ways the cells are damaged is by changing 
the voltage across the mitochondria that further increases the production of superoxide that 
is then transformed into reactive oxygen species. This production of damaging free radicals 
causes epigenetic changes in susceptible individuals, which changes the expression of 
certain genes, including P65 and P65 - dependent proinflammatory genes. These genes are 
known to cause long lasting changes in aortic endothelial cells and other vascular 
endothelial structures (Liesa, Palacin, & Zorzano, 2009). It is this longstanding effect of 
hyperglycemia, that makes it even more important to identify those suffering from glucose 
metabolism disorders at the earliest stages. 
The pathogenesis of the disease means hyperglycemia and the consequences of 
hyperglycemia occur before there is an actual diagnosis of diabetes. This increases the 
importance of early and specific interventions to prevent or delay these changes (Fortson, J. 
et al. , 2008). It is important to understand the consequences for the patient and their 
families that a sustained hyperglycemia or intermittent and postprandial hyperglycemic 
levels state cause. 
There are some racial/ethnic and socioeconomic groups who are at greater risk of 
developing type 2 diabetes then others. Thus, the next subsection will examine the 
various risk factors for type 2 diabetes. 
Risk Factors for Dysfunction of Glucose Homeostasis 
The highest incidence of diabetes is amongst those groups with the lowest 
socioeconomic status, which raises the question of whether it is ethnicity that creates the 
higher risk or poverty (Public Health Agency Canada, 2011). In the United States, the 
highest rates for diabetes exist amongst African Americans, Latinos, and Native 
Americans, who are all known to have generally worse economic status than non-Hispanic 
whites (Beckles, Zhu, & Moonesinghe, 2011). Similarly in Canada, First Nations and Inuit 
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have been shown to have diabetes rates three to five times that of other Canadians (Public 
Health Agency of Canada, 2011). 
Canadian statistics indicate a variety of contributing factors in development of 
glucose metabolism disorders (Public Health Agency Canada, 2011 ). The contributing 
factors can be divided into sociaVgeographic and biology/heredity. The social and 
geographic factors include low socioeconomic status and living in a rural area. 
Biologic/heredity factors include age, sex, family history, diseases, or disabilities that affect 
mobility, obesity, and certain ethnicities. All of these factors can affect the risk of 
developing glucose metabolism disorders (Public Health Agency of Canada, 2011). 
More than 2.4 million Canadians are living with diabetes, and 90% of those have 
type 2 diabetes. Diabetics only account for a portion of those with glucose metabolism 
disorders, with a further 5million Canadians suffering from prediabetes, and this number is 
likely to increase (Public Health Agency of Canada, 2011). The incidence is rising due to a 
variety of factors, including the aging Canadian population, increasing obesity rates, and an 
increasingly sedentary lifestyle (Public Health Agency of Canada, 2011 ). Of particular 
concern are First Nations peoples, who have epidemic rates of diabetes, with rates three to 
five times higher than the general population (Public Health Agency of Canada, 2011). 
First Nations also appear to be suffering from End Stage Renal Failure (ESRD) at an earlier 
age than the non-First Nations population (Dyck, Osgood, Lin, Gao, & Stang, 2010). The 
First Nations population is growing at double the rate ofthe general population in Canada, 
and the proportion of the population that is First Nations is expected to reach 4.1 % by 2017 
(Statistics Canada, 2005). In addition, of those immigrating to Canada, 80% come from 
populations that are at higher risk of developing diabetes. These include people of 
Hispanic, Asian, South Asian, or African descent (Public Health Agency of Canada, 2011 ). 
The anticipated cost of diabetes to the Canadian health care system by 2020 is $16.9 
billion per year. This does not include the personal costs experienced by diabetic patients 
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(Canadian Diabetes Association, 2009). As the burden to the health care system, patients, 
and their families increases, it is critical to understand what causes this disorder in order to 
more rapidly identify and potentially prevent its occurrence or slow its development. It is 
incumbent upon Nurse practitioners to understand the pathology of glucose metabolism 
disorders in order to choose tests, aimed at the detection of these disorders at their earliest 
manifestation to allow for early intervention. Early intervention can prevent progression to 
diabetes and reduce the sequelae suffered by those with glucose metabolism disorders and 
by diabetics. 
Sequelae 
The consequences of hyperglycemic levels either intermittently or chronically can 
be divided into two groups: microvascular and macrovascualar. Microvascular changes 
are those that affect the smallest blood vessels, like capillaries, arterioles, and venules. 
Macrovascular changes are those that affect the larger vessels, including the coronary 
arteries. 
Macrovascular changes. Clinically, dyslipidemia is highly correlated with 
atherosclerosis, and up to 97% of patients with diabetes are dyslipidemic (Dokken, 2008). 
Diabetics are also more likely to have hypertriglyceridema (Dokken, 2008). This occurs in 
part because of the effect of insulin levels on lipids. The combination of the effect of 
hyperglycemia, insulin resistance, and increased oxidation and inflammation contribute to 
endothelial dysfunction and an increase in arthrosclerosis, which contributes to 
macrovascualar disease. The incidence of cardiovascular disease is increasing, with 1.6 
million Canadians suffering from heart disease and the effects of stroke in 2007 (Public 
Health Agency of Canada, 2009). The connection between diabetes and cardiovascular 
disease is well known; however, the connection between glucose metabolism disorders and 
cardiovascular disease appears less well known. A 2010 meta-analysis indicated that, in 
patients with impaired glucose tolerance, there is a twofold risk increase in cardiovascular 
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disease present over those with a normal glucose tolerance (Ford, Zhao, & Li, 2010). 
Diabetes and impaired glucose tolerance increase cardiovascular disease risk 3 to 8 fold. 
More than 30% of patients hospitalised with an acute myocardial infarction have diabetes, 
and 35% have impaired glucose tolerance (Norhammar et al., 2002). 
Cardiovascular disease is the leading cause of death in Canadians with type 2 diabetes 
(Public Health Agency of Canada, 2011 ). It has been established that improving metabolic 
control in people with newly diagnosed type 2 diabetes improves outcomes in terms of 
cardiovascular disease. The United Kingdom Prospective Diabetes Study (UKPDS) 
included 5,102 newly diagnosed type 2 diabetics. The median follow up period was 10 
years, during which time the intensively treated group showed a 12% lower risk of any 
diabetes-related end point: renal failure, blindness in one eye, or vitreous haemorrhage, 
stroke, myocardial infarction (fatal or not), amputation of at least one digit, heart failure, 
and others. For the intensively treated group, there was a 25% reduction in microvascular 
end points, and a 16% reduction in myocardial infarctions (The United Kingdom 
Prospective Diabetes Study Group, 1998). This is an indication of the importance of early 
detection of glucose abnormalities, so that interventions can be started early to prevent the 
life-altering complications of glucose metabolism abnormalities. 
Microvascular changes. Every small vessel in the body is affected by diabetes; this 
includes those in the brain, heart, and peripheral vasculature. The combined effect of an 
increase in the inflammatory process, an increase in the oxidative stress caused by the 
increased production of free radicals, as well as the reduction of nitric oxide and an increase 
in the thickness of basement membrane all contribute to the damage that occurs in the 
vasculature of diabetes (Guyton & Hall, 2010). The state ofvascular constriction, reduced 
nerve signalling, and the increased level of coagulation in the body, all contribute to the 
high rate of end organ damage including strokes and peripheral vascular disease (Dokken, 
2008). 
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Of those newly diagnosed with Type 2 diabetes, 21% have retinopathy (Fong et al., 
2003). Diabetic retinopathy is the most common cause of blindness in adults aged 20-74. 
Retinopathy is a progressive disease with those who have had diabetes the longest, having 
the highest rates of retinopathy. Diabetic retinopathy has few apparent symptoms until 
vision loss occurs. In the landmark UK Prospective Diabetes Study ( 1998), intensive 
control of glycaemia was shown to reduce retinopathy by 76%. While laser 
photocoagulation can slow the progression of retinopathy, it cannot restore lost vision. 
Given the devastating effect of vision loss on both the patient and their families, it would 
seem prudent to delay or prevent retinopathy whenever possible. 
Studies have also demonstrated that 17.34% of newly diagnosed type 2 diabetics have 
nephropathy on diagnosis (Agarwal et al. , 2011). This helps to explain why diabetes is the 
single most common cause of end stage renal disease (ESRD) both in the US and Europe. 
In Canada, the number of people receiving dialysis rose from 10,473 in 1996 to 19,721 in 
2005 (Canadian Institute for Health Information, 2007). The complications of diabetes 
profoundly affect the individual with the disease, their family, and their community. The 
need to have dialysis affects where a family lives and the individual's ability to function in 
the community. The costs to society are great both from the loss of healthy individuals and 
for the cost of providing care to those afflicted by any of the complications. In the next 
section, the reason for screening and what can be done to intervene in the disease trajectory 
are discussed. 
Effects of Early Detection. 
There is little point in testing for a condition for which the course trajectory cannot be 
changed once identified. Therefore, it is important to understand what can be done when 
glucose metabolism disorders are identified. This disordered metabolic state does not 
automatically lead to diabetes; in Chinese, Finnish, American, and Asian Indian studies, the 
untreated or control arms of the studies saw a progression to diabetes of 11%.3%, 6%, 11%, 
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and 18.3% per year, respectively. This may indicate a greater proclivity in some ethnicities 
to develop diabetes (Ramachandan et al. , 2006). In a landmark study on Pima Indians in 
the United States, 50% of the population over age 35 were found to be diabetic (Bennett, 
Burch, & Miller, 1971 ). In Canada, the most recent age standardised prevalence rate for 
diabetes in First Nations living on reserve was 17.2% and a rate of 10.3% for First Nations 
living off reserve. This compares with an overall Canadian prevalence rate for males and 
females of7.2% and 6.4%, respectively (Public Health Agency of Canada, 2011). The 
current number of diabetics in Canada is over 2.4 million, with a prediabetic number of 5 
million; it is estimated there will be an additional 1.9 million diabetics in Canada within the 
next 5 years (Manuel, Rosella, Tuna, & Bennett, 2010). This poses a significant resource 
challenge to the health care system as well as the patients, families and communities 
affected. 
Multiple studies have demonstrated the reversal of a glucose metabolic disorder 
state to a normoglycemic state (Armato et al. , 2012; Gahagan & Silverstein, 2003; 
Lindstrom, et al. , 2003; Norris et al. , 2005; Pan et al. , 1997; Ramachandan et al. , 2006; 
Steyn, et al. , 2004; Talbot, & Dunbar, 2011). It is on this we can focus our attention in an 
effort to stem the tide of diabetes. This state has been shown to be susceptible to several 
interventions: exercise and diet as well as pharmacological measures. Key amongst these 
interventions is the control of the hyperglycaemic state and increased sensitization of cells 
to glucose and the preservation of the function ofbeta cells of the pancreas (Armato et al., 
2012; Talbot, & Dunbar, 2011; The Diabetes Prevention Program Research Group, 2012). 
While impaired glucose tolerance (indicating insulin resistance) and impaired fasting 
glucose (indicating loss of beta cell function) differ in some respects, there is general 
agreement (Lindstrom et al., 2003; Norris et al. , 2005; Pan et al. , 1997) that it is in the 
prediabetic stage of the disease that Type 2 diabetes can be reversed. 
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The role of the primary health care provider is instrumental in uncovering glucose 
metabolism disorders and in intervention in the trajectory of disease. In doing so, the 
primary health care provider must be aware of the strengths and limitations of the tests 
available. This knowledge is imperative in making informed decisions regarding use of 
testing modalities in caring for patients at risk of glucose metabolism disorders. Choice 
of tests and the results will ultimately affect the level of intervention the patient receives. 
Screening Tests 
There are a variety of screening tests that are used for glucose metabolism 
abnormalities. They can effectively be divided into those that require fasting and those that 
do not. Two tests require fasting: the OGTT and fasting plasma glucose (FPG) test. 
Three tests do not require fasting: the glucose challenge test (GCT), testing of glycated 
haemoglobin usually termed haemoglobin Ale (HbAlc), and random blood glucose 
(Pagana & Pagana, 2010). 
One issue that affects all screening tests requiring blood being drawn into a 
vacutainer (vacuum test tube for drawing blood) is the loss of glucose in the tube. This is a 
serious and often underappreciated problem (Bruns & Knowler, 2009). The loss of glucose 
through glycolysis occurs at a rate of 5-7% per hour at a concentration within the reference 
interval. This equates to a loss of0.67 mmol/1 after 2 hours in a blood sample with a 
glucose concentration of 5.5 mmol/1 at room temperature. Higher rates ofloss occur when 
the sample has a higher white cell, erythrocyte, or platelet count or the room is warmer. 
The loss of glucose through glycation continues for at least 4 hours after venipuncture 
(Bruns & Knowles, 2009). It for this reason that most studies use an ice flurry for 
immersion of tubes after venipunctures and have samples spun within 30 minutes of 
collection. With set points for glucose in the diagnosis of diabetes and glucose metabolism 
disorders, the instability of glucose in the tubes is a factor that providers need to take into 
account, particularly in communities where blood is drawn and then shipped some distance 
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for processing. This will affect those with values that lie close to the cut-offs and can result 
in missed diagnoses and, therefore, detection of abnormalities, at the earliest stages for 
those in rural and remote communities particularly. This process affects all plasma glucose 
tests that are analysed by laboratory services. Only point of care testing is not affected by 
glucose loss through glycolysis. 
Each test has strengths and weakness, some of which pertain to the requirement for 
fasting prior to testing. The tests are looked at in more detail in Appendix 1. The tests also 
test for different issues, and this is a point that is of some importance in uncovering glucose 
metabolism abnormalities at their earliest appearance. Understanding what the tests do and 
do not test for is important in understanding their degree of utility in early detection of 
abnormalities. 
There are two tests that test the efficiency of the body to metabolise glucose. These 
are the OGTT and the GCT. Both of these test the baseline glucose level and then 
administer a glucose load to the patient and then retest at varying intervals to determine the 
patient's ability ofmetabolise the glucose load. Each of these tests requires multiple 
venipunctures, and the OGTT requires pretest fasting; for this reason, they are more 
difficult to administer than tests that do not require fasting or multiple venipunctures. 
Despite this, the OGTT is considered the gold standard for detecting postprandial 
hyperglycemia and impaired fasting glucose in the outpatient setting. It is the test against 
which other tests are compared (Sacks et al., 2011). 
An increase in postprandial glucose levels often occurs before there is an increase in 
fasting glucose levels (Sacks et al., 2011). Postprandial glucose is, therefore, a sensitive 
indicator of the risk for the development of diabetes and an early marker of the impairment 
of glucose homeostasis (Sacks et al., 2011). Evidence suggests that in the OGTT, an 
increase in the 2-hour glucose, is a better predictor of both all-cause mortality and 
morbidity than Fasting plasma glucose (FPG) is (WHO, 2006). 
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The other screening tests are tests of hyperglycemia, either over a short time period 
(such as FPG or random plasma glucose (RPG) or over a longer time period as, in the 
HbAlc test. 
While the glucose plasma tests, both random and fasting, have been around for decades, the 
HbAl c has gained widespread acceptance in the last decade as issues with standardization 
of analytes and testing have been resolved. A brief explanation of the HBAl c follows 
(there is additional information on what affects the test in Appendix 1). The HbAlc test 
tests for the amount of non-enzymatic attachment of glucose to theN-terminal valine of the 
beta chain of haemoglobin. Adults have about 98% haemoglobin A in the haemoglobin 
found in the red blood cells. Once the haemoglobin is glycated, it is not easily reversed; the 
haemoglobin remains glycated until the protein degrades. Haemoglobin Al accounts for 
7% of haemoglobin A; it is this form that combines most strongly with glucose during 
glycosylation. There are several types ofhaemoglobin Al; however, Haemoglobin Ale 
most strongly combines with glucose. HbAlc makes up the majority of haemoglobin Al, 
and about 70% ofhaemoglobin Ale is glycosylated. As the red blood cell circulates, some 
of the haemoglobin Al combines with the glucose in the bloodstream. 
While it has long been thought that HbAlc gives a picture of the average of 
glucose over the expected lifespan of the erythrocyte, this is now being challenged. Recent 
studies have indicated that a large change in blood glucose, either higher or lower, is 
accompanied by a change in glycated haemoglobin levels. Regardless of the starting point 
of glucose level, the time needed to reach a constant state is fairly constant, at 30-35 days. 
This means that a large change in mean blood glucose is accompanied by a large change in 
glycated haemoglobin in a matter of 1 to 2 weeks, not 3 to 4 months. This means that 
glycosylated haemoglobin is a weighted measure of mean blood glucose during the 
preceding 120 days, with the previous 30 days of the timeframe prior to testing accounting 
for 50% of the result (Goldstein et al. , 2004). 
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While not generally considered a part of the screening tools used in glucose 
abnormalities, in many rural and remote communities point of care glucose meters are used 
as part of both screening and testing for glucose metabolism abnormalities and diabetes. 
Glucose meters are not laboratory equipment; however, in many situations, they are used in 
both emergency settings and when weather precludes sending specimens out. Capillary 
blood glucose meters are routinely used by patients and by urgent care or emergency 
rooms. These are, in many rural and remote communities, the only tests available on site 
for glucose measurement. Users need to be aware that the current standards are country 
specific, with no internationally recognised performance criteria. The current Canadian 
Standards Association performance criteria for acceptable agreement between glucose 
metres and lab tests is, at <2.5 mmol/1, a coefficient variant of +/-<12.5% and, at ~5.0 
mmol/1, a coefficient variant of +/-<7.5%. This is a much larger margin of error than is 
acceptable in laboratory equipment (Tonyushkina & Nichols, 2009). Meter manufacturers 
do not commonly disclose those substances that interfere with the accuracy of the reading, 
which makes it difficult for patients and caregivers alike to adjust for interference. 
Clinical Practice Guidelines 
There are a number of screening guidelines available for diabetes. The guidelines 
are designed to provide guidance to health care providers in screening asymptomatic 
patients for diabetes. In recent years, some of the clinical guidelines for diabetes have 
included the some categories of glucose metabolism disorders. The testing however is 
aimed at identifying those with diabetes, and not at diagnosis of glucose metabolism 
disorders. 
There are differences in the screening recommendations between Canada, the 
United States, and Europe. The cost of testing does have an effect on the recommendations 
that appear in guidelines as several studies have identified. (Kanavos, van den Aardweg, & 
Schurer, 2012; Norris, Kansagara, Bougatsos, & Fu, 2008). This is a factor of which all 
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health care providers must be cognizant and which must be a consideration when 
contemplating changes to a screening program. 
The most frequently suggested test for screening is the FPG test. Almost all of the 
guidelines also take a stepwise approach to testing. That is, initial testing is done, and 
whether further testing is required is determined from the initial test results. Screening is 
not usually done on a population basis; rather, it is targeted to those who have risks factors 
for diabetes, which include reaching a certain age, obesity, family history, having had a 
baby over 9lbs in weight, and other conditions that tend to accompany diabetes (i.e. 
hypertension or dyslipidemia). The guidelines vary in who should be screened and in the 
recommended frequency of screening, which ranges from 1 to 5 years. 
Appendix B 1 is a brief review of some of the guidelines for diabetic screening. 
The guidelines reviewed include: 
• Canadian Diabetes Association, 
• British Columbia Ministry of Health Services (BC) guidelines, 
• American Diabetes Association Guidelines, 
• The United Kingdom's National Health Service (NHS) National Institute for 
Health and Clinical Excellence (NICE) Guidelines, 
• European Evidence-Based Guidelines for the Prevention of Type 2 Diabetes 
• International Diabetes Federation (IDF) Clinical Guidelines for Type 2 
Diabetes. 
The majority of the guidelines have similar recommendations -that there should be 
some identification of risk factors and that the earliest screening be done on those with 
significant risk factors. There is a general consensus that screening should occur in those 
that are over 45years old, with the exception of the European Guidelines for Prevention of 
Type 2 Diabetes that do not specify an age. Additionally the International Diabetes 
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Federation and NHS NICE guidelines suggest use of a risk assessment questionnaire; 
however, neither specifies which one to use (International Diabetes Federation Clinical 
Guideline Task Force, 2012; NHS National Institute for Health and Clinical Excellence, 
2012). Some of the risk assessments questionnaires have been tested for their ability to 
uncover those with glucose metabolism anomalies; these will be reviewed later in the 
paper. 
In the reviewed guidelines, all except the IDF suggest that impaired fasting glucose 
and impaired glucose tolerance be identified, yet most suggest using FPG as the initial test. 
Although as indicated in the European Guidelines for the Prevention of Type 2 Diabetes, a 
significant number of people will not meet the FPG criteria for a glucose metabolism 
abnormality while meeting those criteria when an OGTT is done (Paulweber et al. , 2010). 
As such, a significant number of people could be left unidentified ifFPG is used as the 
primary tool for detection, which is the case in both the Canadian and BC guidelines. This 
will not be remedied by the anticipated addition ofHbAlc as a screening tool, as the test is 
essentially looking at the same condition: persistent levels of hyperglycemia and not 
glucose metabolism. As already indicated above persistent hyperglycemia is often a later 
stage of disease than altered glucose metabolism, which means that identification of those 
with glucose metabolism disorders at the earliest stages will be compromised and therefore 
interventions will also be delayed. 
As it is recognised that impaired glucose tolerance is frequently a precursor to 
impaired fasting glucose, this would appear to be a weakness in the Canadian and BC 
guidelines. This is of importance to development of effective screening programs by NPs. 
The ability to identify those who may progress to type 2 diabetes permits a longer time for 
intervention and the possible reversal or slowing of the progression of the disease. It 
appears sub-optimal in terms of treatment costs and patient outcomes to set the screening 
up to identify those at a later stage of the disease progression. There are a number of 
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studies that have indicated the ability to slow or halt the progression to type 2 diabetes, 
which makes its early detection worthwhile (Armato et al., 2012; Gahagan & Silverstein, 
2003; Lindstrom, et al., 2003; Norris et al., 2005; Pan et al., 1997; Ramachandan et al., 
2006; Steyn, et al. , 2004; Talbot, & Dunbar, 2011). 
The Role of Nurse Practitioners 
The primary care practitioner is the point of entry to the health care system in 
Canada (Canadian Institute for Health Information, 2009). As most NPs in Canada are in 
primary care, this places them in an ideal location to establish relationships with patients 
and their family and to identify those at risk for developing glucose metabolism disorders 
(DiCenso et al., 2010). 
NPs in Canada have traditionally provided care to those who are most vulnerable 
and most isolated (Health Canada: Office of Nursing Policy, 2006). Thus, they operate 
amongst some of the populations that are at highest risk of developing Type 2 diabetes 
through either genetic predisposition or poverty (Lee et al., 2011). NPs, particularly those 
in primary care, are in a position to both identify and provide care to those who are at the 
highest risk of developing glycaemic disorders (Canadian Institute for Health Information, 
20 10). While not all jurisdictions allow the NP to treat diabetes, in British Columbia, NPs 
have within their scope a role in identification, diagnosis, and treatment of disorders of 
glucose metabolism (College ofRegistered Nurses of British Columbia, 2012). The NP's 
role is also one that incorporates patient education, health promotion, and clinical care 
(College of Registered Nurses of British Columbia, 2012). 
NPs, while having all of the required legal ability to screen and prescribe 
interventions in the progress of Type 2 diabetes, are also prepared as coaches and mentors 
during their educational preparation. NPs in BC have as a specific competency the ability 
to work collaboratively with communities, patients and their families in decision-making 
and priority setting. This is designed to allow the patient and NP to determine a course of 
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action that will promote, restore, or maintain optimal physical mental and emotional health 
(College of Registered Nurses of British Columbia, 201 0). 
NPs work with patients in an ongoing relationship to provide encouragement with 
lifestyle interventions and pharmaceutical interventions (Hayes, et al., 2008). NPs employ 
a collaborative framework with patients to provide relevant and responsive care to clients 
(Ohman-Strickland et al., 2008). This relationship increases the patient's ownership and 
responsiveness to interventions in the disease process. NPs, as autonomous practitioners, 
have much to offer those with glucose metabolism disorders as both lifestyle coaches and 
partners in treatment (Seale, Anderson, & Kindersley, 2006; Mackey et al., 2005). This 
relationship between the NP and patient, allows the NP to determine the patients' 
perception of risk and their ability to act upon perceived risks. Identification of patients 
before the onset of diabetes allows the NP to work with the patient to change their 
behaviour. Being able to be specific about the risk to an individual is inherent in change 
theory (Herschfield, Chirrey, Thesenvitz, & Chandran, 2004). The patient must understand 
and perceive the risk as personal in order to contemplate changes that require altered 
behaviour (Herschfield et al., 2004). 
Therefore, it is incumbent upon the NP to understand what the various tests can and 
cannot identify and the strengths and weakness of the available tests. Understanding how 
to best screen patients for glucose metabolism disorders is critical to providing both early 
identification and intervention. This can delay or may halt progression of diabetes and its 
sequelae. It should also significantly reduce the personal burdens of the patient and their 
family as well as the human and financial costs to society. NPs are ideally placed in 
primary health care to identify glycaemic disorders at their earliest stages and provide care 
aimed at reducing the negative effects of the disorder (Hayes et al., 2008; Mackey, Cole, & 
Lindenberg, 2005; Ohman-Strickland et al., 2008). 
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The following section will present a review of the methods used in undertaking the 
review of the literature to answer the question "What is the best test to screen adults for 
glucose metabolism disorders, for earliest possible detection in a primary care setting in 
Canada". 
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Chapter 2 
Method 
The purpose of the literature review was to examine studies related to testing for 
glucose metabolism dysfunction and diabetes in the primary care context. The review 
of the literature is to answer the question "What is the best test to screen adults for 
glucose metabolism disorders, for earliest possible detection in a primary care setting in 
Canada?" The review was undertaken in four stages: 
1. Development of search terms and identification of key databases. 
2. Establishment of eligibility criteria. 
3. Focused search of the literature. 
4. Comprehensive review of the literature. 
The following sections will explore the search strategy eligibility criteria and 
review processes underpinning this review. 
Development of search terms and key databases. The search terms were 
derived by identifying each of the testing mechanisms normally employed in diagnosis 
and combining them with the glucose abnormalities. The literature found in this 
process was then reviewed and key terms identified and added to the search terms. The 
search included a review of the Biomed Reference Collection, CINAHL, and the 
Cochrane Library. In addition, a search ofProQuest Bodleian Libraries, Digital 
Commons @McMaster, and Digital Archive for theses that matched the topic was 
performed. A hand search of all of the references of commentaries, guidelines, and 
reviews was undertaken to ensure there were no studies overlooked that were not 
located through electronic searching. During this search process, it became clear there 
are several seminal authors who appear in many articles, these were included,- these 
include DeFronzo, Brownlee, Toumilehto, and Lindstrom amongst others. 
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Tablet: Table of Specific Search Terms 
Diabetic testing 
Diabetic testing specificity and 
sensitivity 
Testing for prediabetes and 
diabetes 
Prediabetes 
Prediabetes and diagnosis 
Testing for glucose abnormalities 
Glucose testing modalities 
Glucose testing 
HbAlc 
HbAl c and Diagnosis 
HbAlc and ethnicity 
Oral glucose tolerance test 
Glucose challenge test 
Impaired fasting glucose 
Diabetes screening and primary care 
Diabetes screening and nurse 
Practitioners 
Diabetes testing and nurse practitioners 
Nurse practitioners and diabetes 
Nurse practitioners and diabetes prevention 
Nurse practitioners and prediabetes 
Glucose testing and nurse practitioners 
HbAl c and nurse practitioners 
Impaired fasting glucose and nurse practitioners 
Impaired glucose tolerance 
Impaired glucose tolerance and diagnosis 
Impaired glucose tolerance and nurse 
practitioners 
Impaired fasting glucose and diagnosis 
Fasting plasma glucose and diagnosis 
Eligibility criteria. In order to find the most up to date articles, yet allow 
enough depth of material, the search was restricted to the period between January 1998 
and February 2012. Only articles in English were included to allow for comprehension 
by the author. The focus of this paper is adults and those who attend a primary care 
providers in a community setting; thus, only studies on adults and tests that can be done 
29 
GLUCOSE METABOLI SM DI SORDERS 
on an outpatient setting were included. Those that looked at paediatric groups, testing 
during pregnancy, or testing to elicit other diseases such as neuropathy, nephropathy, 
degree of cardiovascular disease or cognitive impairment alone were excluded. Studies 
that reviewed testing modalities for glucose metabolism abnormalities and other disease 
entities were reviewed. Others that were excluded had discussion of tests but no 
evidence of sensitivity or specificity of testing. This included a large number of articles 
which reviewed the cost effectiveness of screening for diabetes based on one screening 
test or another but no data on the specificity or sensitivity of the testing modalities 
reviewed. 
Review of the literature. There were 2,198 articles found that met the initial 
criteria. This only includes those articles found after modifiers were added. For 
example, in the biomedical reference collection, the input ofHbA1c received 1,492 
results; however, with the modifier of diagnosis, this was reduced to 226, which were 
read, counted, and reviewed. In most of the databases, there was considerable overlap 
in the results, and duplicates were removed. A final cohort of71 papers was selected 
for the review. The flow chart provides an overview of the search strategy and the 
results. 
There were 16 articles found with the search criteria of Nurse Practitioner 
however, none ofthese contained a comparison of testing sensitivities or specificities. 
No articles were found which specified Nurse Practitioner and an exploration of the 
sensitivity and specificity of various testing. Therefore, they did not meet the eligibility 
criteria for inclusion, but informed the background of this study. The articles that had 
NP or advanced practice nurse specified focused on treatment of those with glucose 
metabolism abnormalities or on prevention of diabetes. There were several instructive 
articles, which advised on a number of guidelines, and implementation of them, as well 
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as review for the implementation of guidelines by primary care practitioners but none 
which reviewed testing modalities. These articles were therefore not included in the 
review. 
Comprehensive review ofthe literature. After reviewing the literature, 71 
articles were selected for review in this project; this included one thesis. The articles 
chosen were all read in detail, all met the eligibility criteria and were deemed the most 
relevant to primary health care in the outpatient setting. The articles were reviewed 
using the "guide to an overall critique of a quantitive research report" in Polit & Beck's 
Canadian Essentials of Nursing Research (Loiselle, Profetto-McGrath, Polit, and 
Tatano Beck 2011, p 359). The use of this guide allowed critical appraisal of the 
studies with particular attention to research methods and outcomes. 
The literature reviewed typically involved a comparison of two or more 
methods of testing. Much of the literature did not focus on the Canadian context but 
looked at populations that were at high risk, such as those of African, South Asian, 
Asian or Aboriginal descent. They also examined those who had other risk factors (of 
age, obesity, family members with diabetes and sedentary lifestyles). This research is 
applicable to Canada, with its multi-ethnic population, an aging population with 
increased obesity rates, and an increasingly sedentary lifestyle (Public Health Agency 
of Canada, 2011). There were 7 key themes and 5 subthemes identified during the 
literature review. The key themes were HbA1c, OGTT, GCT, RPG, FPG, 
Questionnaires, and Novel testing methods. The subthemes were HbA1c for glucose 
metabolism disorders, HbAlc results in different raciaVethnic groups, effect of anaemia 
on HbA1c, new technology and novel uses of current testing modalities. These themes 
were based upon the hypothesis/ research question the study attempted to answer. In 
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doing so, the study also answered the question as to which of the modalities had the 
best sensitivity and specificity for screening for glucose metabolism disorders. 
Some themes had a greater number of associated studies then others. For 
instance, 37 articles were reviewed related to HbAlc while 3 were reviewed related to 
the glucose challenge screening test. Articles, which were deemed the most relevant 
and reliable to address the question "What is the best test to screen adults for glucose 
metabolism disorders, for earliest possible detection in a primary care setting in 
Canada", were chosen for detailed analysis in this paper. 
The following chapter will present the findings of the comprehensive literature 
review. This will be followed by a discussion section, identifying key 
recommendations for practice and research. 
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Figure 1 
r Flow Chart of Search Strategy 
Search terms used 
See Above 
Exclusion criteria: 
-Not available in English 
-Not within date range 
-Non-human study 
-Editorial or book review 
-Study participants 
diabetic/pregnant or under 18 
years old 
-Type 1 Diabetes 
-No data on specificity or 
sensitivity of testing modality 
Databases searched: 
-Biomedical Reference Collection 
-Cochrane Collaboration 
-CINAHL 
-ProQuest Bodleian Libraries 
-Digital Commons @ McMaster 
-Digital Archive 
-Plus a hand search of references 
1 
Inclusion Criteria: 
-Available in English 
-Published between January 1998 and 
February 2012 
-Tests done in an outpatient setting 
-Applied research to tests for 
hyperglycemia, and/or impaired 
glucose tolerance and/or type 2 diabetes 
2,198 articles found _______.._ Resulted in 103 articles, 71 of which will 
Combined searches and removed _____,... 
be discussed in the findings section 
duplicates. Removed any that did 
not meet criteria on review. 
Testing performance of 
-HbA1c 37 studies 
-Fasting plasma or random plasma glucose 13 studies 
-Oral glucose tolerance and challenge tests 8 studies 
-Novel methods 4 studies 
-Questionnaires 9 studies 
-Nurse Practitioners and diabetes 16 articles (not discussed m findings 
section) 
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Chapter 3 
Findings 
The following section will examine the literature to address the question of 
"What is the best test to screen adults for glucose metabolism disorders, for earliest 
possible detection in a primary care setting in Canada". A final cohort of71 papers was 
selected for review and critically appraised, and 7 major themes of Haemoglobin Ale, 
Oral Glucose tolerance testing, Glucose Challenge testing, Random Plasma glucose, 
Fasting Plasma glucose, questionnaires and novel testing methods were identified. 
Novel testing methods are subdivided into new technologies, and the combined use of 
OGTT and plasma insulin levels. 
Haemoglobin AlC as a Screening Tool. 
The section will examine studies that looked at the HbAlc test to answer the 
question of what is the best test to identify glucose metabolism abnormalities at earliest 
presentation in adults over the age of 18. Thirty-seven studies were selected for review 
and critically appraised, 15 of these will be presented in detail. The theme ofHbAlc is 
subdivided into detection of glucose metabolism disorders, race/ethnicity differences, 
and the effect of anemia on testing. 
HbA 1 c is attractive as a testing mechanism, as it offers the promise of a test that 
requires no preparation and yet gives a result that is the average of glucose 
concentrations within circulating blood. The test has been standardised, and many of 
the analytical difficulties have been overcome (Hanas & John, 2010; Little et al., 2001). 
The test has, thus become popular for use in both monitoring those with diabetes, and 
uncovering those who were not previously recognised as diabetics. As of July 2011, 
the WHO, American Diabetic Association, and the Canadian Diabetes Association 
recommend the use ofHbAlc as a screening mechanism for diabetes and glucose 
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metabolism disorders (American Diabetes Association, 2012; Goldenberg, Cheng, 
Punthak:ee, & Clement, 2011; WHO, 2011). The recommendations for use include a 
caution against use ofHbA1c in those with conditions, such as heamoglobinopathies, 
which might affect the accuracy of the test. Further, the International Diabetes 
Federation (IDF) suggests that if a test is used to diagnose patients with diabetes, it 
should also have a reasonable specificity and sensitivity within the population most at 
risk of developing diabetes, such as those with glucose metabolism disorders 
(International Diabetes Federation Clinical Guideline Task Force, 2012). 
There has been extensive debate regarding the use ofHbA1c as a screening tool 
or diagnostic tool for glucose metabolism disorders other than diabetes. As HbA1c 
promises the opportunity of indication of long-term glucose levels without the problems 
caused by fasting or in-tube glycation, it looks attractive as a screening mechanism for 
all glucose metabolism disorders. Some authorities, such as the American Diabetes 
Association, have been quicker than others in adopting HbA1c as a screening tool for 
all glucose metabolism abnormality disorders. The American Diabetes Association has 
introduced the use ofHbA1c with cut-offpoints or values of 5.7-6.4% as a diagnostic 
criterion for prediabetes (a glucose metabolism disorder), which is now being termed a 
high risk of progression to diabetes in the future (American Diabetes Association, 
2010). The American Diabetes Association has decided to no longer use the term 
"prediabetes", and will use the term "high risk of progression to diabetes" in its place. 
The International Expert Committee (2009) makes the point that, as the 
screening tests used to identify those at risk for diabetes are the same as those that 
diagnose diabetes, the use ofHbA1c as a screening test is valid. The Committee 
suggests that those who have a HbA1 c of 6-6.5% be considered for interventions to 
reduce risk. The committee adds the caveat that those who have a HbA1 c lower than 
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6%, who have other risks, such as cardiovascular issues, hypertension, obesity, and 
family history, be evaluated to determine the need for further intervention (International 
Expert Committee, 2009). 
Of the 37 studies that assessed the ability ofHbA1c to uncover glucose 
metabolism disorders, 20 studies recommended that HbA1 c not be used alone to 
identify either those with or at high risk of diabetes (Anand et al., 2003; Bersoux et al., 
2011; Cavagnolli et al., 2011; Costa et al., 2011; Cosson et al., 2011; Droumaguet et al., 
2006; Ford, Cowie, Chaoyang, Handelsman, & Bloomgarden, 2011; Hajat, Harrison, & 
AI Siksek, 2011; Heath, 2012; (Heianza et al., 2012; Heianza et al., 2011; Herman et 
al., 2007; Kim, Kim, Lee, Park, & Cho, 2008; Kumaravel et al., 2012; Kumar et al., 
2010; Mann et al., 2010; Pajunen et al., 2011;Pinelli, Jantz, Martin, & Jaber, 2011; van 
'T Riet et al., 2010; Ziemer et al., 2010). Seven of the remaining 17 studies supported 
the use ofHbA1c as a standalone test (Hajat, Harrison, & AI Siksek, 2011; Lu, Walker, 
O'Dea, Sikaris, & Shaw, 2010; Mukai et al., 2012; Nakagami et al., 2007;Rowley, 
Daniel, & O'Dea, 2005; Tankova, Chakarova, Dakovska, & Atanassova, 2012; Zhou et 
al., 2009), five of the seven added recommendations such as the use oflower cut off 
points than are currently recommended when using the test to monitor diabetes (Hajat, 
Harrison, & AI Siksek, 2011; Lu, Walker, O'Dea, Sikaris, & Shaw, 2010; Mukai et al. , 
2012; Nakagami et al. , 2007). While this section will not discuss all37 studies in 
detail, a review of study strengths, weaknesses, and key findings is attached in the form 
of a table in Appendix C. Thirteen of the articles, which were deemed the most 
relevant and reliable to address the question "What is the best test to screen adults for 
glucose metabolism disorders, for earliest possible detection in a primary care setting in 
Canada", were chosen for presentation here in detail. 
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HbAlc for Glucose Metabolism disorders. Anand et al, 2003 undertook a 
randomised controlled trial of the use ofHbA1c in a multiethnic population to detect 
glucose intolerance. In this Canadian study, a random sample of 936 participants were 
recruited from three Canadian cities to examine whether using FPG and HbA1c tests 
together could improve the classification of individuals with impaired glucose tolerance 
and diabetes in a multiethnic cohort. The study included three distinct ethnic groups of 
European, Chinese, and South Asian descent. South Asian is a geo-political grouping 
that includes Afghanistan, Bangladesh, Butan, India, Iran, the Maldives, Nepal, 
Pakistan, and Sri Lanka (United Nations Statistics Division, 2012). This study lacked 
details about participant selection or the locations of the study; but provided a 
comprehensive overview of the quality control and testing mechanisms used. 
The researchers found that the utility ofHbA1c to identify those with glucose 
intolerance was poor, even when combined with FPG, HbA1c could not reliably 
identify those with impaired glucose tolerance. The American Diabetes Association 
(ADA) cut-off points for HbA1 c of 6-6.5% used in the study resulted in a sensitivity of 
only 48% for glucose metabolism disorders. When combined the two tests (HbA1c and 
FPG) improved sensitivity to 71.2%, and specificity to 95% (Anand et al., 2003). This 
is consistent with several other studies, which suggested that HbAlc should either be 
combined with FPG or a questionnaire in order to improve sensitivity for diagnoses 
(Costa et al., 2011; Heianza et al., 2011 ;Heianza et al., 2012; Lauritzen, Sandback, 
Skriver, & Borch-Johnsen, 2011; Mostafa et al., 2010). This is an interesting finding 
when one considers that HbA1c and FPG actually test for the same issue (i.e., a state of 
hyperglycemia). The difference is that the HbA1c determines a longer and more 
persistent state ofhyperglycemia than the FPG, which is a snapshot in time. Neither 
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test is able to determine glucose tolerance; thus, the mechanism for the increased 
sensitivity with the two tests together is not clear. 
Anand et al, (2003) further identified significant differences in sensitivity and 
specificity, for both FPG and HbA1c between different ethnic groups. FPG having 
sensitivity ranging between 68.4% in those of European origin to 92.6% in those of 
South Asian origin, while HbA1c had a sensitivity ranging from 47.4% amongst the 
participants of European origin to 88.9% in those of South Asian origin. Likewise, two 
other longitudinal studies, the TOPIC studies 3 and 4, (2011 , 2012) identified similar 
ethnic and racial differences in the use ofHbA1c in Japan. These TOPIC studies have 
a slightly different focus but both identify that HbA1c with cut-offpoints of 5.7-6.4% 
had a sensitivity of 54%, and a specificity of 89%, in identifying those at increased risk 
for developing diabetes. While a combination ofFPG of5.6-6.9mmol/l and HBA1c of 
5.7-6.4% improved the sensitivity to 86 %, the specificity was reduced to 70% 
(Heianza et al. , 2012; 2011). The TOPIC studies were undertaken predominantly with 
government workers during annual health screening. TOPIC study 3 determined the 
prevalence of progression to diabetes diagnosed by HbA1c at various cut-offs, and 
TOPIC study 4 reviewed the prevalence of progression to diabetes, based on a variety 
of testing modalities. 
A further seven studies identified that a variation in cut off for FPG and HbA1c 
resulted in different populations being diagnosed (Cavagnolli et al., 2011 ; Droumaguet 
et al. , 2006; Heianza et al. , 2012; Kim, Kim, Lee, Park, & Cho, 2008; Manley et al., 
2009; Nakagami et al. ,2007; Wang et al. , 2011). A number of explanations for these 
differences were proposed. For example, it was suggested that, because HbA1c 
measures the level of glucose over a longer period of time, it is more likely to be high 
later in the disease when hyperglycemia is a more persistent feature. In contrast FPG, 
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simply captures a single incidence of hyperglycemia (Cavagnolli et al., 2011; 
Droumaguet et al., 2006; Heianza et al., 2012; Kim, Kim, Lee, Park, & Cho, 2008; 
Manley et al., 2009; Nakagami et al. , 2007; Wang et al. , 2011). 
In the TOPIC 3 and 4 studies (20 11 & 20 12), and a study by Costa et al. (20 11 ), 
the degree of congruence between the testing modalities was measured. All three 
studies demonstrated a remarkably similar degree of overlap. Overlap refers to the 
different testing modalities (FPG and HbA1c), identifying the same participants as 
having glucose metabolism disorders. The TOPICS studies had a 19.6% degree of 
overlap between FPG and HbA1c in identifying glucose metabolism disorders, while 
the Costa study had a finding of 20.9% of overlap for the same group. 
While ethnicity was identified as an issue in these studies, no differences were 
observed for age, sex, BMI, waist circumference, blood pressure, smoking behaviour, 
or haemoglobin levels in those groups diagnosed only by FPG or HbA1c. While the 
TOPIC studies did not perform an OGTT, the profile of those diagnosed by HBAlc and 
not FPG was different. Those participants diagnosed solely by HbAlc tended to be 
women, older, with less hypertension, with a lower BMI, triglycerides, uric acid, HDL 
Cholesterol, and y-glutamyltransferase and a higher leucocyte count than those 
diagnosed by FPG alone. This is contradictory to what was found in Norberg et al. 
(2006), which found that those diagnosed as diabetic by HbAlc alone were more often 
men who were more obese and had higher fasting glucose levels. Further, Pajunen et 
al. (2011) also found that those identified by HbA1c alone had a higher BMI, larger 
waist circumference, and fasting plasma level, but no difference between the sexes. It 
is unclear from the evidence whether ethnic/racial or population selection differences 
caused the contrasting results; however, one fmding they all shared was that FPG and 
HgAlc uncovered glucose metabolism disorders in different populations. The reason 
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for that is not clear; further research is warranted to examine why two tests that 
essentially both test for hyperglycemia differ in outcomes. 
HbAlc and results in different racial/ethnic groups. Ethnic and racial 
differences, with respect to screening, emerged as a key finding in this review. This 
review found that ifHbAlc is to be used as a standalone test then there must be 
ethnically/ racially specific cut-off points for HbAlc levels for glucose metabolism 
disorders and diabetes in order to achieve the highest level of accuracy. Of the 37 
studies reviewed related to HbAlc, seven found HbA1c to have utility as a standalone 
test. Among these seven studies, only one found that the current cut-off of points 
suggested by the WHO and ADA were suitable for the study population. Rowley, 
Daniel, and O'Dea, (2005) studied Indigenous participants who, either through 
ethnicity, family history, or weight were at higher risk of developing diabetes. This 
study was relatively small, with a total participation of 431 subjects. The study 
participants were recruited from amongst three high-risk groups: Torres Strait Islanders, 
Aboriginal group in Australia and a First Nations community in Canada. Recruitment 
was undertaken through community meetings, was voluntary, and included anyone over 
the age of 15 years, who were not on any medication that could lower or raise blood 
sugar. Blood sampling and analytical methods were well described. Of note the 
sampling techniques, transport, and analysis were performed differently in Australia 
and Canada. Australian samples were centrifuged within 6 hours and then plasma 
frozen to -2o·centigrade. In contrast, the Canadian samples were kept at 4·centrigrade, 
the HBA1c kept as whole blood, and the FPG as plasma, and analysed within one day. 
This is not a National Glycoheamoglobin Standardization Programme certified method. 
The researchers found that using a cut-off of >7%, as recommended by ADA and 
Canadian guidelines, to diagnose diabetes in previously unknown diabetics resulted in 
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a sensitivity of73% and a specificity of98%- with a 95% confidence interval. This 
resulted in a positive predictive value that a person with HBAlc of7% or more would 
have diabetes ranging from 4.5 to 93.2%, while an HbAlc of less than 7% gave a 
positive predictive value ofbetween 4.5 and 27.7%. Even within this study, there was 
an indication of significant variance between the different indigenous groups. At a cut-
off of 7%, the specificity for the First Nations group was only 43.9%, which was the 
lowest of the three groups. There were some differences between the three groups; 
however, these do not explain the difference in sensitivity ofHbAlc. Thus, it appears 
the differences in HbAlc are inherent within the different raciaVethnic groups and are 
not solely a result of sex or anthropometric measures. 
Demographic differences were found between the groups. The Torres Strait 
Islanders women and Aboriginal (Australian) women included in the Rowley, Daniel, 
and O'Dea, (2005) study had greater BMI's when compared with the male participants. 
However, the Torres Strait and First Nations men had greater waist-to-hip ratios than 
their female counterparts. The First Nations participants were older than both other 
groups but were heavier than the Aboriginal group and lighter than the Torres Strait 
group. There was some concern that the different analytical techniques used in the 
Australian and Canadian sites may have accounted for the difference between the levels 
ofHbAlc in the First Nations participants and the other two groups. The study did not 
provide a direct comparison of these methods, but relied upon previous published 
comparisons that suggested no systematic difference or error patterns between both 
approaches, but did confirm random errors in both. Therefore, we cannot rule out 
analytical differences as one of the causes of the difference between the First Nations 
and the other two groups. While this study supported the use ofHbAlc as a screening 
tool, it did so with some important reservations. The authors acknowledge that using 
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HbA1 c and not an OGTT meant there was a reduced sensitivity overall. A major 
limitation of this study was the lack or direct comparison between the two types of 
laboratory analysers and methods of pre-analytical preparation. 
Rowley et al. (2005) also makes the point that, while not the most accurate test 
for those who live in isolation and have difficulty in accessing care, HbA1c has utility 
as a testing mechanism to identify those at risk of diabetes. This was supported by 
Wang et al. (2011) who studied Aboriginal people in the United States, from a number 
of different communities across four states. Wang et al. (2011) found that HbA1c 
identified only 54% of those who were identified by FPG. This study suggested (like 
Rowley, Daniel, & O'Dea, 2005) that HbA1c be used as a screening tool because of its 
ease of use. However, the authors suggested that those who had a HbA1c of 4.75 to 
6.5% be further tested using FPG, as this was a more sensitive test for uncovering 
glucose abnormalities than HBA1c. They did note the fasting requirements caused 
problems in participants completing the tests in this study. 
While several of the above studies uncovered ethnic/racial differences in 
sensitivity and specificity ofHbA1c, others specifically looked at ways to improve the 
sensitivity and specificity ofHbA1c in different ethnic racial groups by using different 
cut off points for diagnosis. This is an important point for practitioners to explore, 
particularly as some ethnic groups (such as First Nations, those of African or Caribbean 
descent, and Asians) are at higher risk of glucose metabolism disorders than other 
groups. It is therefore, important for the practitioner to know which screening test is 
most accurate and sensitive for different ethnic groups in order to optimize the 
identification of glucose metabolism disorder/abnormalities in adults. 
Of the 38 studies reviewed in relations to the use of the HbA1c test, 12 included 
a multi-ethnic or racial cohort (Anand et al. , 2003; Cosson et al., 2011; Edelman, 
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Olsen, Dudley, Harris, & Oddone, 2004; Ford, Cowie, Chaoyang, Handelsman, & 
Bloomgarden, 2011;Grimsby eta!. , 2012; Heath, 2012; Herman eta!., 2007; Manley 
eta!., 2009;Mann eta!., 2010; Mostafa eta!., 2010; Perry, Shankar, Fineberg, McGill, 
& Baron, 2001; Ziemer eta!., 2010). All of these studies found statistically significant 
differences between the different racial/ethnic groups. For example, Herman et a! 
(2007) compared HbAlc results across five different racial/ethnic groups (African 
American, Asian, Caucasian, First Nations, Hispanics), while controlling for age, sex, 
education, marital status, blood pressure, BMI, waist circumference, beta cell function, 
and insulin resistance. This randomised controlled study examined the safety and 
efficacy of interventions that delay or prevent the development of type 2 diabetes in 
3,819 participants (aged over 25 years) from 27 centres in the United States. To be 
included in the study, participants were required to have a BMI of >24 kg/m2 
(>22kg/m2 for Asians) without known diabetes and a 2-hour-post 75g-glucose load of 
7.8-11.1 mmol/1 as well as a FPG of5.3-6.9mmolll (or any FPG of~6.8mmolll for 
Native Americans). The usual quality control measures of standardised interviewer 
administered questions were employed to obtain data regarding ethnicity/race, 
education, marital status. Participants received standardised education regarding 
preparation for tests, including hours of fasting and intake in the days leading up to the 
OGTT. All blood samples were drawn according to a pre-set protocol. Samples were 
frozen to -2o·c, then shipped on dry ice, and processed in batches on an analyser, 
which had undergone quality controls within 24 hours of sampling. 
In the participants ' self-reported data, race/ethnicity was reported as 55% white, 
20% African American, 16% Hispanic and 5% Native American and 4% Asian. The 
mean age was 51 years, and two thirds were women. Almost two thirds of the study 
populations were married, and one quarter had received college or higher education. 
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Women demonstrated a greater mean BMI score, with a BMI of35kg/m2 and a mean 
waist circumference of 1 04cm. In comparison, the male cohort had a mean BMI of 
32kg/m2, and mean waist circumference of 108cm. In the overall group, the mean 
hematocrit was 41.1 %, FPG 5.9mmol/1, fasting insulin 184.5 pmol/1, and HbA1c was 
5.91 %, and mean blood pressure of 124178 mmHg. Those of African American, 
Hispanic, Native American, and Asian descent were more likely to be female and 
younger than those of Caucasian descent. Asians participants were more likely to be 
college graduates and have much lower BMis, which is why the inclusion BMI for 
Asians was lower. Of all ethnicities, African Americans and Hispanics participants had 
the highest BMI's, with Native Americans having lower BMI followed by Caucasians 
with Asians having the lowest. Despite adjusting for variables, such as age, sex, 
education marital status, blood pressure, BMI, hematocrit, fasting, post load glucose 
levels, glucose under the curve levels, beta cell function, and insulin resistance (all of 
which might have caused HbA1C differences), the differences between races persisted. 
Even after controlling for the above-mentioned factors (age, sex, education etc), 
only 22% of the variance in HbA1c could be explained. African Americans, Native 
American, and Asians had persistently higher HbA1c levels than non-Hispanic whites 
did. This would appear to suggest there is a raciaVethnic variation in glycation rates 
and/or red cell survival rates. Grimsby et al. (2012), in a study on the single nucleotide 
polymorphisms (SNPs) in three ethnic/racial groups, found that the presence of the 
SNPs, which affects erythrocytes and glycaemic control, were more prevalent in non-
Hispanic whites and in Mexican Americans but not in African Americans. This 
appears to indicate that something other than genetic trait causes the difference. Similar 
to Herman (2007), Heath (2011), identified gender, ethnic and racial differences in 
testing results using FPG, HbAlc, or OGTT. Heath used the National Health and 
44 
TESTING FOR GLUCOSE METABOLISM DISORDERS 
Nutrition Examination Survey (NHANES) 2005-2008 data. This study is a secondary 
analysis of the NHANES data. NHANES studies have been done since the 1960s in the 
United States they are used to guide healthcare practice. The data used in Heath study 
includes information from 20,497 participants. Heath found that both FPG and HEAl c 
identified less than 15% of the type 2 diabetes mellitus cases. A combination of the 
FPG and HbAlc found only 37% of men with glucose metabolism disorders and 42% 
of the women compared with OGTT alone. OGTT was the found to be most sensitive 
test for identifying diabetes and glucose metabolism disorders, while HBAlc and FPG 
had differing sensitivities depending on the ethnicity/race of the individual tested. In 
non-Hispanic Whites HbAlc, detected glucose metabolism abnormalities at a 
sensitivity of 55%, which was higher than the FPG (at a rate of 52%). Among non-
Hispanic African Americans, the rate was 66% for HbAlc and 42% for FPG. Thus in 
all three groups both FPG and HbAlc performed poorly in identifying those with 
diabetes or glucose metabolism disorders. In African Americans, FPG identified less 
than 50% of those with both disorders and HbAlc left 40% unidentified. The results 
were equally poor for the non-Hispanic White population with just over 50% being 
identified leaving almost 50% unidentified. 
It is unclear as to why those of African descent have persistently higher HbAlc 
levels, and whether it has any clinical impact. In a study by Ziemer et al. (20 1 0), in 
which the participants had no glucose metabolism abnormalities, African Americans 
consistently had higher HbAlc than non-Hispanic Whites did. It is possible then that a 
cut-off point of2:6.5% for African Americans would see them over represented as 
diabetics. 
Understanding the need to adjust HbA1c cut-off points based on ethnicity was 
also apparent in Hajat, Harrison, & AI Siksek's (2011) study. In this Abu Dhabi based 
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study, data from a Middle Eastern population of 1,028 individuals from the United 
Arab Emirates was presented. This study drew data from the larger Weqaya study 
(meaning prevention in Arabic) which carried out cardiovascular screening including 
diabetes. Weqaya captured 92% of the native Emiratis in Abu Dhabi. Screening with 
Weqaya for those aged 18 to 75 years old was a condition of registering for the United 
Arab Emirates new free comprehensive insurance plan, which was available to all 
Emiratis living in Abu Dhabi. In 2008-2009 a total of 200,000 people were screened. 
Diabetes was included as one of the diseases to be screened for because the United 
Arab Emirates has the 2"d highest prevalence of diabetes globally (International 
Diabetes Federation, 2009). 
As part of this study, screening was undertaken using self-reported 
anthropometric measures of waist-to-hip ratios and BMI, blood pressure, and blood 
tests including an RPG, HbA1c, low-density lipoproteins, and high-density 
lipoproteins. An analysis ofthe findings showed that a HbA1c of6.4% had a 
sensitivity of 72% and a specificity of 84.3%. Those with HbAl c 2':6.1% or an RPG of 
2':11.1 mmoVl were invited back for an OGTT. The group identified for secondary 
screening had a mean BMI of30.4kg/m2 and a mean waist circumference of97cm. 
This study showed that a HbA1c of6.4% had the best accuracy in detecting diabetes, 
with a confidence interval of95%. Using an HbA1c threshold of 6.4% would have 
resulted in 73% of the population being correctly diagnosed with diabetes (as validated 
by the OGTT) and 16% being incorrectly diagnosed. The interesting point about this 
study is that the American, Canadian, and WHO threshold of2':6.5% HbA 1 c would 
have missed some of diagnosis. Of note, this study did not look at glucose metabolism 
disorder rates. 
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In other ethnicities/races, the opposite may be true. In Japan, the cut-off for 
HbA1c is 5.6%, which is the equivalent in North America of2:5.9%. This is due the 
difference in reference range, with the Japanese using the Japanese Diabetes Society 
standardization scheme, whilst most of North America uses the National 
Glycohemoglobin Standardization Program (Weykamp, John & Mosca, 2009). In the 
Japan National Diabetes Study (2007), even 5.6% is considered high for the Japanese 
population. Nakagami et al. (2007) demonstrated the current cut-off of 5.6% in Japan, 
(which was chosen because it was the equivalent of the diagnostic cut-off points for 
FPG and 2-hour plasma glucose in an OGTT), did not offer the high sensitivity and 
specificity of a cut-offof5.3%, (equal to 5.6% in Canada). The HbAIC of~5.6%, 
(equal to 5.9% in Canada), offered a sensitivity of 56.5%, specificity of95.1 %, positive 
predictive value (PPV) of 44.2%, and a negative predictive value (NPV) of97%. This 
contrasted with the cut-off of 5.3%, (5.6% in Canada), which gave a sensitivity of 
77.4%, specificity of 82.1 %, PPV of22.8% and NPV of98.2%. While some of the 
specificity is sacrificed to get a higher sensitivity, this is somewhat compensated for by 
the much greater NPV of the lower cut-off point. This level of cut-off point, would 
lead to fewer positive patients being declared negative and would appear to have a 
greater chance of identifying those that are indeed positive. 
These are similar to results found in Korea by Choi et al. (2011) and Kim et al. 
(2008), who found a cut off point below that recommended by the ADA or WHO was 
more accurate in identify Koreans with glucose metabolism disorders or diabetes. The 
need to identify appropriate cut-off points for different populations is critical to 
maximising the identification of glucose metabolism disorders at its earliest stages. In a 
multiethnic population as in Canada, this could cause much confusion as to which cut-
off to use for a particular individual or community. What is not clear from these studies 
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is what the difference in HbA1 c actually means for the patient. Does it mean that some 
races suffer worse macrovascualar and microvascular effects with the same level of 
HbA1 c, or do some races/ethnicities suffer worse damage with levels that are 'normal' 
for other races/ethnicities? Further research is warranted to explore the impact of race 
and ethnicity, as well as other factors, on the identification of glucose metabolism 
disorders. 
Effect of Anemia on HbAlc. Anaemia is commonplace, affecting over 50% of 
the global population and between 4-5% amongst Canadians as a whole. In women 
rates of anaemia rise to 5-20% and 20-30% in preschoolers (de Benoist, McLean, Egli, 
& Cogswell, 2008). In addition, anaemia is significantly higher in the Canadian First 
Nations populations with rates of between 14-50% (Christofides, Schauer & Zlotkin, 
2005). Three studies were identified exploring the impact of anaemia on HbA1c 
screening for glucose metabolism disorders (Co ban et al. 2004; Ford et al. 2011 ; 
Hardikar et al. , 2012). 
The following three studies demonstrated an increase in HbA1c levels in people 
with iron deficiency anaemia (Cohan et al. 2004; Ford et al. 2011 ; Hardikar et al. , 
2012). The largest of the three studies was undertaken by Ford et al. (2011), using data 
from the NHANES ill study of 6911 participants. This study showed that HbAl c 
levels are higher in those with iron deficiency anemia and lower in the presence of non-
iron deficient anaemia. One of the explanations was that, in iron deficiency, the 
erythrocyte lifespan is slightly longer than in a non-iron deficient state; thus, there is 
more opportunity for glycation to take place. One weakness of this study was the 
limited levels of anaemia involved. There were almost no participants with 
haemoglobins below 1 OOg/1 or those with more severe anaemia. The general rate of 
anaemia was low throughout the entire group, with 2.3 ± 0.2% for iron deficient 
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anaemia and 3.2 ± 0.3% for non -iron deficient anaemia. It is therefore, in this study, 
unclear on how screening in those with severe anaemia may be affected. 
In a much smaller study by Coban et al. (2004), 50 patients with iron deficiency 
anaemia, but no glucose metabolism abnormalities or any other haemoglobin 
abnormalities or conditions that could affect HbA1c, were tested pre- and post-
treatment for anaemia. Prior to treatment for anaemia, the mean HbA1c was 7.4%. 
After treatment for anaemia for three months, using 1 OOmg iron orally per day, the 
mean HbA1c for the anaemic group was 6.2%. Similar results were found in a study 
with 243 participants done in India (Hardikar et al. , 2012). This study found that the 
prevalence of prediabetes, as found by HbA1c among those with anaemia, was 23.3% 
and diabetes prevalence was 2.3%, whereas by OGTT on the same group the 
prevalences were 7.8% and 2.6%, respectively. This study postulated that the 
differences might be that anaemia affected the glycation rates and not just the length of 
erythrocyte survival. It is noted that, further research is needed to clarify this further. 
In summary, the evidence suggests that HbA1c lacks the sensitivity and 
specificity for identifying those with glucose metabolism disorders that other tests, such 
as OGTT offer. This lack of sensitivity and specificity is compounded in some ethnic 
and racial groups, which may see them over or under represented by HbAlc in either 
the glucose metabolism disorders or diabetes. Groups such as the Japanese will be 
under represented by HbA1c while those of Mrican heritage will be over represented. 
There may be a place for different cut-off points for different ethnic groups for HbA1c 
but in a multi ethnic society such as Canada that begs the question as to which cut-off 
an NP would use with a patient of mixed racial heritage. The HbA1c is also affected by 
the presence of iron deficiency anaemia, which causes an increase in the HbA1c levels. 
The utility of the HbA1 c lies in the lack of any preparation for the test and the stability 
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of the test during transportation. It is however incumbent upon the NP to know what 
conditions affect the validity of the test and the possible affect of race/ethnicity on the 
results. There is a lack of sensitivity and specificity particularly in identifying glucose 
metabolism disorders when used as a standalone test. This is a problem for two 
reasons: first, they may not get the interventions required to reduce or prevent 
progression to diabetes; second, it may give a false sense of security that will reinforce 
poor lifestyle choices. 
Oral Glucose Tolerance Test as a Screening Tool 
This section will examine studies that examined the OGTI to answer the 
question of what is the best test to identify glucose metabolism abnormalities at its 
earliest presentation in adults over the age of 18 years. As indicated in Appendix A, the 
OGTI requires that the patient not engage in vigorous exercise or smoke the day of the 
test must consume at least 150g of carbohydrates in the days prior to the test, must have 
fasted for 8-12 hours pre-test, and must commence the test before 11am to account for 
diurnal variations in plasma glucose. Four studies were retrieved and selected for 
review (Azizi, 2006; Brohall, Behre, Hulthe, Wikstrand, and Fagerberg 2006; Davies, 
Muehlbayer, Garrick, & McNally, 1999; Hosseinpanah, Rambod, Reza Ghaffari, 2006; 
Janus et al.2000) 
The OGTI was the mainstay of diabetes diagnosis and screening until 2003 
(American Diabetes Association), when non-fasting tests, primarily HbA1c, became 
more widely used (Canadian Agency for Drugs & Technologies in Health, 2009). 
Nevertheless, the OGTI is still the gold standard against which other tests are measured 
(Sacks eta!., 2011). The difficulty with OGTT is the lack of reproducibility and the 
time and effort it takes to do the test (Behan, 2005; Goldstein eta!., 2004). This 
difficulty of replication is discussed in Appendix A; it is for this reason there are few 
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studies which examine the OGTT as a primary screening tool, and even fewer that do 
multiple OGTT tests in an effort to determine reproducibility and consistency of results. 
A study by Brohall, Behre, Hulthe, Wikstrand, and Fagerberg (2006) 
undertaken on a cohort of 64-year-old Swedish women examined the prevalence of 
diabetes and impaired glucose tolerance in middle-aged women. This study explored 
the variability and practical use of the OGTT in screening for IGT and diabetes; 2,595 
women participated in the screening examination. Women with a recent cancer 
diagnosis, chronic inflammatory disease, severe illness of any kind, drug addictions, or 
could not speak Swedish were excluded from the study. In addition, those women with 
known diabetes who were being treated with an oral anti-diabetic agent or insulin were 
also excluded; however, those who had diet controlled diabetes were included. In this 
study, the OGTI was performed on two separate occasions following standardised 
preparation instructions, including food intake, and avoiding strenuous exercise in the 
three days prior to the test, and instructions not to smoke on the day of the test. All 
tests were commenced prior to 11 am for consistency. The second OGTI was 
performed within 2 weeks of the first test in all participants. The variability in the 
number of hours patients fasted, which ranged between 7 to 20 hours (mean of 11.8 
hours) did not affect FPG results. 
The results of the first OG TT found two hundred and fifty of the 25 9 women 
(96.5%) met the diabetic criteria; of these 119 still met the diabetic criteria on the 
second OGTT. Of these, 77 of these were then identified as impaired glucose tolerance 
(IGT) and 45 as normal glucose tolerance (NGT). In the 119 women who persistently 
tested as diabetics, 23 (19.4%) had FPG repeatedly within the normal range for FPG. 
The authors noted that if only FPG had been done (albeit on two separate occasions), 44 
fewer diabetics would have been diagnosed (i.e., 37% would have been missed). 
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Brohall et a!. (2006) did hypothesis about the lack of reproducibility between the two 
OGTT tests, particularly in those women who were initially diagnosed as diabetic and 
with repeat testing became either IGT or NGT. It was suggested that, having received 
information about a possible diagnosis of diabetes, the women had changed their 
behaviour between tests. However, as the two tests were done within 2 weeks of each 
other, it is not plausible that lifestyle changes could totally explain the change. This 
study also found differences between those who were persistent in demonstrating either 
diabetes or IGT in that they had higher BMI, larger waist circumference, and a higher 
blood pressure. This study demonstrated the difficulty in reproducibility of the OGTT 
tests. 
A limitation of the study is that it was done on a homogenous population of 64-
year-old Swedish women. In addition, the authors identified difficulties associated with 
reproducing OGTT testing. The study failed to explain the reasons for the difficulties 
in reproducing OGTT results in 45 (1.7%) of the women, who became NGT on the 
second testing having been within diabetic range on the first OGTT test. 
In a study on a different population with a mixed ethnic /racial background, 
similar results regarding OGTT and FPG were found (Davies, Muehlbayer, Garrick, & 
McNally, 1999). This British study was undertaken to compare the prevalence of 
diabetes and abnormal glucose metabolism using conventional and suggested World 
Health Organisation (WHO) and American Diabetic Association criteria in a group of 
participants with symptoms of diabetes. The key difference between the WHO and the 
ADA criteria was that WHO still recommends that OGTT be done on patients who 
have risk factors for diabetes, while the ADA makes a strong recommendation that FPG 
can be used on its own as a screening mechanism (American Diabetes Association, 
2012; World Health Organisation, 2006). The study by, Davies eta!., (1999) found 
52 
TESTING FOR GLUCOSE METABOLISM DISORDERS 
42% fewer participants were identified as having a glucose metabolism disorder by 
FPG, than was identified using OGTT. This study had a large proportion offudo-Asian 
participants (57.8%). 
The OGTT consistently uncovers glucose metabolism disorders amongst 
people with normal FPG. As already indicated, this was found in the study by Brohall 
et al. (2006) and Davies et al. (1999), Hosseinpanah, Rambod, Reza Ghaffari, and 
Azizi, (2006) and Janus et al. (2000) found similar fmdings. The results of these 
studies all indicated that, across a number ofraces/ethnicities Chinese, fudo-Asian, 
Nepalese, and Caucasian, that OGTT testing uncovers glucose metabolism disorders in 
the presence of normal FPG. The studies had similar findings in that the likelihood of 
having an abnormal OGTT increased with the level ofFPG; however, for the almost 
50% who had FPG under 7mmol/l, other factors gave clues to the presence of glucose 
metabolism disorders. These included increasing age, waist circumference, blood 
pressure, and triglyceride levels. However, in the study by Hosseinpanah et al. found 
that even adding the variables of age, gender, triglyceride levels, systolic blood 
pressure, and waist circumference only explained 47.7% of the difference between the 
FPG and OGTT results. 
Several of the studies suggested that the differences between FPG and OGTT 
were, in part, a result that the two tests are measuring for different conditions (Azizi, 
2006; Hosseinpanah, Rambod, Reza Ghaffari, 2006; Janus et al.2000). The studies all 
concluded that measurement of OGTT is a measure of insulin resistance, while FPG is 
a measure of beta cell dysfunction, and that the two are not always present 
simultaneous! y. 
fu summary, the OGTT was shown to be the most sensitive and most specific 
test for identifying glucose metabolism disorders and diabetes in all racial/ethnic 
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groups. It is not affected by the heamoglobinopathies as HbA1c is, however it does 
require the patient to be in a fasting state for eight hours prior to the test and to have the 
test started before 11 am. There are also multiple phlebotomies that require the patient 
to stay in the outpatient department for at least two hours. In a study by Selvin, 
Craininceanu, Brancati & Coresh (2012) of2,596 participants 1394 presented as not 
having fasted for at least eight hours. This means that 50% of participants arrived 
improperly prepared for the test. It is reasonable to assume if this occurs in a study 
population who have agreed to participate, and had received education about the test, 
that the same levels of poor preparation would be true for the general patient 
population. These pretest and test conditions make it an unpopular choice for both 
primary care practitioners and patients. However, NPs should be aware that it offers 
the best chance to identify glucose metabolism disorders at the earliest presentation and 
in all populations. It requires educating the patient on the need for this test over other 
tests and the preparation required. Primary health care providers, such as NPs are well 
placed to deliver the education to the patient regarding preparation and need for the test. 
In the next section, use of glucose challenge testing as screening tool will be examined. 
The Glucose Challenge Test as a Screening Test 
The glucose challenge test (GCT) has traditionally been used as a preliminary 
screening tool with pregnant women. When prenatal women are found to have 
impaired glucose tolerance with GCT testing, then further testing with OGTT is 
performed. The test is not widely used in the non-pregnant population. The advantages 
of the GCT are that it does not require the patient to be fasting, takes less time and 
requires fewer phlebotomies in comparison to the OGTT and can be done at any time of 
day. This section will examine studies that examined the glucose challenge test (GCT) 
to answer the question of what is the best test to identify glucose metabolism 
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abnormalities at its earliest presentation in adults over the age of 18. Two studies were 
selected for review (Chatterjee, Narayan, Lipscomb, and Phillips, 2010; Phillips et al. 
2009). 
Phillips et al. (2009) examined post challenge glucose levels in 1 ,573 non-
pregnant patients with a mean age of 48 years. Phillips et al., (2009) found that post 
challenge glucose was a uniform predicator of progression from impaired glucose 
tolerance to diabetes compared to FGT. This study was one of the few found for GCT 
on non-pregnant adults. The study hypothesis was that diabetes screening could be 
done using the GCT at any time of day, regardless of meal status and with a one-hour 
sample. Study participants had a mean BMI of 30.3kg/m2; 58% were women and 58% 
African American. None of the participants was known to have diabetes, be pregnant 
or nursing, or had been on steroids. The participants were required to go through two 
phases of testing on the flrst visit: the RPG and random capillary glucose (RCG), 
followed by a GCT with plasma and capillary plasma glucose measured 1 hour after a 
50g glucose load. On the second visit, a HbA1c and 75g OGTT were performed. The 
participants were recruited through advertising; there was an effort to ensure that 
participant sex and race were balanced. The testing mechanisms were well detailed, as 
were the measurements and analysis. In order to avoid confounding variables because 
of changes in behaviours caused by test results, participants were not given the results 
of the flrst tests ofRPG, RCG, and GCT. 
Phillips et al., identified that diabetes was found in 4.6%, and prediabetes in 
18.7% of the participants. The GCT provided an area under the curve (AUC) of0.90, 
0.82, and 0.79 for detection of diabetes, diabetes or prediabetes, and prediabetes, 
respectively. When compared with other convenient screening tests ofRPG, RCG, and 
HbA1 c, the GCT performed better. The GCT plasma glucose was unaffected by the 
55 
TESTING FOR GLUCOSE METABOLISM DISORDERS 
time after meals or time of day the test was done. The test performed with higher 
sensitivity and specificity amongst African Americans than White participants; with no 
difference in sensitivity and specificity between men and women. Thus, screening with 
GCT plasma appears to provide an efficient and palatable screening method for both 
glucose metabolism disorders and diabetes. 
Chatterjee, Narayan, Lipscomb, and Phillips (2010) reported similar findings in 
a study to examine whether screening adults for glucose metabolism disorders and 
diabetes would be cost saving. 1 ,259 adults without diagnosed diabetes were recruited 
and tested on two separate occasions. On the first visit, participants were tested without 
an overnight fast, and at different times of the day using a RCG, RPG, and a 50g GCT 
with a 1-hour post-load plasma and capillary glucose test. On the second visit, 
participants were tested after an overnight fast, with HbA1c and an OGTT being 
performed before 11am. The participants were volunteers recruited through 
advertising; no participants were known to have diabetes. The methods, case 
definitions, costs assessment, and the sensitivity analysis were all explained in detail in 
the article. Costs were based on the 2007 Medicare, Medicaid, and Veterans Affairs 
test and medication reimbursement amounts. The conclusion was that for this 
population, which was 55% African Americans with 62% of the cohort being female 
with an average age of 48 years and a BMI 30kg/m2 , GCT provided a specificity of 
70% when compared to the results of the OGTT used as the gold standard. In 
summary, this study found the GCT to be an efficient and cost effective method of 
screening in non-pregnant adults. However, a weakness of this study was that it was 
not a randomized controlled study but relied on a convenience sample of volunteers, 
which may have caused some selection biases. However, the rates of diabetes and 
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glucose metabolism abnormalities were found to be similar to those reported in larger 
studies and randomised control trials (Cowie et al., 2009). 
In summary, both of the studies that examined the use ofGCT as a screening 
tool for non-pregnant adults found a high level of specificity and sensitivity. The 
authors also postulated that the lack of fasting and the reduction in number of 
phlebotomies compared to OGTT would make it more cost effective and acceptable to 
patients. One of the limitations ofthese studies was the small cohorts used. The GCT 
needs to be tested much more widely in a variety of populations to ensure that similar 
results are achieved. NPs need to be aware of the limitations and the possible 
advantage of such testing. GCT offers the opportunity to do opportunistic testing on 
patients though it requires further research to determine its applicability to a larger 
patient population. In the next section, the use of randomised blood glucose screening 
as a screening tool will be examined. 
Randomised Blood Glucose as a Screening Tool 
Randomised blood glucose is a readily available test and can be done as both 
plasma blood and capillary blood tests. Testing usually takes place at the point of care 
and is considered one of the easiest and most accessible tests, requiring little if any 
preparation (Pagana & Pagana, 2010). The test is frequently used in emergency rooms, 
acute care settings, and primary care settings and can be particularly useful in rural 
settings where access to laboratory services may be limited. Four studies were 
identified from contemporary literature, of which two examined RPG as a screening 
test (Johnson, Tabael, & Herman, 2005 ; Ziemer et al. , 2008), and the remaining two 
examined point of care testing accuracy (Carstensen et al. , 2008; Rush, Crook, and 
Simmons, 2008). These are presented in this section. 
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Ziemer et al., (2008) undertook a cross-sectional study with 990 adults who 
were not known to have diabetes. In this study, RPG identified impaired fasting 
glucose (AUC 0.75) better than impaired glucose tolerance (IGT) (AUC 0.67). The 
study cohort had a mean age of 48 years and a BMI of 30.4kg/m2 ; of whom 66% were 
women, and 52% were African American. There is no mention of any other 
raciaVethnic group. Over a two-year period, employees of two health care systems and 
two medical schools, plus members of the public, were invited to participate in this 
study. Participants known to be diabetic, pregnant, breastfeeding, taking 
glucocorticoids, or had been unwell in the previous week were excluded from 
participating. Detail was reported regarding the testing protocol including the 
collection of anthropometric measures, and significant information regarding the 
analysis of data. The participants had an RPG test performed at various times of day 
with no fasting on the first visit. On the second visit, which took place within 3 weeks 
of the first, participants had an OGTT with a 75g glucose drink performed before 11 
am. The RPG showed an AUC of0.80 for identifying diabetes and 0.72 in identifying 
glucose intolerance- both highly significant, with a p-value of <0.001. The screening 
was consistent regardless of the time of day and length of time since the participant had 
eaten. The authors felt that RPG was an effective screen for diabetes, although not an 
effective screening tool for glucose metabolism abnormalities. Other studies have 
found similar results (Johnson, Tabael, & Herman, 2005). Of note, the authors used 
three different cut points to determine the best one for uncovering diabetes, finding that 
a cut point of 130mg/dl (7.2mmoVl) offered a specificity of 89% and sensitivity of 63% 
for diabetes diagnosis. 
As discussed, RPG is often performed at the point of care. Rush, Crook, and 
Simmons, (2008) studied 5309 New Zealanders (aged over 28years), using a point of 
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care test for either FPG or as part of an OGTT. The study cohort was a high-risk group 
of adults with either a history of gestational diabetes, two parents with known diabetes, 
or at least one Maori resident of the household. An analysis of the findings 
demonstrated a significant underestimation of glucose metabolism disorders when 
compared to laboratory-based testing. The authors found that when using a cut-off of 
7.0mmolll, the point of care testing would have diagnosed only 73% of those with a 
venous glucose of above 7.0mmolll. The authors found that as the venous glucose level 
increased to >7.0mrnol/l there was greater agreement (73%) between the point of care 
test and the laboratory tests (Rush, Crook, & Simmons, 2008). These findings were 
supported in a study by Carstensen et al. (2008), which looked at eleven different 
combinations of specimens and testing modalities in measuring blood glucose using 
294 samples from 74 people. The capillary samples were the most imprecise, with 
standard deviations (SD) three times the size of the other testing methods. Therefore, 
using venous blood in point of care testing made it a better method; nevertheless, the 
point of care test and the capillary sample gave the least precise measurements 
(Carstensen et al. , 2008). 
In summary, RPG offers an easy test with little or no preparation, which can 
also be performed on site as a point of care test. This offers significant advantages of 
immediacy, especially in hard to reach populations, where follow-through for testing is 
problematic. The RPG does offer a viable first test; however, it requires confirmation 
with other OGTT or HbA I c tests. When RPG tests are performed using point of care, 
there is less accuracy as the POCT machines predominantly used are those designed as 
personal glucose meters. These are less precise than other forms of equipment. In 
addition, as discussed in the pathophysiology section, persistent hyperglycemia is a 
later presentation than impaired glucose tolerance and therefore offers low sensitivity 
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for identifying glucose metabolism disorders. While useful for a point of care testing, 
this should not be used as a diagnostic tool for glucose metabolism disorders. NPs, 
especially those who by location are compelled to rely on point of care tests, need to be 
aware of the reduced accuracy of such testing devices compared to those that are 
laboratory based. Care should also be taken to further test those whose anthropometries 
or symptoms suggest a glucose metabolism abnormality but whose RPG is within 
normal range (British Columbia Ministry of Health Services & British Columbia 
Medical Association, 201 0). 
In the following section, Fasting plasma glucose (FPG) will be examined. This 
test is the test suggested as a first line screening mechanism in both the Canadian and 
BC guidelines. 
Fasting Plasma Glucose Testing as a Screening Tool. 
Fasting plasma glucose testing is a mainstay for the testing for diabetes. It is the 
primary test used in the BC guidelines to test for diabetes and informs whether further 
testing should take place (British Columbia Ministry of Health Services & British 
Columbia Medical Association, 2010). In preparation for FPG testing, patients must 
fast for a minimum of 8 hours. The test can be performed either with venous or 
capillary samples, although for diagnostic purposes in Canada venous samples are the 
norm. FPG informs the OGTT test, but it is also a diagnostic test in and of itself when a 
fasting of over 7 .Ommol/1 is present. Many of the studies already included in this 
review have incorporated FPG as part of the study process (Heianza et al., 20 12; 
Heianza et al., 2011; Kim, Kim, Lee, Park, & Cho, 2008; Kumar et al., 2010 ;Mann et 
al., 2010; Ziemer et al., 2010). Most have commented on the ability ofFPG to 
identify those with glucose metabolism disorders. Nine studies focusing on the 
application ofFPG were identified and reviewed, five of which will be addressed 
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directly (Heianza et al. , 20 12; Mannucci, Bardini, Ognibene, and Rotella, 1999; 
Mannucci et al., 2003; Nakagami et al., 2002; Wang et al. , 2011). The key findings 
related to FPG will now be presented. 
Wang eta!. , (2011), in a longitudinal study (median follow up 7.8 years) of 
1,677 nondiabetic American First Nations sought to examine the incident rates of 
glucose metabolism abnormalities and diabetes risk factors. This study was part of the 
Strong Heart Study, which is a population-based study of cardiovascular disease and its 
risk factors in 13 tribes across 4 states. The baseline examination included a personal 
interview, and complete physical examination including collection offasting bloods, 
followed by a 75g OGTT. These examinations were repeated on two other occasions 
over 2.5 to 10 years. The authors found that men and women with glucose metabolism 
disorders were significantly older, had higher BMl's, larger waist circumferences, 
larger waist to hip ratios, higher triglycerides levels, fasting insulin levels, and more 
elevated HbA1c than those who were NGT. Wang eta!. (2011) found that FPG 
identified 94% of those found to have diabetes. However, one study's findings 
indicated that even in the diagnosis of diabetes FPG had a low rate of sensitivity in 
screening obese patients (Mannucci, Bardini, Ognibene, and Rotella, 1999). 
A study by Mannucci, Bardini, Ognibene, and Rotella ( 1999) on 528 obese 
adults found that FPG identified only 56.7% of those with diabetes. In part, this may be 
due to the pathology of diabetes with glucose intolerance preceding constant 
hyperglycaemia. In this study, only 19.1% of those found to have impaired glucose 
tolerance were identified by FPG. This is supported by another study by Mannucci et 
a!. (2003 ), which in a study of 7 67 suburban Italians found that of the 163 found to have 
diabetes, 79 had FPG >6.1 but less than 7 mmol/1. In this study, all those that were 
normal weight and diabetic had FPG of >7mmol/l, while overweight diabetics had FPG 
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in the 6.1-6.9mmoVl range. The majority of patients in this study with impaired 
glucose tolerance had normal FPG. In normal weight men with IGT, only 23% also 
had IFG; in obese women with IGT, only 20% had IFG. 
Conversely, a study by Nakagami et al. (2002) in a study of 17,512 subjects 
across six Asian countries involving 12 study sites found that the sensitivity ofFPG 
increased with increasing BMI. This study was part of the Diabetes Epidemiology: 
Collaborative Analysis of Diagnostic criteria in Asia (DECODA) study. The 
DECODA study has previously shown that using FPG alone as a test for diabetes 
would reduce the prevalence of diabetes by 1.8% compared to OGTT. In this study, 
one new centre in Chennai India was included in the analysis. This study is 
combination of the studies done in a variety of centres. Centres in Asia that had 
published studies on the prevalence of diabetes, which they had determined by use of 
75g OGTT, and FPG were invited to participate. All data was submitted to the 
Diabetes and Genetic Epidemiology Unit of the National Public Health Institute in 
Helsinki, Finland. As these studies were done independently, there is no uniform 
quality control of the blood sample analysis. In order for a study to be included, the 
study had to be a general population study. The mean age for the centres combined was 
54 years, the mean BMI was 23.7kg, /m\ and none were known to have diabetes. On 
initial testing, 4% of the subjects were found to be diabetic by FPG alone, in 
comparison to 6% by OGTT. This gave sensitivity by FPG of 45.5% and a specificity 
of 98.6%, PPV of 68%, and NPV of 96.6% for this Asian population. When including 
only those who had a BMI above 26kg/m2, the sensitivity increased to 47% while 
specificity dropped slightly to 98%. This study suggested that the optimal cut off points 
for FPG might be different for different populations based on phenotypic characteristics 
(Nakagami et al., 2002). This finding of a need for different cut-off points was 
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identified when attempting to use FPG to identify glucose metabolism disorders other 
than diabetes. As identified in a number of studies, the ability ofFPG to identify those 
with hyperinsulinemia, rather than hyperglycemia, is limited (Heath, 2012; Kim et al., 
2008; Kumar et al., 2010; Perry et al. , 2001). 
A number of studies that sought to compare, HbA1 cas a screening tool with 
FPG and OGTT as comparisons highlighted the need for ethnically/racially specific 
cut-off points. In studies such as Heath (2012), which was a secondary analysis of 
NHANES 2005-2008 data, FPG offered similar rates of detection of diabetes to HgA1c 
at rates of25% and 38%, respectively. Other studies have found higher figures but only 
in combination with lower the cut-off points, such as a study by Heianza et al. (2012). 
This study of6241 patients receiving annual health screening in Japan with FPG of6.1-
6.9 mmoVl gave a sensitivity of 46% and specificity of 96% for developing diabetes 
within the next five years. These results were similar to studies done by Kim et al. 
(2008), Kumar et al. (2010); Mann et al. (2010), and Perry et al. (2001). One study 
found lower rates of diabetes using FPG than HgA1 c, but hypothesised that they had 
tried to replicate ' real world' situations and, thus, had not immersed samples in an ice 
flurry after phlebotomy. The authors speculated that the result of a low sensitivity of 
FPG could be a result of pre-analytical error caused by glycolysis in the test tube prior 
to processing. 
In summary, FPG is an excellent test for those who have persistent 
hyperglycaemia but not those with intermittent hyperglycemia as in glucose metabolism 
disorders. It requires the patient to fast but is a quick and easy to do test requiring only 
one phlebotomy. However, it does have several limitations: it is a snap shot in time 
and, therefore, requires confirmatory testing. It is also affected by glycolysis in the test 
tube; in the non- study testing in which ice flurry are not routinely used, this could have 
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the effect of excluding those who are close to cut-off from being considered to have a 
glucose metabolism abnormality. There is also some concern expressed in some of the 
studies regarding the need for different cut-offs in different racial/ethnic groups and 
different phenotypes. The FPG is less sensitive for the obese who are at greater risk of 
developing glucose metabolism disorders. As discussed in the pathophysiology section, 
this may be a result of the affect of adipose tissue on insulin sensitivity and production. 
Testing is expensive and care should always be taken to ensure that health care 
resources are used wisely. As, such the use of questionnaires to evaluate the degree of 
risk a particular patient has of developing glucose metabolism disorder offers a fine 
tuning of testing use at little or no cost to the health care system. In the following 
section, the use of questionnaires to identify those with glucose metabolism 
abnormalities will be examined. 
Questionnaires as Screening Tools 
While questionnaires are not strictly considered a testing mechanism, they have 
been used in a number of ways for screening patients to determine risk of diabetes, with 
some having shown utility in identifying those who may have glucose metabolism 
disorders. As with many of the screening approaches discussed, a positive result from a 
questionnaire screening tool requires further clinical investigation. The questionnaires 
available have a variety of targets; some are aimed at specific ethnic or racial groups, 
while others are more general in focus . The questionnaires typically comprise a range 
of easily measured parameters; such as weight, height, waist and hip measurement, 
blood pressure, age sex etc. Many of the guidelines for diabetes screening suggest the 
use of a questionnaire to determine the degree of risk of a patient developing diabetes 
(Canadian Diabetes Association, 2008; British Columbia Ministry of Health & British 
Columbia Medical Association, 201 0). The risk score is then used to determine if 
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further testing is needed and the frequency of testing. Although most of the guidelines 
suggest the use of a questionnaire to determine risk, none of these actually recommend 
a specific risk measurement tool for use in outpatient adult populations. 
Seven studies were identified during the review of the literature. These each 
examined questionnaires for use in the assessment of risk of diabetes and glucose 
metabolism disorders. These will now be discussed in relation to their accuracy and 
potential clinical application (Behan, 2005 ; Lindstrom et al, 2003; Otero, Pong, 
Papineau, Thorne, & Zanetti, 2011; Papineau & Pong, 2011; Schwartz et al., 2009; 
Talbot and Dunbar, 2011 ; Tankova, Chakarova, Atanassova, & Dakovska, 2011) 
The Canadian Diabetes Risk Assessment Questionnaire (CANRISK) is a 16-
item questionnaire that was developed by the Public Health Agency of Canada 
(Appendix D). It is based on the 8-item Finnish Diabetes association Type 2 Diabetes 
Risk Assessment Form (FINDRlSK). The FINDRlSK questionnaire has been in 
existence longer, although research that has examined this tool was undertaken almost 
exclusively with Caucasian populations (Tankova, Chakarova, Atanassova, & 
Dakovska, 2011 ). 
There have been three studies undertaken using the CANRISK tool; one of 
which was undertaken in Vancouver (British Columbia) Coastal Health Authority as 
part of a pilot study for the tool (Papineau & Pong, 2011 ). This questionnaire was 
tested on 556 participants from a variety of ethnic groups, the majority (60%) of which 
being East Asian (Chinese, Vietnamese, and Filipino). A follow up OGTT was also 
undertaken to compare the risk assessment questionnaire with biochemical indicators of 
glucose metabolism disorders. The participants of the study were also asked to review 
the content and format of the questionnaire. Although the researchers indicated that 
one of the objectives of the study was to include persons of Aboriginal ancestry, it 
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states clearly that in order to be classified as a particular ethnicity, both parents had to 
be from the same ethnic/racial group. This would preclude many Metis as, by 
definition, they are from mixed ancestry. In the research report, the authors additionally 
fail to identify the backgrounds of those participants categorized as being from 'other' 
ethnic groups. 
In their research article, Papineau and Fong (2011) discuss the number of those 
participants found to be moderate to high and low risk (n=3 and 33 respectively), as 
well as indicating the number of patients found to have glucose metabolism disorder 
(n=17) or diabetes (n=15) through the OGTT performed . Unfortunately, they do not 
put the information regarding risk rating with the results of the OGTT to indicate the 
correlation between the two. There is no indication of the sensitivity and specificity of 
the CANRISK tool in finding diabetics or glucose metabolism disorders. This is a 
major weakness of the study. 
Similarly, a second study by Talbot and Dunbar (2011) undertaken in Nova 
Scotia examined the use of the CANRISK questionnaire and OGTT in 417 individuals 
(ages 40-74). In this study, a significant association was found between the glycaemic 
status and the CANRISK score (p<0.01). Of those patients who fell in the low risk 
category, 98% had normal blood glucose, while only 46% of those in the high-risk 
category had blood glucose in the normal range (Talbot & Dunbar, 2011). This study 
was comprised predominantly of Caucasian participants, with 70% being women. 
While it made some correlations between the screening questionnaire and the outcomes 
of the OGTT, it did not specifically indicate the specificity or sensitivity of the 
CANRISK tool in identifying those with glucose metabolism disorders or diabetes. 
Otero, Fong, Papineau, Thome, & Zanetti, (2011) undertook a study of Latin 
American immigrants living in a large urban Canadian centre using a convenience 
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sample of 44 participants. This study aimed to determine the validity of the CANRISK 
questionnaire as part of a screening program to identify those at risk of developing 
diabetes among an immigrant population living in Canada. The participants were 
between 31 to 71 years of age with BMis ranging from 20.1 to 66.4kg/m2 , ofthese 
38.6% were overweight and 9.1% obese. Waist circumference ranged from 68 to 116 
em, with 40.9% being within the normal range and 22.7% within the increased range. 
The researchers administered the questionnaire in addition to HbA1c, FPG and OGTT 
testing. An analysis of the results indicated a high level of false positives in this study 
The CANRISK score indicated that 43.2% of the participants had a slightly elevated 
risk score and 9.1% a moderate risk with 11.4% at high risk. The laboratory values 
showed that the FPG levels ranged from 4.4 to 6.2mmolll, with the OGTT levels from 
2.6 to 8.5mmol/l and HBA1c from 5.1 to 6.4%. This put 90% of the participants within 
the normal range for laboratory values. Of those that did demonstrate abnormal 
laboratory values, all had some level of increased risk in the CANRISK score. There 
were five participants with abnormal lab values: two had a slightly elevated risk, two a 
moderate risk and one a high risk. However, when reviewing this study, there were five 
participants who scored as high risk, four as moderate risk, and 19 as slightly elevated 
risk (Otero, Fong, Papineau Thorne, & Zanetti, 2011). There is no mention of the 
differences between participants with the same risk scores and different laboratory 
values. This throws into doubt the stated fmdings of the authors, as apparently there 
were far more people who would have been tested because of elevated scores then had 
abnormal blood work. 
These findings are echoed in a study by Behan (2005) which separated the risk 
factors and simply assigned risk by counting the number of risk factors a particular 
individual had. In this study, the sensitivity of identifying those with diabetes by risk 
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factors was 97.8% for those with~ 2 risk factors (Behan, 2005). However, there were a 
large number of false positives: of the 480 participants who had normal FPG, 36 had 
more than 4 risk factors. Behan (2005), and Otero, Fong, Papineau Thome, & Zanetti, 
(20 11) all demonstrated high rates of false positives which defeats the purpose of a 
questionnaire. The inclusion of those who do not truly need testing in large numbers 
makes screening more expensive. It also uses more of the patient and health care 
providers' time and resources. The purpose of a risk-screening questionnaire is to 
include only those for testing that are at risk of the disease being screened. It would 
appear that the CANRISK tool requires further evaluation to determine if changes are 
in order to improve the accuracy of the tool. 
In comparison, the Finnish Diabetes Risk Score (FINDRISC), upon which the 
CANRISK is based, is an 8 question risk score that has been specifically studied for its 
ability to identify those with glucose metabolism abnormalities as well as diabetes. 
Three studies were identified and will be reviewed which compare the ability of 
FINDRISC to a variety of tests, including FPG and OGTT, to detect glucose 
abnormalities and predict development of diabetes, (Saaristo et al. 2005; Schwartz et 
al., 2009; Tankova, Chakarova, Atanassova, & Dakovska, 2011). Importantly, all of 
these three studies do so using glucose metabolism disorders as an end point as well as 
diabetes. 
The FINDRISC score was developed to identify subjects at high risk for 
developing type 2 diabetes in the future (Lindstrom et al, 2003). In one study, which 
specifically looked at the ability ofFINDRISC to identify those at risk ofiGT, IGT and 
undiagnosed diabetes, a significant correlation was found between the FINDRIC scores 
and the testing parameters included (Tankova, Chakarova, Atanassova, & Dakovska, 
2011). This Bulgarian study had 2,169 participants (aged over 45 years) who all had at 
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least one risk factor for diabetes. Risk factors included were central obesity, being 
overweight, gestational diabetes, delivery of a baby over 4kg, and a history of IFG, 
IGT, hypertension, lipid abnormalities, or atherosclerotic disease. All participants 
completed the FINDRISC score and had an OGTT performed. The results showed that 
those with NGT had a mean score of 10.1, while those with IFG, or IGT had a mean 
score of 13.8 and 14.4 respectively. When compared to the results of the OGTT, the 
FINDRISC score of > 10 gave a sensitivity of 84% and a specificity of 61%. This 
fmding was supported by other studies (Saaristo et al. 2005; Schwartz et al., 2009). Of 
note, the higher the FINDRISC score the more likely the patient was to have diabetes. 
For example, those with undiagnosed diabetes had a mean score of 15.5. The 
FINDRISC score therefore offers an easy non-invasive short questionnaire, which has 
been proven to identify those with glucose metabolic disorders. The FINDRISC 
demonstrated a much lower rate of false positive risk scores than did the CANRISK 
score. All three studies however consisted of causation populations. A major weakness 
of the FINDRISC tool is the lack of evaluation data available for non-Caucasian 
populations. Further research is needed to explore the use of questionnaires to assist in 
the identification of those with glucose metabolism disorders or at risk of developing 
diabetes. In particular, these questionnaires require further examination to determine 
the clinical application within the context of a multi-ethnic Canadian population. 
Novel Testing Methods. 
This section will examine studies that looked at novel methods to testing to 
answer the question of what is the best test to identify glucose metabolism 
abnormalities at earliest presentation in adults over the age of 18. Three studies were 
identified and selected for review (Abdul-Ghani, Williams, DeFronzo, and Stem, 2007; 
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Maynard, Rohrscheib, Way, Nguyen, & Ediger, 2007; Schwarz, Brunswick, & Calvert, 
2011). For the purposes of ease of reading, the studies have been divided by the kind of 
test methodology used. 
New technology. There were two new non-invasive testing modalities 
examined as part of this review the Ezscan and transcutaneous testing for the presence 
of skin advanced glycation end products. One of these new technologies uses the 
change in conductance of the sweat glands using reverse iontophoresis. Reverse 
iontophoresis is the term used to describe a process in which molecules are removed 
from within the body for detection. In reverse iontophoresis, the negative charge of the 
skin at buffered pH causes it to be selectively permeable to cations causing solvent flow 
towards the anode. This flow is the dominant force allowing movement of neutral 
molecules, including glucose, and sodium, across the skin (Paulley, Delgado-Charro, & 
White, 2010). This technique essentially assesses the function ofthe sweat glands on 
the forehead, palmer surfaces of the hands, and plantar surfaces of the feet. It uses sets 
of electrodes that measure the electrochemical reaction between these electrodes in 
contact with the patient's hands and feet and the chloride ions released by the sweat 
glands (Schwarz, Brunswick, & Calvert, 2011). In order for this screening test to be 
used, the patient must have all four limbs and must be able to stand. Patients who are 
using beta-blockers or any drug that affects the sympathetic nervous system, those with 
nickel allergies, or patients with implantable devices such as pacemakers or 
defibrillators, are not candidates for using this method (Schwartz, Brunswick & Calvert, 
2011). 
Impeto Medical manufactures the device, called EzScan. It has been authorised 
for use in Canada by Health Canada. The use of this device to screen for diabetes has 
been studied in India with a high-risk group of212 participants who also underwent 
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anthropometric testing, blood pressure, OGTT, HBAlc, and FPG (Ramachandran et al., 
201 0). In this comparative study, participants between the ages of 21 and 7 5 years of 
age attending four different facilities (for non-diabetes related conditions), who had risk 
factors for diabetes, such as high BMI or a family history of diabetes, were invited to 
participate. The testing required participants to stand on two of the electrodes in bare 
feet, place the palmer surface of their hands on the other two electrodes, and place a 
headband around the forehead and stand for three minutes. 
When comparing EzScan to FPG and HBAlc on the same participants, EzScan 
had a higher sensitivity (70% and 75%) in uncovering IGT and diabetes then did FPG 
(32% and 29%); the specificity is not stated. The comparison of the sensitivity of 
EzScan to HbAl c in uncovering IGT and diabetes is not presented in numerical values; 
however, it is presented through a graph. Upon analysis of these graphs, it appears that 
EzScan performs better than HbAlc in uncovering both IGT and diabetes. However, a 
more comprehensive report of the associated numerical or statistical values would have 
aided the analysis and interpretation of the findings of this research. 
This research was undertaken on Asian participants exclusively and the authors 
state that this was important given the high prevalence of diabetes and frequently 
having a late onset of IFG in this population. It remains to be seen whether these 
results will hold true for other populations and in larger studies. 
In summary, the research on EzScan found that it had a high sensitivity for 
detecting IGT and diabetes; however, a weakness of the study is that the specificity of 
the testing mechanism is not given. Another limitation of this study is that the validity 
of these fmdings, within the context of a broader multi-ethnic population, is unclear. 
This technology is new and further research is needed to identify the application of 
these novel technologies to a wider population, the specificity and sensitivity, as well as 
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the practical considerations (including cost per test and ease and robustness of the 
equipment) associated with its use. In the next section, another new novel technology 
is examined for use in identifying those with glucose metabolism disorders. 
Transcutaneous testing of the presence of elevated levels of skin advanced 
glycation end products (AGEs) has been developed for use in those at risk of glucose 
metabolism disorders. This testing encompasses spectroscopic measurements of the 
dermal AGEs. It measures the fluorescence of the skin due to AGEs and provides a 
quantitative risk score based on multivariate algorithms. The patient is required to 
place their left forearm in a cradle while seated, and near ultraviolet and blue light are 
emitted on the patients volar arm surface (inside or flexor surface of lower arm); the 
subsequent fluorescence and reflectance are measured within 1 minute (Maynard, 
Rohrscheib, Way, Nguyen, & Ediger, 2007). This method of testing was studied in 351 
participants from a multiethnic population in Albuquerque, New Mexico. The aim of 
the study was to undertake a head-to-head comparison of this testing methodology in 
comparison to FPG and HbA1c. In addition, all patients also underwent an OGTT that 
was used as the reference test. The authors used the ADA guidelines for diagnostic 
classification of diabetes, IGT and IFG to underpin the interpretation of the findings. 
The participants were recruited through advertising in local newspapers and flyers, and 
prospective participants were required to have one or more risk factors for diabetes, as 
per the ADA care guidelines. Participants without a left arm or a previous diagnosis of 
Type 1 or 2 diabetes were excluded from the study. 
The AGE skin testing had a specificity of77.4% and had a sensitivity of74.7%, 
which was greater than the sensitivity ofFPG and HbA1c in this study. The technology 
looks impressive, when compared to the OGTT, given the reported ease of use. As this 
is new technology, there were no other studies identified which did a comparison of the 
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new technology to existing testing mechanisms. The authors concluded that the testing 
mechanism is easy to use and has a good sensitivity when compared to existing testing 
mechanisms (OGTT, HbAlc, and FPG). However, several weaknesses existed in this 
study. There were no indications as to the cost of the new technology, or the skills 
required to use it in a reliable manner. Additionally, there was no indication in the 
study as to the dietary habits of the participants, or whether the results are the same in 
those of different dietary habits. This is important as AGE's levels can be increased by 
the amount of cooked food ingested, particularly if the food is deep-fried. There is also 
no indication whether the sensitivity was better or worse in different age groups. This 
is a consideration with this technology, as AGE's are associated with other age-related 
diseases, cardiovascular disease, and strokes, which may or may not be associated with 
glucose metabolism disorder (Ramasamy et al. , 2005). Therefore, there remain a 
number of unanswered questions about the use of this technology among different age 
groups and those with different dietary habits. Importantly, it should be noted that two 
of the authors of this study, among others, hold the patent on this technology. In 
summary, the new technologies offer the tentative promise of a non-invasive method of 
screening for glucose metabolism disorders, however, further research is warranted. 
In summary, the strengths of these studies examining new modalities of testing 
include the comparison with existing testing modalities. Overall, the limitations are the 
possible cost and the lack of testing on a wide diversity of populations to ensure that the 
findings are consistent across populations. The two studies reviewed had a small 
sample size and had numerous methodological weakness, such as incomplete reporting 
of those excluded from participation in addition to limited detail regarding the costs, 
dietary information, reproducibility, and requirements for use of the technology. Further 
independent research, on a variety of populations, is required to examine the wider 
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clinical application of these novel technologies. The next section will look at the use of 
existing information and tests in a new way to uncover glucose metabolism disorders. 
Novel uses of current testing modalities. There have been a number of 
surrogate indexes of insulin sensitivity, many of which use information derived from 
tests that are done routinely. These indices include the Matsuda index, Stumvoll index, 
A vignon index, oral glucose sensitivity index, and others, all of which use information 
obtained during an OGTT to calculate insulin sensitivity (Muniyappa, Lee, Chen, & 
Quon, 2008). These indexes can be used with others to attempt to identify high-risk 
populations and to clarify the pathogenesis of diabetes. The use ofOGTT and plasma 
insulin levels not only to identify those with glucose metabolism disorders but in an 
equation can assist in the prediction of those who will develop diabetes. This is an 
important feature, given that not all of those who have glucose metabolism disorders 
develop diabetes (Ramachandan et al., 2006). Knowing who is most likely to develop 
diabetes permits much more targeted interventions to delay or prevent progression. 
Abdul-Ghani, Williams, DeFronzo, and Stern (2007) undertook a study to 
identify the best predictor of future Type 2 diabetes. In this study, which was part of 
the San Antonio Heart study, a modified Matsuda index and an insulinogenic index was 
used to determine those who are most at risk of developing Type 2 diabetes. A sample 
of 1551 participants were followed for 7 to 8 years and completed a variety of 
anthropomorphic measures, as well as having plasma glucose and insulin measurements 
undertaken at 0-, 30-,60- and 120-minute intervals during a baseline OGTT. The 
participants were Mexican Americans and non-Hispanic whites aged 25-68, none of 
whom was known to be diabetic at the time. The Matsuda index formula uses the mean 
glucose and insulin concentrations divided by 100,000. The mean is from the five 
74 
TESTING FOR GLUCOSE METABOLI SM DISORDERS 
measurements of insulin and glucose from baseline to 120 minutes in 30-minute 
increments. 
The study by Abdul-Ghani, Williams, DeFronzo, and Stem (2007) used a 
modified Matsuda index, which used plasma insulin and glucose measurements at the 
30-minute post-load point in place of the mean insulin and glucose concentrations. The 
insulinogenic index was obtained by dividing the increase in serum insulin at 30-
minutes post-load by the increase in plasma glucose at 30 minutes post load. These two 
indices together formed the insulin secretion/insulin resistance (disposition) index. 
Ofthe 1,551 subjects included, 1,257 had NGT, 88 had IFG, 154 had IGT, and 
52 had both IFT and IFG at baseline. Over the course of the study, 179 participants 
developed type 2 diabetics. The insulin secretion /insulin resistance indices had the 
greatest ROCs: 0.85 and 0.86, respectively with a P value of <0.0001. Using the 
modified Matsuda index along with the San Antonio Diabetes Prediction Model 
(SADPM) gave an ROC of0.83 , which was still greater than the OGTT which gave an 
ROC of 0. 79. The SAD PM is a risk prediction model that includes age, sex, Mexican-
American ethnicity, BMI, and a family history of diabetes (parent or sibling). The 
SAD PM is similar to other risk scores such as FINDRISC except that it is specifically 
targeted at Mexican Americans in an attempt to estimate the risk of incident diabetes. 
In the course of this study, it was identified that the plasma glucose concentration at 60 
minutes was more strongly correlated with insulin secretion and insulin resistance. The 
authors then looked at the ability of the 60-minute concentration to predict future 
diabetes, which gave an ROC of0.86 (Abdul-Ghani, Williams, DeFronzo, and Stem, 
2007). Likewise, these finding were supported by a study by Bozorgmanesh, Hadaegh, 
Zebetian, and Azizi (201 0) in their study of 3,242 Iranians over 6.3 years. This study 
75 
TESTING FOR GLUCOSE METABOLISM DISORDERS 
similarly found that the SAD PM was a good predictor of diabetes within an Iranian 
target population. 
In summary, this method of testing used a modified OGTT and plasma insulin 
levels to detect both current glucose metabolism abnormalities and predict with a 
significant degree of accuracy the development of future abnormalities. The weakness 
is that the method still requires the patient to fast and to have several phlebotomies. 
This method needs to be tested further amongst different populations with different 
races/ethnicities to determine if there would be the same level of accuracy. 
In the following discussion section, a discussion of the key findings of the 
respective studies examining the testing mechanisms for glucose metabolism disorders 
is presented. In addition, the strengths and weakness of testing mechanisms, their 
applicability to the NP-served population, and overall recommendations for practice, 
research, and education will be presented. 
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Chapter 4 
Discussion 
A cohort of71 studies was critically appraised and a comprehensive overview 
of the available screening tests for glucose metabolism disorders has been presented. 
The review of the literature revealed a number of strengths and weakness in 
contemporary screening modalities for glucose metabolism disorders. In addition, these 
were appraised as to their suitability to the NP-served population and recommendations 
for practice, research and education were identified. 
Key findings 
The literature reviewed for this project clearly indicates that there is no perfect 
test for all populations. There are issues of reduced sensitivity and specificity in some 
populations with almost all glucose metabolism screening tests. The key findings of the 
review indicated the superiority of OGTT in identifying those with glucose metabolism 
disorders regardless of ethnicity/race or heamoglobinopathies (Brohall et al., 2006; 
Coban et al., 2004; Davies et al., 1999; Ford, 2011; Heath, 2011; Herman et al., 2007; 
Hosseinpanah et al., 2006; Janus et al., 2000). The review also identified the 
inaccuracy ofHbA1c as a standalone test in identifying those with glucose metabolism 
abnormalities, particularly in populations with anaemia, and of certain races/ethnicities 
(Anand et al., 2003; Bersoux et al., 2011; Cavagnolli et al., 2011; Cosson et al., 2011). 
It is inherent upon the primary care practitioner to use tests that are best suited to the 
population(s) most at risk. As identified in the findings of this review, the population at 
risk for diabetes is also one that is frequently affected by iron deficiency anaemia. Iron 
deficiency anaemia is an extremely common phenomenon occurring in up to 50% of 
the global population (de Benoist, McLean, Egli, & Cogswell, 2008). Further, the 
review identified there is limited sensitivity and specificity ofFPG in indentifying 
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glucose metabolism disorders; the test's sensitivity/specificity is further reduced when 
used in obese populations and certain raciaVethnic groups (DeFronzo, 2004; Sesti, 
2006). While novel technologies provide some offer the tentative promise of a non-
invasive method of screening for glucose metabolism disorders, these approaches 
require further research to assess its potential clinical application (Maynard, 
Rohrscheib, Way, Nguyen, & Ediger, 2007;Schwartz, Brunswick & Calvert, 2011). 
Finally, analysis of the literature evaluating the use of an insulinogenic index, 
such as the Matsuda index, to identify future diabetics would indicate that these indexes 
should not be done on a universal screening basis. Most individuals who are at risk of 
glucose metabolism disorders have risk factors that can be identified based on their 
medical history or by having the patient complete a questionnaire. The choice of 
questionnaire would depend also on patient literacy level and efficacy within the 
population served. Thus, an opportunistic form of screening would prove to have fewer 
costs and be more efficient than universal screening of asymptomatic patients. 
Obviously, some populations will be the target of a greater amount of screening as their 
race/ ethnicity or socioeconomic standing puts them at a higher risk than others. 
Overall, the analysis of the fmdings of the contemporary research literature 
would indicate that practitioners need to offer biochemical testing after a risk evaluation 
has been completed, regardless of the testing modality chosen. The evidence supports 
the use of a validated risk calculator in primary care practice to inform the type and 
frequency of screening a given patient might require (Bozorgmanesh, Hadaegh, 
Zebetian, and Azizi, 2010 ; Saaristo et al., 2005; Schwartz et al. , 2009). 
As discussed previously, there are several diabetes screening guidelines most 
have included recommendations for screening for glucose metabolism disorders (see 
Appendix B). It is important to remember that the guidelines were developed in order 
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to screen for diabetes, not glucose metabolism disorders. This is an important point that 
is sometimes overlooked, as the tests used to identify the one may not be suitable for 
identifying the other. The first biochemical tests indicated by most guidelines are those 
that seek to identify persistent hyperglycemia, not to evaluate glucose metabolism. The 
BC guidelines indicate that FPG is the initial test for screening, with other testing being 
implemented based on the initial FPG values (British Columbia Medical Association & 
British Columbia Ministry of Health, 2010). As has been noted above, many patients 
will remain normoglyceamic on an FPG in the presence of glucose metabolism 
disorders. Thus, this condition will be missed ifFPG alone is used to screen patients 
who, for reasons of body habitus, familial conditions, or co-morbidities, are at risk of 
glucose metabolism disorders. What is also reported, but often in general terms, is the 
need to exclude certain conditions when using HbA1c. Both the Canadian and BC 
guidelines caution not to use HbA1c in patients who have conditions that may affect the 
test, though these are not clearly articulated. It is for this reason that one of the key 
recommendations from this comprehensive literature review is that the OGTT be used 
to identify those with glucose metabolism disorders. While HBA1c may also be used, 
its sensitivity and specificity are only significantly increased in identifying glucose 
metabolism disorder when it is used in conjunction with FPG, and therefore is not 
recommended as a standalone test. 
Another key finding of this review is that patients are frequently not adequately 
prepared for testing, particularly for those tests that require fasting. As discussed in the 
section examining the OGTT literature, even in studies that undertook specific 
education of participants regarding fasting and preparation requirements, typically, 50% 
of the study participants showed up for testing without having done the required fast 
(Selvin, Craininceanu, Brancati & Coresh, 2012). Such screening is costly and time 
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intensive, even more so if these processes are compromised due to poor preparation. 
Strategies for improved patient uptake of fasting and preparation information is 
required to optimize the outcomes of screening for glucose metabolism disorders. 
Applicability to the NP-served population 
NPs in primary care, similar to other primary care providers, can play an 
integral role in the identification of those with glucose metabolism disorders. After a 
careful history and anthropomorphic measures, the clinician must make an educated 
assessment of the probability of disease presence. In assessing the disease presence, 
they must go further and try to determine where (given the patient history and 
presentation) that patient might be in the continuum of diabetes. In part, the decision of 
the best test for the individual patient is determined by the ability of the patient to meet 
the preparation requirements for testing, as well as through an examination of racial or 
ethnic factors and haematological conditions that may impact upon the choice of testing 
modality. Overall, the NP in primary care is well situated to choose the best test for the 
patient on an individual basis. NP's are also able to assess the patient perception of risk 
and their readiness to participate in possible interventions. 
In health belief and change behaviour studies, the perception of risk is inherent 
in the change theory (Herschfield, Chirrey, Thesenvitz, & Chandran, 2004). The 
patient must understand and perceive the risk as personal in order to contemplate 
changes that require altered behaviour (Herschfield et al., 2004). The NP is well 
prepared by education to help patient both recognise the risk and plan interventions to 
reduce the risk. Coaching and working with patients on interventions is time 
consuming, it is therefore important that those at the greatest risk of developing 
diabetes are identified early and have the opportunity for delay or prevention of onset. It 
is in this capacity that instruments like the Matsuda index become valuable. This index 
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provided 86% accuracy in identifying those who, within the next 5 years, would 
become diabetic (Abdul-Ghani, Williams, DeFronzo, and Stern, 2007). 
This offers a significant ability for NPs to identify those at greatest risk at an 
early stage, and on whom time and resources expended could change the course of the 
disease trajectory. It offers the patient a clear indication of a future disease that they 
can prevent or reduce in impact. It also offers the NP a clear population on which to 
focus interventions either lifestyle or pharmaceutical to attempt to prevent or delay the 
development of diabetes and its consequent sequelae. This therefore, should offer a 
cost benefit to those who have interventions that prevent diabetes or its sequelae from 
developing. 
As discussed in the background section it is estimated that at the current rates 
diabetes will cost the Canadian healthcare system $16.9 billion per year (Canadian 
Diabetes Association, 2009; Public Health Agency of Canada, 2011). It is true that at 
present there is limited evidence that early intervention in glucose metabolism disorders 
offer a saving to the health care system or the patient. One such study was a small 
investigation undertaken in the UK with 55 participants from 7 different practices 
(Savas & Grady, 2012). This study included primary care practices that offered 
interventions through a pre-existing call service. This service provided motivational 
support with lifestyle and dietary changes by telephone from non-clinical staff to those 
patients identified as having a glucose metabolism disorder through an OGTT. The 
study hypothesised that targeted interventions would reduce the number of those who 
develop diabetes over 10 years and would provide cost saving. The study demonstrated 
a reduction in the number of patients who developed diabetes. The costs of the 
program were recovered by saving in expenditures on patients who did not become 
diabetic within 3 years and 5 months. Of note, only the primary costs of care for 
81 
TESTING FOR GLU COSE METABOLI SM DIS ORDERS 
diabetic patients, such as primary care contact and prescriptions, were included in the 
cost of care. The secondary costs of hospitalization and costs to the patient were not 
included. If these costs were included, cost recovery would be much more pronounced. 
Recommendations 
The recommendations arising from this review are summarised in table 2. The 
recommendations that arise out of this comprehensive review are that all biometric 
testing be preceded by a validated risk calculator. In particular, the OGTT is 
recommended to be the foremost test as it has the highest rate of sensitivity and 
specificity in identifying glucose metabolism disorders and is not affected by 
heamoglobinopathies, like anemia, or by race/ethnicity. Consideration must be given 
for doing plasma insulin levels with the OGTT to allow a Matsuda index for prediction 
of the development of diabetes. In those areas or patients were this is not possible, a 
HbAl c and FPG could be used together to increase the accuracy of identification of 
glucose metabolism disorders. It is also incumbent upon primary care practitioners to 
perform adequate assessment or testing of possible confounding factors for tests, such 
as anaemia. 
The analysis of the fmdings of this review revealed a wide range of factors that 
can impact upon screening for glucose metabolism disorders. It is essential that all 
primary care providers be provided with adequate education to identify some of these 
common factors that may affect common laboratory tests and the implication this has 
for patient care. These factors would include the impact ofhaematological disorders 
such as anaemia, but also consideration of issues of race/ethnicity, obesity and tube 
glycation. In those areas where points of care devices, such as glucose meters, are used 
for screening, it is critical that the user understands the limitations and level of 
inaccuracy inherent in their use. In addition, providing easily available patient 
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education related to the preparation for tests, such as OGTT, is a key strategy to 
optimizing the accuracy of testing. As previously discussed, patients frequently to not 
understand the purpose of the tests or the preparation required. There is a need for 
consistent, easily comprehendible patient education material that can be provided 
regarding screening tests. 
A number of areas for future research were identified during this comprehensive 
review. Firstly, research into the ability ofGCT to identify glucose metabolism 
disorders in non-pregnant adults would also be of great benefit. The glucose challenge 
test has many of the benefits ofOGTT with fewer drawbacks. For example, the GCT 
can be done at any time of day, in a non-fasting state, and still offers an accurate test of 
glucose metabolism. Secondly, further research is warranted to explore screening 
modalities in broad and multi-ethnic populations to assist clinicians in their decision 
making with regard to selecting appropriate screening tests. Thirdly, further research is 
needed to explore new technologies, particularly those that offer non-invasive testing 
which is more palatable to most patients. 
Finally, while not a focus of this review, further research is needed to explore 
the cost benefit of testing for glucose metabolism disorders, as well as for interventions 
to slow or prevent progression to diabetes. There is a great deal of research available 
on the analysis of cost benefits of early intervention and tight glycemic control of 
diabetics, but much less on the benefit of intervention prior to development of diabetes. 
Understanding the need to test for glucose metabolism disorders and the mechanism 
with which to do so it critical to addressing the epidemic of diabetes in Canada. 
Diabetes can be prevented and identification of glucose metabolism abnormalities in 
their earliest stages is key to prevention and delay. 
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Table 2 Recommendations for Practice, Education, and Research. 
Practice OGTT should be the first line screening test used for identification of those with 
glucose metabolism disorders. 
Consideration should be given to doing plasma insulin levels at the same time to allow 
insulinogenic index, such as the Matsuda index, to be calculated. 
In those situations where OGTT is not feasible, HbAlc and FPG need to be performed 
together to maximise accuracy. 
Where HbAlc is to be used as a standalone test for GMD, providers should consider 
the need to test for confounding factors such as anaemia. 
Education Primary health care providers, include NPs, would benefit from education regarding 
common factors that affect laboratory tests. 
General education for both health care providers and the public regarding the 
limitations and accuracy of personal glucose meters 
Preparation and distribution of education materials related to blood test preparation at 
appropriate literacy levels would improve test preparation. 
Research Research related to the use of Glucose Challenge tests in non-pregnant adults for 
identification of glucose metabolism disorders would be beneficial. 
Further research is needed to explore screening modalities in broad and multi-
ethnic populations. 
Costs benefit analysis on screening for glucose metabolism disorders and for 
interventions prior to the occurrence of diabetes is required. 
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Summary 
Glucose metabolism disorders are a major and growing problem in Canada. 
There is an estimated 5 million people in Canada that are known to have glucose 
metabolism disorders that are often a precursor to Type 2 diabetes (DeFronzo, 2004; 
Sesti, 2006). There are a variety of tests that are used in screening for diabetes and 
have been used to screen for glucose metabolism disorders. A comprehensive review 
of the contemporary literature was undertaken to answer the question "What is the best 
test to identify glucose metabolism abnormalities at its earliest presentation in adults 
over the age of 18". A review of 71 studies identified strengths and weaknesses of 
screening modalities, including novel technologies. The key finding was that OGTT is 
the most sensitive test in all populations for identification of glucose metabolism 
disorders. It is also clear that despite recommendations by contemporary clinical 
guidelines, the use ofHbAlc in screening is ill suited to identification of glucose 
metabolism abnormalities. It is therefore recommended that OGTT be used were 
feasible in testing for glucose metabolism abnormalities, preferably with plasma insulin 
levels being undertaken at the same time to facilitate the use of an insulinogenic index. 
If this is not possible, consideration should be given for whether GCT or HbAlc and 
FPG done together should be undertaken. 
Identification of patients with glucose metabolism disorders at the earliest stage 
gives both the patient and the primary health care provider the opportunity to 
implement interventions that can delay or prevent the progression to diabetes. The 
prevention of diabetes has the potential to significantly reduce health care costs and in 
turn will improve the quality of life for patients. 
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rs
 
P
o
p
u
la
ti
o
n
 a
n
d
 S
et
ti
ng
 
E
xc
lu
si
on
 C
ri
te
ri
a 
S
tr
en
g
th
s 
W
ea
k
n
es
s 
K
ey
 f
in
di
ng
s 
A
na
nd
 e
t 
al
. 
-9
48
 m
ul
ti
-e
th
ni
c 
-K
no
w
n 
di
ab
et
ic
s,
 c
hi
ld
re
n,
 
-U
se
d 
bo
th
 F
PG
 a
nd
 O
G
T
T
 to
 
-S
ay
s 
ra
nd
om
ly
 r
ec
ru
it
ed
: 
U
si
ng
 A
D
A
 c
ut
-o
ff
fo
r 
pa
rt
ic
ip
an
ts
. 
in
ab
ili
ty
 to
 f
as
t 
fo
r 
8 
ho
ur
s 
co
m
pa
re
 
no
 m
et
ho
do
lo
gy
 g
iv
en
 
H
bA
 I 
c 
ga
ve
 s
en
si
ti
vi
ty
 o
f 
(2
00
3)
 
-R
an
do
m
ly
 r
ec
ru
it
ed
 
-T
es
ti
ng
 c
ri
te
ri
a 
cl
ea
rl
y 
la
id
 o
ut
 
-N
o 
in
di
ca
ti
on
 o
f s
cr
ee
ni
ng
 
48
%
. 
C
on
si
de
ra
bl
e 
et
hn
ic
 
sa
m
pl
e 
in
vi
te
d 
to
 
or
 te
st
in
g 
fo
r 
th
os
e 
di
ff
er
en
ce
s.
 
B
es
t C
ut
-o
ff
 fo
r 
un
de
rg
o 
ca
rd
io
va
sc
ul
ar
 
co
nd
it
io
ns
 w
hi
ch
 e
ff
ec
t 
se
ns
it
iv
it
y 
an
d 
sp
ec
if
ic
it
y 
as
se
ss
m
en
t 
H
bA
 I c
 s
uc
h 
as
 
ov
er
al
l:
 >
5.
9%
. 
-U
rb
an
 C
an
ad
a 
he
am
og
lo
bi
no
pa
th
ie
s,
 
C
on
cl
us
io
n 
th
at
 H
b
A
lc
 
al
co
ho
li
sm
 o
r 
li
ve
r 
fa
il
ur
e 
sh
ou
ld
 n
ot
 b
e 
us
ed
 a
lo
ne
 
-N
o 
in
di
ca
ti
on
 o
f t
ho
se
 o
n 
(u
se
 i
n 
co
m
bi
na
ti
on
 w
it
h 
m
ed
ic
at
io
n 
w
hi
ch
 e
ff
ec
t 
F
P
G
).
 
H
bA
 I 
c 
an
d 
FP
G
 e
xc
lu
de
d 
B
er
na
l-
L
op
ez
 
-2
27
0 
C
au
ca
si
an
 
-K
no
w
n 
di
ab
et
ic
s,
 te
rm
in
al
ly
 i
ll,
 
-E
xc
lu
si
on
 c
ri
te
ri
a 
cl
ea
rl
y 
la
id
 
-D
id
 n
ot
 d
o 
a 
O
G
T
T
 f
or
 
H
bA
 I 
c 
ga
ve
 a
 h
ig
he
r 
S
pa
ni
ar
ds
 w
ho
 a
tt
en
d 
an
 
pr
eg
na
nt
, o
r 
su
ff
er
in
g 
a 
se
ve
re
 
ou
t: 
di
d 
no
t e
xc
lu
de
 th
os
e 
w
it
h 
co
m
pa
ri
so
n 
pr
ev
al
en
ce
 o
f p
re
di
ab
et
es
 
et
 a
l. 
(2
01
1)
 
ur
ba
n 
he
al
th
 c
en
tr
e.
 
ps
yc
hi
at
ri
c 
di
so
rd
er
 
an
ae
m
ia
 o
r 
ki
dn
ey
 f
ai
lu
re
 i
t d
id
 
-O
nl
y 
di
d 
a 
si
ng
le
 b
lo
od
 
an
d 
di
ab
et
es
 t
ha
n 
F
P
G
. 
-A
na
ly
ti
ca
l 
cr
os
s 
te
st
 f
or
 b
ot
h 
an
d 
in
cl
ud
e 
in
 
te
st
 f
or
 F
P
G
 a
nd
 H
B
A
 I 
c 
no
 
A
ut
ho
rs
 h
yp
ot
he
si
se
d 
th
at
 
se
ct
io
na
l 
st
ud
y 
in
 a
 
fi
nd
in
gs
. 
co
nf
ir
m
at
or
y 
te
st
in
g 
th
is
 c
ou
ld
 b
e 
du
e 
to
 
ra
nd
om
 s
am
pl
e 
-D
id
 d
o 
ed
uc
at
io
na
l, 
-P
ar
ti
ci
pa
nt
s 
w
er
e 
al
l 
gl
yc
ol
ys
is
 d
ur
in
g 
tr
an
sp
or
t 
-U
rb
an
 S
pa
in
 
ch
ol
es
te
ro
l,
 a
nd
 s
m
ok
in
g 
C
au
ca
si
an
 
o
fF
P
G
 a
nd
, 
th
er
ef
or
e,
 is
 a
 
as
se
ss
m
en
ts
. 
pr
e-
an
al
yt
ic
al
 e
rr
or
. 
D
oe
s 
-T
es
ti
ng
 c
ri
te
ri
a 
la
id
 o
ut
 
re
in
fo
rc
e 
th
e 
pr
e-
an
al
yt
ic
al
 
sp
ec
if
ic
al
ly
 d
id
 n
ot
 i
m
m
er
se
 
in
st
ab
il
it
y 
o
f p
la
sm
a 
gl
uc
os
e.
 
F
P
G
 in
 i
ce
 f
lu
rr
y 
an
d 
di
d 
'n
or
m
al
' t
ra
ns
po
rt
at
io
n 
an
d 
an
al
ys
is
 o
fF
P
G
 to
 r
ep
li
ca
te
 
'r
ea
l 
w
or
ld
' r
es
ul
ts
. 
B
er
so
ux
 e
t a
l. 
-2
42
 p
ar
ti
ci
pa
nt
s 
al
re
ad
y 
-U
ns
ta
bl
e 
he
al
th
, n
ot
 a
m
bu
la
to
ry
, 
C
om
pa
ri
so
n 
to
 b
ot
h 
F
P
G
 a
nd
 
-V
er
y 
sm
al
l 
st
ud
y,
 o
ld
er
 
S
ub
st
an
ti
al
 n
um
be
r 
o
f 
kn
ow
n 
to
 h
av
e 
pr
eg
na
nt
 
O
G
T
T
 a
t 
ba
se
li
ne
, 
6 
an
d 
12
 
ad
ul
ts
 m
ea
n 
ag
e 
62
 y
ea
rs
, 
pa
ti
en
ts
 w
ith
 p
re
di
ab
et
es
 
pr
ed
ia
be
te
s 
in
 c
li
ni
c-
-R
ec
en
t 
hi
st
or
y 
o
f a
cu
te
 i
ll
ne
ss
, 
m
on
th
s 
m
os
tl
y 
C
au
ca
si
an
 8
8%
 
w
ou
ld
 b
e 
m
is
se
d 
if
H
b
A
lc
 
1
1
3
 
T
E
S
T
IN
G
 
FO
R
 
G
L
U
C
O
SE
 
M
E
T
A
B
O
L
IS
M
 
D
IS
O
R
D
E
R
S 
(2
01
1)
 
ba
se
d 
di
ab
et
es
 
ho
sp
it
al
iz
at
io
ns
, 
tr
an
sf
us
io
ns
, o
r 
-E
xc
lu
si
on
 c
ri
te
ri
a 
cl
ea
rl
y 
la
id
 
-T
im
e 
o
f d
ay
 o
f t
es
ti
ng
, 
an
d 
al
on
e 
w
as
 u
se
d 
fo
r 
di
ag
no
si
s.
 
pr
ev
en
ti
on
 p
ro
gr
am
. 
ev
id
en
ce
 o
f a
na
em
ia
 
ou
t. 
te
st
in
g 
m
od
al
it
y 
im
m
er
si
on
 
O
nl
y 
28
%
 o
f p
re
di
ab
et
ic
 
-C
on
ve
ni
en
ce
 s
am
pl
e 
-A
na
ly
ze
r 
us
ed
 i
s 
de
ta
il
ed
. 
et
c.
 i
s 
no
t g
iv
en
 a
lt
ho
ug
h 
pa
ti
en
ts
 h
ad
 H
bA
 I c
 o
f 6
-
-U
ni
te
d 
S
ta
te
s 
re
fe
re
nc
e 
is
 m
ad
e 
to
 t
he
 
6.
4%
 e
ve
n 
if
 u
si
ng
 H
b
A
lc
 o
f 
la
rg
er
 D
E
A
L
 s
tu
dy
 o
f 
5.
7-
6.
4%
, o
nl
y 
65
.3
%
 w
er
e 
w
hi
ch
 t
hi
s 
w
as
 a
 p
ar
t 
di
ag
no
se
d
. 
C
av
ag
no
ll
i 
et
 
-4
98
 h
ig
h 
ri
sk
 p
at
ie
nt
s 
-A
ll 
pa
rt
ic
ip
an
ts
 w
it
h 
co
nd
it
io
ns
 
-D
id
 t
es
t 
fo
r 
an
em
ia
, 
ki
dn
ey
 
-S
m
al
l 
nu
m
be
r 
be
ca
us
e 
o
f 
H
b
A
ic
 o
f>
6.
5%
 h
ad
 
w
ho
 h
ad
 b
ee
n 
re
fe
rr
ed
 
kn
ow
n 
to
 a
ff
ec
t 
H
bA
 I 
c 
w
er
e 
fa
il
ur
e 
an
d 
ri
sk
 g
ro
up
 h
ad
 a
 h
ig
h 
se
ns
it
iv
it
y 
o
f2
0
.9
%
 b
ut
 
al
. 
(2
01
1)
 
fo
rO
G
T
T
 
ex
cl
ud
ed
. 
he
am
og
lo
bi
no
pa
th
ie
s 
as
 w
el
l 
pr
ev
al
en
ce
 r
at
e 
o
f d
ia
be
te
s 
sp
ec
if
ic
it
y 
of
95
.3
%
. 
' 
-C
on
ve
ni
en
ce
 s
am
pl
e 
-A
du
lt
s 
as
 e
xc
lu
di
ng
 p
at
ie
nt
 w
it
h 
us
in
g 
O
G
T
T
 a
nd
 F
P
G
 2
3 
H
b
A
IC
 o
f6
%
 h
ad
 
-U
rb
an
 B
ra
zi
l 
di
so
rd
er
s 
kn
ow
n 
to
 a
ff
ec
t 
I%
 d
ia
gn
os
ed
 w
it
h 
se
ns
it
iv
it
y 
o
f7
4
.2
%
 a
nd
 
H
b
A
ic
. 
di
ab
et
es
 a
t 
ba
se
li
ne
 
sp
ec
if
ic
it
y 
o
f7
2
%
. 
P
oo
r 
-D
id
 a
na
ly
se
 u
si
ng
 a
 v
ar
ie
ty
 o
f 
-8
6%
 C
au
ca
si
an
: 
do
es
 n
ot
 
di
ag
no
st
ic
 p
er
fo
rm
an
ce
 o
f 
cu
t-
of
fs
 to
 d
et
er
m
in
e 
if
 
in
di
ca
te
 w
ha
t 
et
hn
ic
it
y 
o
f 
H
bA
 I 
c.
 
G
lu
co
se
-b
as
ed
 
se
ns
it
iv
it
y 
im
pr
ov
ed
 w
ith
 
ot
he
r 
14
%
 w
as
 
m
et
ho
d 
an
d 
H
bA
 I c
 a
pp
ea
r 
ch
an
ge
 o
f c
ut
-o
ff
. 
to
 i
de
nt
if
y 
di
ff
er
en
t 
-D
id
 c
om
pa
re
 H
bA
 I 
c 
to
 b
ot
h 
po
pu
la
ti
on
s.
 
FP
G
 a
nd
 O
G
T
T
. 
C
ho
i 
et
 a
l. 
-9
37
5 
ad
ul
t 
pa
rt
ic
ip
an
ts
: 
-n
ot
 m
en
ta
ll
y 
an
d 
ph
ys
ic
al
ly
 w
el
l 
-L
ar
ge
 n
um
be
r 
o
f p
ar
ti
ci
pa
nt
s 
-D
oe
s 
no
t 
gi
ve
 d
at
a 
o
f t
he
 
T
ha
t 
H
bA
 I 
c 
w
it
h 
a 
cu
t-
of
f o
f 
re
si
de
nt
s 
o
f t
w
o 
en
ou
gh
 to
 p
ar
ti
ci
pa
te
, 
kn
ow
n 
to
 
fo
ll
ow
ed
 f
or
 6
 y
ea
rs
 
30
%
 w
ho
 r
ef
us
ed
 to
 
5.
9%
 p
ro
du
ce
d 
th
e 
(2
01
1)
 
ge
og
ra
ph
ic
al
 l
oc
at
io
ns
 in
 
be
 d
ia
be
ti
c,
 u
nd
er
 4
0 
or
 o
ve
r 
69
 
-O
G
T
T
 d
on
e 
in
 a
dd
it
io
n 
to
 
pa
rt
ic
ip
at
e 
m
ax
im
um
 s
en
si
ti
vi
ty
 o
f6
8
%
 
K
or
ea
. 
ye
ar
s 
o
fa
g
e 
H
bA
 I 
c 
on
 a
ll 
pa
rt
ic
ip
an
ts
 
-D
oe
s 
no
t 
in
di
ca
te
 i
ft
he
re
 
an
d 
sp
ec
if
ic
it
y 
of
91
 %
. 
In
 
-P
ro
sp
ec
ti
ve
 p
op
ul
at
io
n-
-M
ul
ti
pl
e 
cu
t-
of
f p
oi
nt
s 
us
ed
 to
 
w
as
 e
xc
lu
si
on
 o
r 
sc
re
en
in
g 
th
os
e 
w
it
h 
a 
H
B
A
 I c
 o
f 
ba
se
d 
co
ho
rt
 s
tu
dy
 
de
te
rm
in
e 
op
ti
m
um
 s
en
si
ti
vi
ty
 
fo
r 
he
am
og
lo
bi
no
pa
th
ie
s 
>
5.
6%
, 
m
en
 h
ad
 a
 2
.4
 f
ol
d 
-5
0%
 r
ur
al
 5
0%
 u
rb
an
 
an
d 
sp
ec
if
ic
it
y 
-D
oe
s 
re
fe
r 
to
 a
no
th
er
 
an
d 
w
om
en
 a
 3
 .I
 f
ol
d 
K
or
ea
 
ar
ti
cl
e 
fo
r 
pa
rt
ic
ip
an
t 
in
cr
ea
se
 in
 r
is
k 
o
f 
de
ta
il
s 
bu
t t
ha
t a
ls
o 
do
es
 
de
ve
lo
pi
ng
 d
ia
be
te
s 
in
 t
he
 
no
t 
in
di
ca
te
 s
cr
ee
ni
ng
 f
or
 
ne
xt
 6
 y
ea
rs
. 
U
su
al
 
an
y 
co
nd
it
io
ns
 w
hi
ch
 
sc
re
en
in
g 
te
st
 a
nd
 p
re
di
ct
iv
e,
 
w
ou
ld
 a
ff
ec
t 
H
B
A
ic
 
bu
t o
nl
y 
fo
r 
th
os
e 
ab
ov
e 
cu
t-
-H
om
og
en
ou
s 
K
or
ea
n 
of
fs
 
po
pu
la
ti
on
 
C
o 
ba
n,
 
-5
0 
pa
ti
en
ts
 w
it
h 
ir
on
 
-G
lu
co
se
 m
et
ab
ol
is
m
 
D
es
cr
ip
ti
on
 o
f 
-V
er
y 
sm
al
l 
st
ud
y 
M
ea
n 
H
b
A
ic
 in
 a
na
em
ic
 
de
fi
ci
en
cy
 a
na
em
ia
 
ab
no
rm
al
it
ie
s,
 
in
cl
us
io
n/
ex
cl
us
io
n 
cr
it
er
ia
 
-E
th
ni
ca
ll
y 
si
m
il
ar
: 
al
l 
gr
ou
p 
w
as
 7
.4
%
 b
ef
or
e 
11
4 
T
E
S
T
IN
G
 
FO
R
 
G
L
U
C
O
SE
 
M
E
T
A
B
O
L
IS
M
 
D
IS
O
R
D
E
R
S 
O
zd
og
an
, a
nd
 
m
at
ch
ed
 w
it
h 
50
 n
on
-
he
am
og
lo
bi
no
pa
th
ie
s,
 h
em
ol
yt
ic
 
w
as
 c
le
ar
, a
s 
w
as
 t
es
ti
ng
 
C
au
ca
si
an
 T
ur
ki
sh
 
tr
ea
tm
en
t 
an
d 
O
G
T
T
 w
as
 n
o 
ir
on
 d
ef
ic
ie
nt
 p
at
ie
nt
s 
fo
r 
an
ae
m
ia
, 
ch
ro
ni
c 
al
co
ho
l 
pr
ot
oc
ol
 a
nd
 t
re
at
m
en
t 
-D
oe
s 
no
t 
sa
y 
ho
w
 
di
ff
er
en
t 
fr
om
 c
on
tr
ol
 g
ro
up
. 
T
im
ur
ag
ao
gl
u 
ag
e 
an
d 
se
x.
 
in
ge
st
io
n,
 c
hr
on
ic
 r
en
al
 f
ai
lu
re
 o
r 
pr
og
ra
m
 f
or
 i
ro
n 
de
fi
ci
en
cy
 
re
cr
ui
te
d 
A
ft
er
 tr
ea
tm
en
t,
 m
ea
n 
-N
o 
in
di
ca
ti
on
 o
f 
li
ve
r 
di
se
as
e 
pa
rt
ic
ip
an
ts
. 
H
bA
 I 
c 
o
f a
na
em
ic
 g
ro
up
 
(2
00
4)
 
re
cr
ui
tm
en
t t
ec
hn
iq
ue
s 
-U
nd
er
 a
ge
 1
8.
 
w
as
 6
.2
%
. I
ro
n 
de
fi
ci
en
cy
 
-U
rb
an
 T
ur
ke
y 
an
ae
m
ia
 v
er
y 
co
m
m
on
 a
nd
 i
t 
is
 s
ho
w
n 
to
 i
nc
re
as
es
 H
bA
 I 
c 
an
d 
m
us
t 
be
 t
ak
en
 i
nt
o 
ac
co
un
t 
w
he
n 
te
st
in
g.
 
C
os
so
n 
et
 a
l. 
-I
 1
57
 o
ve
rw
ei
gh
t 
-u
nd
er
 2
0 
ye
ar
s 
o
f a
ge
, 
-H
ig
h 
ri
sk
 g
ro
up
 t
ha
t 
w
ou
ld
 
-N
o 
in
di
ca
ti
on
 o
f a
ny
 
O
G
T
T
 a
nd
 H
bA
 I 
c 
id
en
ti
fi
ed
 
pa
ti
en
ts
 w
ho
 w
er
e 
pr
ev
io
us
ly
 k
no
w
n 
to
 b
e 
di
ab
et
ic
 -
us
ua
ll
y 
be
 s
cr
ee
ne
d 
in
 m
os
t 
ch
ec
ks
 f
or
 c
on
di
ti
on
s 
pa
ti
en
ts
 w
it
h 
th
e 
sa
m
e 
ri
sk
s 
(2
01
1)
 
re
fe
rr
ed
 f
or
 t
re
at
m
en
t o
f 
ac
ut
el
y 
ill
, 
B
M
I 
o
f 
le
ss
 t
ha
n 
pr
ac
ti
ce
s.
 
w
hi
ch
 m
ig
ht
 a
ff
ec
t 
H
bA
 I 
c 
bu
t d
id
 n
ot
 i
de
nt
ifY
 t
he
 s
am
e 
ob
es
it
y.
 
25
kg
/m
2 
-M
ix
ed
 e
th
ni
ci
ty
: E
ur
op
ea
ns
 
le
ve
ls
 
pa
ti
en
ts
. 
H
bA
 I 
c 
ga
ve
 4
1.
3%
 
-A
ll
 a
du
lt
s 
(7
9
.8
%
),
 fr
om
 N
or
th
 A
fr
ic
a 
-D
id
 n
ot
 b
re
ak
do
w
n 
re
su
lt
s 
o
f p
at
ie
nt
 in
te
rm
ed
ia
te
 
-E
co
no
m
ic
al
ly
 d
ep
ri
ve
d 
(1
2.
3%
),
 a
nd
 f
ro
m
 S
ub
-
by
 e
th
ni
c 
gr
ou
p 
so
 n
o 
w
ay
 
hy
pe
rg
ly
ca
em
ia
, a
nd
 9
.8
%
 
su
bu
rb
 o
f P
ar
is
, F
ra
nc
e 
S
ah
ar
an
 A
fr
ic
a 
(6
.3
%
) 
an
d 
of
kn
ow
in
g 
if
 re
su
lt
s 
di
ab
et
es
, w
he
re
as
 O
G
T
T
 
-C
on
ve
ni
en
ce
 s
am
pl
e 
A
si
a 
(2
.1
%
).
 
-T
es
ti
ng
 
am
on
gs
t C
au
ca
si
an
s 
w
er
e 
ga
ve
 2
6.
5%
 i
nt
er
m
ed
ia
te
 
-U
rb
an
 F
ra
nc
e 
m
ec
ha
ni
sm
 i
s 
cl
ea
rl
y 
la
id
 o
ut
. 
di
ff
er
en
t f
or
m
 t
ha
t o
f o
th
er
 
hy
pe
rg
ly
ce
m
ia
 a
nd
 6
.6
%
 
-T
es
ti
ng
 f
or
 b
ot
h 
dy
sg
ly
ce
m
ia
 
et
hn
ic
it
ie
s/
ra
ce
s 
di
ab
et
es
. 
U
nc
le
ar
 w
he
th
er
 
an
d 
D
ia
be
te
s.
 
th
is
 i
s 
du
e 
to
 e
th
ni
c 
di
ff
er
en
ce
 o
r 
be
ca
us
e 
o
f 
ob
es
it
y_.
 
C
os
ta
 e
t a
l. 
-1
14
4 
in
di
vi
du
al
s 
-C
au
ca
si
an
s 
yo
un
ge
r 
th
an
 4
5 
or
 
-S
iz
e 
o
f g
ro
up
 
-D
oe
s 
no
t 
gi
ve
 d
et
ai
ls
 o
f 
F
in
di
ng
s 
di
d 
no
t 
su
pp
or
t 
us
e 
at
te
nd
in
g 
18
 d
if
fe
re
nt
 
ol
de
r 
th
an
 7
5 
ye
ar
s 
ol
d 
-P
ri
m
ar
y 
he
al
th
 c
ar
e 
se
tt
in
g 
ho
w
 o
r 
w
hy
 i
nd
iv
id
ua
ls
 
o
fH
b
A
lc
 a
lo
ne
 a
s 
a 
(2
01
1)
 
pr
im
ar
y 
he
al
th
 c
ar
e 
-H
av
in
g 
a 
se
ve
re
 p
sy
ch
ia
tr
ic
 
-U
se
d 
F
IN
D
R
IS
C
 8
 i
te
m
 
w
er
e 
re
.cr
ui
te
d 
sc
re
en
in
g 
to
ol
. 
D
ef
in
in
g 
ce
nt
er
s.
 
di
so
rd
er
, c
hr
on
ic
 k
id
ne
y
, l
iv
er
, o
r 
qu
es
ti
on
na
ir
e 
fi
rs
t 
th
en
 O
G
T
T
 
di
ab
et
es
 w
it
h 
H
bA
 I
 c 
-P
ro
sp
ec
ti
ve
 p
op
ul
at
io
n-
bl
oo
d 
di
se
as
e,
 i
nc
lu
di
ng
 s
ev
er
e 
an
d 
H
bA
lc
. 
si
gn
if
ic
an
tl
y 
re
du
ce
d 
ba
se
d 
st
ud
y 
ir
on
 d
ef
ic
ie
nc
y 
an
ae
m
ia
 
-L
oo
ke
d 
fo
r 
al
l 
fo
rm
s 
o
f 
pr
ev
al
en
ce
 c
om
pa
re
d 
to
 
-U
rb
an
 S
pa
in
 
gl
uc
os
e 
m
et
ab
ol
is
m
 d
is
or
de
rs
 
O
G
T
T
: 
1.
3%
 v
s.
 8
.6
%
, 
-G
oo
d 
gr
ap
hi
ng
 o
fO
G
T
T
/F
P
G
 
re
sp
ec
ti
ve
ly
. 
an
d 
H
B
A
 I c
 g
ro
up
s 
sh
ow
in
g 
am
ou
nt
 o
f o
ve
rl
ap
 
D
ro
um
ag
ue
t 
et
 
-2
82
0 
pa
rt
ic
ip
an
ts
 
-N
on
-C
au
ca
si
an
s 
un
de
r 
30
 o
r 
ov
er
 
-S
iz
e 
o
f g
ro
up
 
-N
o 
ev
id
en
ce
 o
f e
xc
lu
si
on
 
H
b
A
lc
 p
re
di
ct
ed
 d
ia
be
te
s 
in
 
fo
ll
ow
ed
 f
or
 6
 y
ea
rs
. 
65
 y
ea
rs
 o
f a
ge
 
-P
ri
m
ar
y 
ca
re
 s
et
ti
ng
 a
im
ed
 a
t 
ba
se
d 
on
 m
ed
ic
at
io
ns
 o
r 
th
os
e 
w
ho
 h
ad
 I
FG
, b
ut
 w
as
 
-I
n 
se
ve
n 
he
al
th
 c
en
te
rs
 
-K
no
w
n 
to
 b
e 
di
ab
et
ic
s 
ev
al
ua
ti
on
 o
fH
b
A
lc
 a
s 
a 
co
nd
it
io
ns
 th
at
 a
ff
ec
t 
le
ss
 s
en
si
ti
ve
 a
nd
 s
pe
ci
fi
c 
1
1
5
 
T
E
S
T
IN
G
 
FO
R
 
G
L
U
C
O
SE
 
M
E
T
A
B
O
L
IS
M
 
D
IS
O
R
D
E
R
S 
al
. 
(2
00
6)
 
in
 t
he
 c
en
te
r 
w
es
t o
f 
pr
ed
ic
to
r 
o
f D
ia
be
te
s 
w
it
hi
n 
6 
H
b
A
lc
 
th
an
 F
P
G
. 
S
ug
ge
st
ed
 u
se
 f
or
 
F
ra
nc
e 
ye
ar
s 
-P
eo
pl
e 
in
vi
te
d 
w
er
e 
th
os
e 
w
he
n 
F
P
G
 c
an
no
t b
e 
-C
on
ve
ni
en
ce
 s
am
pl
e 
-U
se
d 
a 
va
ri
et
y 
o
f c
ut
-o
ff
 
w
ho
 a
tt
en
d 
fo
r 
an
nu
al
 
ob
ta
in
ed
 o
r 
po
ss
ib
ly
 i
n 
fr
om
 a
n 
ep
id
em
io
lo
gi
ca
l 
po
in
ts
 f
or
 l
-IB
 A
 I c
 p
re
di
ca
ti
ve
 
ch
ec
ku
ps
 s
o 
da
ta
 m
ay
 b
e 
co
m
bi
na
ti
on
 w
it
h 
ei
th
er
 F
P
G
 
st
ud
y 
an
al
ys
is
 
sk
ew
ed
 
or
 P
G
T
T
. 
C
ut
-o
ff
 fo
r 
be
st
 
-R
ur
al
 a
nd
 u
rb
an
 F
ra
nc
e 
-L
ow
 r
at
e 
o
f 
in
ci
de
nt
 
se
ns
it
iv
it
y 
on
 p
re
di
ca
ti
ng
 
di
ab
et
es
 c
om
pa
re
d 
to
 a
ge
 
di
ab
et
es
: 
5.
9%
. 
an
d 
co
un
tr
y 
av
er
ag
e 
-N
o 
O
G
T
T
 d
on
e 
on
ly
 F
P
G
 
E
de
lm
an
, 
-1
19
7 
pa
ti
en
ts
 a
tt
en
di
ng
 
-K
no
w
n 
di
ab
et
ic
s,
 te
rm
in
al
ly
 il
l, 
-D
el
ib
er
at
el
y 
se
t 
ou
t 
to
 m
im
ic
 
-D
id
 n
ot
 d
o 
O
G
T
T
 
A
s 
H
bA
 I 
c 
in
cr
ea
se
d 
ov
er
 
a 
V
et
er
an
s 
m
ed
ic
al
 
ta
ki
ng
 a
 h
yp
og
ly
ce
m
ic
 m
ed
ic
at
io
n 
re
al
 w
or
ld
 t
es
ti
ng
 s
tr
at
eg
y 
-F
P
G
 g
lu
co
se
 w
er
e 
on
ly
 
4.
5%
, i
nc
id
en
ce
 o
f d
ia
be
te
s 
O
ls
en
, 
D
ud
le
y,
 
ce
nt
er
 f
or
 c
ar
e 
-U
nd
er
 4
5 
or
 o
ve
r 
64
 y
ea
rs
 o
f a
ge
 
-S
cr
ee
ni
ng
 w
as
 d
on
e 
in
 
do
ne
 o
n 
th
os
e 
th
at
 h
ad
 a
 
al
so
 i
nc
re
as
ed
. 
B
as
el
in
e 
-2
9%
 A
fr
ic
an
 A
m
er
ic
an
. 
pa
ti
en
ts
 a
tt
en
di
ng
 a
 p
ar
ti
cu
la
r 
H
b
A
lc
 o
f>
6%
 -
T
he
re
 
H
b
A
lc
 o
f6
.5
 to
 6
.9
%
; h
ad
 
H
ar
ri
s,
 a
nd
 
-P
ro
sp
ec
ti
ve
 c
oh
or
t 
he
al
th
 u
ni
t 
w
er
e 
16
0 
pa
ti
en
ts
 w
it
h 
an
 1
8%
 i
nc
id
en
ce
 o
f 
st
ud
y 
on
 c
on
ve
ni
en
ce
 
-A
nn
ua
l 
qu
es
ti
on
na
ir
es
 w
er
e 
<
6%
 w
ho
 h
ad
 a
 F
P
G
 a
nd
 I
 
de
ve
lo
pm
en
t o
f d
ia
be
te
s.
 
O
dd
on
e 
(2
00
4)
 
sa
m
pl
e 
do
ne
, b
ut
 t
es
ti
ng
 w
as
 o
nl
y 
o
f t
he
m
 h
ad
 a
 F
PG
 >
7 
-U
ni
te
d 
S
ta
te
s 
do
ne
 a
s 
pe
r 
U
S
P
S
T
F
 g
ui
de
li
ne
 
O
m
m
ol
/1
 
ev
er
y 
3 
ye
ar
s.
 
-A
nn
ua
l 
sc
re
en
in
g 
no
t 
do
ne
 
-D
id
 r
em
ov
e 
H
bA
 I 
c 
fr
om
 
-N
o 
in
di
ca
ti
on
 o
f s
cr
ee
ni
ng
 
ca
lc
ul
at
io
ns
 to
 d
et
er
m
in
e 
if
 
fo
r 
di
so
rd
er
s 
th
at
 w
ou
ld
 
ot
he
r 
m
ea
su
re
s 
pr
ed
ic
te
d 
af
fe
ct
 H
bA
 I 
c 
di
ab
et
es
. 
F
or
d
, C
ow
ie
, 
-6
91
1 
pa
rt
ic
ip
an
ts
 in
 t
he
 
-L
ar
ge
 s
am
pl
e 
co
m
pa
re
d 
-H
ad
 t
oo
 f
ew
 p
ar
ti
ci
pa
nt
s 
H
bA
 I 
c 
co
nc
en
tr
at
io
ns
 
N
H
A
N
E
S
 s
tu
dy
. 
T
hi
s 
is
 
H
bA
 I c
 in
 t
ho
se
 w
ith
 n
or
m
al
 
w
it
h 
he
m
og
lo
bi
n 
le
ss
 t
ha
n 
te
nd
ed
 to
 b
e 
hi
gh
er
 in
 
C
ha
o y
an
g,
 
a 
se
ri
al
 c
ro
ss
 s
ec
ti
on
al
 
he
m
og
lo
bi
n 
le
ve
ls
 a
nd
 i
ro
n 
I O
Og
/1
 t
o 
an
al
ys
e 
pr
es
en
ce
 o
f i
ro
n 
de
fi
ci
en
cy
 
su
rv
ey
 i
nc
lu
di
ng
 
st
ud
ie
s,
 n
or
m
al
 h
em
og
lo
bi
n 
-G
en
er
al
ly
 r
at
e 
o
f i
ro
n 
an
ae
m
ia
. 
H
b
A
lc
 te
nd
ed
 t
o 
H
an
de
ls
m
an
, 
na
ti
on
al
ly
 r
ep
re
se
nt
at
iv
e 
an
d 
lo
w
 i
ro
n
, n
or
m
al
 
de
fi
ci
en
cy
 w
as
 l
ow
 i
n 
be
 l
ow
er
 in
 p
re
se
nc
e 
o
f 
no
n-
sa
m
pl
es
 o
f n
on
-
he
m
og
lo
bi
n 
an
d 
lo
w
 i
ro
n.
 
pa
rt
ic
ip
an
ts
 2
 3
±.
_0
 2
%
 a
nd
 
ir
on
 d
ef
ic
ie
nc
y 
an
ae
m
ia
. 
an
d 
in
st
it
ut
io
na
li
ze
d 
ci
vi
li
an
 
-A
ls
o 
co
m
pa
re
d 
H
b
A
lc
 r
es
ul
ts
 
fo
r 
no
n-
ir
on
 d
ef
ic
ie
nc
y 
N
ee
d 
to
 i
nt
er
pr
et
 H
bA
 I 
c 
U
S 
po
pu
la
ti
on
 i
de
nt
if
ie
d 
w
it
h 
er
yt
hr
oc
yt
e 
si
ze
 
an
ae
m
ia
 w
as
 3
 2
±
 0
 3
%
 
re
su
lt
s 
w
it
h 
ca
ut
io
n 
in
 
B
lo
om
ga
rd
en
 
th
ro
ug
h 
st
ra
ti
fi
ed
 
-M
ul
ti
 e
th
ni
c 
st
ud
y 
an
em
ia
. 
T
he
 t
re
nd
 r
em
ai
ns
 
m
ul
ti
st
ag
e 
pr
ob
ab
il
it
y 
tr
ue
, n
ot
 th
e 
nu
m
be
rs
. 
(2
01
1)
 
sa
m
pl
in
g 
de
si
gn
. 
-U
ni
te
d 
S
ta
te
s 
1
1
6
 
T
E
S
T
IN
G
 
FO
R
 
G
L
U
C
O
SE
 
M
E
T
A
B
O
L
IS
M
 
D
IS
O
R
D
E
R
S 
G
ri
m
sb
y 
et
 a
l. 
-3
04
1 
pa
rt
ic
ip
an
ts
 o
ft
h
e 
-U
nd
er
 a
ge
 2
0 
w
it
ho
ut
 f
as
ti
ng
 f
or
 
-I
nc
lu
de
d 
ge
no
ty
pi
ng
 o
f a
ll 
II
 
S
m
al
l 
nu
m
be
r 
o
f e
ac
h 
P
re
se
nc
e 
o
f S
N
P
s 
ex
pl
ai
ne
d 
N
H
A
N
E
S
 I
ll
 s
tu
dy
. 
at
 l
ea
st
 8
 h
ou
rs
 
kn
ow
n 
H
bA
 I c
 a
ss
oc
ia
te
d 
et
hn
ic
 g
ro
up
 
so
m
e 
o
ft
h
e 
hi
gh
er
 i
nc
re
as
e 
(2
01
2)
 
T
hi
s 
is
 a
 s
er
ia
l 
cr
os
s 
-K
no
w
n 
di
ab
et
ic
s 
si
ng
le
 n
uc
le
ot
id
e 
-D
ia
be
te
s 
di
ag
no
si
s 
w
as
 
in
 H
b
A
ic
 in
 n
on
-H
is
pa
ni
c 
se
ct
io
na
l 
su
rv
ey
 
po
ly
m
or
ph
is
m
s 
(S
N
P
s)
. 
ba
se
d 
on
ly
 o
n 
FP
G
 n
ot
 o
n 
w
hi
te
s 
an
d
, t
o 
a 
le
ss
er
 e
xt
en
t, 
in
cl
ud
in
g 
na
ti
on
al
ly
 
-U
se
d 
th
re
e 
et
hn
ic
/r
ac
ia
l 
O
G
T
T
 
in
 M
ex
ic
an
 A
m
er
ic
an
s 
in
 
re
pr
es
en
ta
ti
ve
 s
am
pl
es
 o
f 
gr
ou
ps
: 
N
on
-H
is
pa
ni
c 
w
hi
te
s,
 
-N
o 
an
ce
st
ry
 m
ar
ke
rs
 
w
hi
ch
 t
he
y 
w
er
e 
pr
es
en
t,
 b
ut
 
no
n-
in
st
it
ut
io
na
li
ze
d 
N
on
 H
is
pa
ni
c 
A
fr
ic
an
 
av
ai
la
bl
e 
so
 u
na
bl
e 
to
 
no
t 
in
 n
on
-H
is
pa
ni
c 
A
fr
ic
an
 
ci
vi
li
an
 U
S
 p
op
ul
at
io
n 
A
m
er
ic
an
s,
 a
nd
 M
ex
ic
an
 
de
te
rm
in
e 
if
 th
er
e 
w
as
 a
 
A
m
er
ic
an
s 
id
en
ti
fi
ed
 t
hr
ou
gh
 
A
m
er
ic
an
s 
su
bs
tr
uc
tu
re
 w
hi
ch
 w
ou
ld
 
st
ra
ti
fi
ed
 m
ul
ti
st
ag
e 
ha
ve
 e
xp
la
in
ed
 o
r 
lo
ca
te
d 
pr
ob
ab
il
it
y 
sa
m
pl
in
g 
di
ff
er
en
ce
s 
m
or
e 
ac
cu
ra
te
ly
 
de
si
gn
. 
-U
ni
te
d 
S
ta
te
s 
H
ar
di
ka
r 
et
 a
l. 
-2
43
 p
ar
ti
ci
pa
nt
s 
av
er
ag
e 
-B
or
n 
be
fo
re
 1
98
7 
or
 a
ft
er
 1
98
9 
-
-N
o 
co
-m
or
bi
d 
co
nd
it
io
n
: 
-S
m
al
l 
nu
m
be
rs
 
P
re
va
le
nc
e 
o
f p
re
di
ab
et
es
 in
 
ag
e 
o
f2
1
.6
 y
ea
rs
 w
ho
 
N
ot
 b
or
n 
at
 t
he
 K
in
g 
E
dw
ar
d 
es
se
nt
ia
ll
y 
he
al
th
y 
yo
un
g 
-D
oe
s 
no
t 
gi
ve
 
st
ud
y 
us
in
g 
H
bA
 I 
c 
to
 
(2
01
2)
 
ha
d 
be
en
 p
ar
t o
f a
 
M
em
or
ia
l 
H
os
pi
ta
l 
pe
op
le
. 
so
ci
oe
co
no
m
ic
 d
at
a 
on
 
di
ag
no
se
 w
as
 2
3.
3%
 a
nd
 
lo
ng
it
ud
in
al
 s
tu
dy
 o
f 
-M
ea
su
re
d 
de
m
og
ra
ph
ic
, 
pa
rt
ic
ip
an
ts
 b
ut
 a
ll
ud
es
 to
 i
t 
D
ia
be
te
s 
at
 2
.3
%
. 
O
G
T
T
 
in
fa
nt
s 
bo
rn
 a
t a
 h
os
pi
ta
l 
an
th
ro
po
m
et
ri
c,
 h
em
at
ol
og
ic
al
, 
pr
ev
al
en
ce
 o
f p
re
di
ab
et
es
 
in
 I
nd
ia
 
bi
oc
he
m
ic
al
 a
nd
 n
ut
ri
ti
on
al
 
w
as
 7
.8
%
 a
nd
 d
ia
be
te
s 
2.
6%
. 
-C
on
ve
ni
en
ce
 s
am
pl
e 
fa
ct
or
s 
In
 a
na
em
ic
 p
ar
ti
ci
pa
nt
s,
 
fr
om
 e
xi
st
in
g 
st
ud
y 
-D
id
 O
G
T
T
 a
s 
w
el
l 
as
 H
bA
 I 
c 
H
bA
 I 
ch
ad
 3
3%
 p
re
di
ab
et
ic
 
-U
rb
an
 I
n
d
ia
 
-T
es
te
d 
fo
r 
a 
w
id
e 
va
ri
et
y 
o
f 
vs
. 
12
%
 b
y 
O
G
T
T
. 
A
ne
m
ia
 
co
nd
it
io
ns
 w
hi
ch
 m
ig
ht
 a
ff
ec
t 
di
d 
no
t 
fu
lly
 e
xp
la
in
 th
e 
H
bA
 I 
c 
re
su
lt
s 
di
ff
er
en
ce
s.
 T
hi
s 
su
gg
es
ts
 
th
at
 a
ls
o 
al
te
rs
 g
ly
ca
ti
on
 
ra
te
s.
 
H
bA
 I c
 in
 a
ne
m
ic
 
pa
ti
en
ts
 s
ho
ul
d 
be
 
in
te
rp
re
te
d 
w
it
h 
gr
ea
t 
ca
ut
io
n.
 
H
aj
at
, 
-I
 ,0
28
 p
ar
ti
ci
pa
nt
s 
w
ho
 
-U
nd
er
 a
ge
 1
8,
 n
ot
 a
tt
en
di
ng
 a
 
-D
id
 t
es
t 
us
in
g 
F
P
G
, O
G
T
T
 
-D
id
 n
ot
 t
es
t 
fo
r 
pr
e-
H
b
A
ic
 c
u
t-
o
ff
o
f6
.4
%
 
w
er
e 
pa
rt
 o
fl
ar
ge
r 
st
ud
y 
pu
bl
ic
 f
ac
ili
ty
 
an
d 
H
b
A
ic
 
ex
is
ti
ng
 c
on
di
ti
on
s 
th
at
 
de
m
on
st
ra
te
d 
th
e 
hi
gh
es
t 
H
ar
ri
so
n,
 a
nd
 
on
 c
ar
di
ov
as
cu
la
r 
ri
sk
 
-D
id
 u
se
 m
ul
ti
pl
e 
H
bA
 I 
c 
cu
t-
m
ay
 h
av
e 
ef
fe
ct
ed
 H
bA
 I 
c 
se
ns
it
iv
it
y 
72
%
 a
nd
 
fa
ct
or
s 
in
cl
ud
in
g 
of
fs
 t
o 
de
te
rm
in
e 
se
ns
it
iv
it
y 
-T
he
 c
oh
or
t c
ho
se
n
, b
ot
h 
sp
ec
if
ic
it
y 
o
f8
4
%
. 
U
si
ng
 
1
1
7
 
T
E
S
T
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G
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R
 
G
L
U
C
O
SE
 
M
E
T
A
B
O
L
IS
M
 
D
IS
O
R
D
E
R
S 
A
I 
S
ik
se
k 
di
ab
et
es
 
an
d 
sp
ec
if
ic
it
y 
fo
r 
po
pu
la
ti
on
 
di
ab
et
ic
 a
nd
 n
on
-d
ia
be
ti
c,
 
H
b
A
!c
 o
f6
.4
%
 w
ou
ld
 h
av
e 
-C
on
ve
ni
en
ce
 s
am
pl
e 
-P
op
ul
at
io
n 
ha
s 
hi
gh
 i
nc
id
en
ce
 
is
 o
ld
er
, 
ha
s 
a 
hi
gh
er
 B
M
I 
re
su
lt
ed
 i
n 
72
%
 b
ei
ng
 
(2
01
1)
 
-U
rb
an
 A
bu
 D
ha
bi
 
o
f d
ia
be
te
s 
w
ai
st
 c
ir
cu
m
fe
re
nc
e 
bl
oo
d 
co
rr
ec
tl
y 
di
ag
no
se
d 
an
d 
16
%
 
pr
es
su
re
, 
an
d 
L
D
I 
in
co
rr
ec
tl
y 
di
ag
no
se
d 
us
in
g 
ch
ol
es
te
ro
l 
th
an
 t
he
 r
es
t o
f 
O
G
T
T
 a
s 
th
e 
go
ld
 s
ta
nd
ar
d.
 
th
e 
W
eq
ay
a 
co
ho
rt
; 
th
e 
U
se
 o
fH
b
A
ic
 a
t 6
.4
%
 w
as
 
re
as
on
 i
s 
no
t 
ex
pl
ai
ne
d 
co
ns
id
er
ed
 f
ea
si
bl
e 
fo
r 
sc
re
en
in
g 
in
 t
hi
s 
po
pu
la
ti
on
. 
H
ea
th
 (
20
 1
2)
 
-I
 0
,5
66
 s
ec
on
da
ry
 
-U
nd
er
 a
ge
 1
8 
-L
ar
ge
 n
um
be
r,
 m
ul
ti
et
hn
ic
 
-D
es
pi
te
 o
ve
r 
sa
m
pl
in
g 
o
f 
O
G
T
T
 r
em
ai
ns
 t
he
 m
os
t 
an
al
ys
is
 o
fN
H
A
N
E
S
 
po
pu
la
ti
on
 
et
hn
ic
 m
in
or
it
ie
s 
in
 
ac
cu
ra
te
 w
ay
 t
o 
de
te
ct
 b
ot
h 
20
05
-2
00
8.
 T
hi
s 
is
 a
 
-A
ll
 t
es
ts
 w
el
l 
de
sc
ri
be
d 
N
H
A
N
E
S
 s
am
pl
e 
st
ill
 t
he
 
pr
ed
ia
be
te
s 
an
d 
di
ab
et
es
 i
n 
se
ri
al
 c
ro
ss
 s
ec
ti
on
al
 
m
ul
ti
ra
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 m
ig
ht
 a
ff
ec
t 
H
bA
 I 
c 
-
fo
r 
de
te
ct
in
g 
IF
G
 a
nd
 
al
. 
(2
01
2)
 
di
ab
et
es
 p
re
ve
nt
io
n 
-K
no
w
n 
di
ab
et
ic
 n
ot
 h
av
in
g 
at
 
-U
se
d 
m
ul
ti
pl
e 
cu
t-
of
f f
or
 b
ot
h 
P
ar
ti
ci
pa
nt
s 
ar
e 
se
lf
-
T
2D
M
. 
U
si
ng
 c
ur
re
nt
 A
D
A
 
! 
pr
og
ra
m
m
e.
 
le
as
t o
ne
 o
f t
he
 f
ol
lo
w
in
g:
 
F
P
G
 a
nd
 H
B
al
c 
to
 d
et
er
m
in
e 
se
le
ct
ed
 a
nd
 s
o 
th
er
ef
or
e 
cu
t-
of
ff
or
 H
bA
 I c
 f
or
 I
FG
 
I 
-P
at
ie
nt
s 
se
lf
-s
el
ec
te
d 
to
 
-F
ir
st
 d
eg
re
e 
re
la
ti
ve
 w
it
h 
T
2D
M
 
ac
cu
ra
cy
 b
ot
h 
al
on
e 
an
d 
m
ay
 n
ot
 r
ef
le
ct
 g
en
er
al
 
w
ou
ld
 m
is
s 
40
%
 o
f!
F
G
 
at
te
nd
. 
-B
M
I>
25
 k
g/
m
2 
to
ge
th
er
 f
or
 b
ot
h 
IF
G
 a
nd
 
po
pu
la
ti
on
 
co
m
pa
re
d 
to
 F
P
G
. 
U
se
 o
f t
he
 
-U
rb
an
 E
ng
la
nd
. 
-W
ai
st
 c
ir
cu
m
fe
re
nc
e 
>
94
cm
 m
en
 
T
2D
M
 
-L
ar
ge
ly
 W
hi
te
 E
ur
op
ea
n 
tw
o 
H
B
A
 I c
 a
nd
 F
PG
 
or
 >
80
cm
 w
om
en
 
co
ho
rt
 
im
pr
ov
es
 s
en
si
ti
vi
ty
 a
nd
 
-H
is
to
ry
 o
f c
or
on
ar
y 
he
ar
t 
di
se
as
e 
sp
ec
if
ic
it
y 
bu
t 
in
cr
ea
se
s 
co
st
. 
-H
is
to
ry
 o
f g
es
ta
ti
on
al
 d
ia
be
te
s 
-T
ol
d 
th
at
 th
ey
 h
av
e 
IF
G
 
L
u,
 W
al
ke
r,
 
-8
50
8 
to
ta
l 
pa
rt
ic
ip
an
ts
 
-N
ot
 h
av
in
g 
co
nc
ur
re
nt
 O
G
T
T
 
-S
iz
e 
o
f t
he
 c
oh
or
t 
-N
o 
te
st
in
g 
fo
r 
co
nd
it
io
ns
 
S
up
po
rt
s 
us
e 
o
f 
H
bA
I c
 in
 
dr
aw
n 
fr
om
 t
w
o 
an
d 
H
bA
 I c
 r
es
ul
ts
 
-U
se
 o
f a
n 
id
en
ti
fi
ed
 h
ig
he
r 
w
hi
ch
 m
ig
ht
 a
ff
ec
t 
H
bA
 I 
c 
sc
re
en
in
g 
a n
d 
D
ia
gn
os
is
 b
ut
 
O
'D
ea
, 
S
ik
ar
is
, 
po
pu
la
ti
on
s:
 2
49
4 
fr
om
 
-K
no
w
n 
di
ab
et
ic
s 
ri
sk
 p
op
ul
at
io
n 
al
re
ad
y 
re
fe
rr
ed
 
-N
o 
br
ea
kd
ow
n 
o
f 
us
ed
 t
w
o 
cu
t-
of
fs
 n
ot
 o
ne
 to
 
pa
ti
en
ts
 r
ef
er
re
d 
fo
r 
by
 p
ri
m
ar
y 
ca
re
 f
or
 O
G
T
T
 a
nd
 
et
hn
ic
it
y/
ra
ce
 -
M
ak
eu
p 
o
f 
op
ti
m
iz
e 
se
ns
it
iv
it
y 
an
d 
an
d 
S
ha
w
 
O
G
T
T
 a
nd
 6
0 
14
 f
ro
m
 
ge
ne
ra
l 
po
pu
la
ti
on
 
co
ho
rt
 
sp
ec
if
ic
it
y
. 
U
se
d 
<
5.
5%
, 
th
e 
A
us
D
ia
b 
po
pu
la
ti
on
-
-U
se
 o
f t
w
o 
cu
t-
of
fs
 to
 r
ul
e 
in
 
w
hi
ch
 g
av
e 
a 
ne
ga
ti
ve
 
(2
01
0)
 
ba
se
d 
st
ud
y 
on
 d
ia
be
te
s.
 
ru
le
 o
ut
 d
ia
be
te
s 
an
d 
IF
G
 
pr
ed
ic
ti
ve
 v
al
ue
 o
f>
95
%
, 
-A
us
tr
al
ia
 
an
d 
7%
 g
av
e 
a 
sp
ec
if
ic
it
y 
o
f 
92
.9
%
 a
nd
 a
 p
os
it
iv
e 
pr
ed
ic
ti
ve
 v
al
ue
 o
f9
2.
9%
. 
T
hu
s,
 t
ho
se
 f
al
lin
g 
be
tw
ee
n 
th
e 
tw
o 
sh
ou
ld
 h
av
e 
ad
di
ti
on
al
 t
es
ti
ng
, s
uc
h 
as
 
O
G
T
T
. 
M
an
le
y 
et
al
. 
-T
ot
al
 o
f2
1
7
5
 
-K
no
w
n 
ha
em
og
lo
bi
n 
va
ri
an
ts
. 
-S
cr
ee
ni
ng
 f
or
 h
ae
m
og
lo
bi
n 
-O
nl
y 
lo
ok
ed
 a
t d
ia
gn
os
in
g 
U
se
d 
F
P
G
 a
nd
 H
B
al
c 
in
 
pa
rt
ic
ip
an
ts
 in
 t
hr
ee
 
-K
no
w
n 
di
ab
et
es
 
va
ri
an
ts
 
di
ab
et
es
 n
o 
ot
he
r 
gl
uc
os
e 
st
ep
w
is
e 
al
go
ri
th
m
 to
 d
et
ec
t 
(2
00
9)
 
gr
ou
ps
: 
50
0 
in
 i
ni
tia
l 
-H
av
in
g 
ha
d 
re
ce
nt
 s
ur
ge
ry
, 
or
 
-S
iz
e 
o
f c
oh
or
t 
an
d 
va
li
da
ti
on
 
m
et
ab
ol
is
m
 a
bn
or
m
al
it
ie
s 
th
os
e 
w
ho
 e
it
he
r 
ha
d 
de
ri
ve
d 
gr
ou
p 
an
d 
50
0 
in
 
bl
oo
d 
tr
an
sf
us
io
n 
o
f a
lg
or
it
hm
 w
it
h 
di
ff
er
en
t 
-A
lt
ho
ug
h 
no
t c
le
ar
ly
 
di
ab
et
es
 o
r 
ne
ed
ed
 O
G
T
T
. 
th
e 
va
li
da
ti
on
 g
ro
up
 b
ot
h 
-M
is
si
ng
 d
at
a 
po
pu
la
ti
on
 
st
at
ed
 t
he
 A
us
tr
al
ia
n 
A
lg
or
it
hm
 i
s 
if
F
P
G
 
in
 t
he
 U
K
, w
it
h 
a 
fu
rt
he
r 
-U
se
 o
f b
ot
h 
ca
pi
ll
ar
y 
an
d 
va
li
da
ti
on
 g
ro
up
 w
er
e 
o
f 
>
7m
m
ol
/l
 &
 s
ec
on
d 
F
P
G
 
11
75
 i
n 
va
li
da
ti
on
 a
rm
 i
n 
ve
no
us
 s
am
pl
es
 f
or
 F
P
G
 a
nd
 
hi
gh
er
 r
is
k 
th
an
 t
he
 a
ve
ra
ge
 
sa
m
e,
 t
he
n 
di
ab
et
es
 
A
us
tr
al
ia
 
O
G
T
T
 m
ea
su
re
s 
an
d 
po
pu
la
ti
on
 a
s 
ha
d 
be
en
 
di
ag
no
se
d.
 
If
F
P
G
 
-U
ni
te
d 
K
in
gd
om
 a
nd
 
co
m
pa
ri
so
n 
w
hi
ch
 m
im
ic
s 
re
fe
rr
ed
 f
or
 O
G
T
T
 f
or
 
<
7m
m
ol
/l
 a
nd
 H
b
A
ic
 <
6,
 
A
us
tr
al
ia
 
re
al
it
y 
in
 m
an
y 
co
nt
ex
ts
 
ha
vi
ng
 r
is
k 
fa
ct
or
s 
or
 
th
en
 n
o 
di
ab
et
es
 d
ia
gn
os
ed
. 
1
2
1
 
T
E
S
T
IN
G
 
FO
R
 
G
L
U
C
O
SE
 
M
E
T
A
B
O
L
IS
M
 
D
IS
O
R
D
E
R
S 
el
ev
at
ed
 f
as
ti
ng
 o
r 
ra
nd
om
 
T
ho
se
 w
it
h 
FP
G
<
7m
m
ol
 a
nd
 
I 
gl
uc
os
e 
H
b
A
lc
>
6 
th
en
 n
ee
d 
O
G
T
T
. 
T
hi
s 
id
en
ti
fi
ed
 2
34
 o
f2
41
 
• 
pa
ti
en
ts
 in
 t
he
 U
K
 a
nd
 3
82
 
I i 
o
f4
1
2
 in
 A
us
tr
al
ia
. 
W
ou
ld
 
I 
re
du
ce
 t
he
 n
ee
d 
fo
r 
O
G
T
T
 in
 
U
K
 b
y 
33
%
 a
nd
 b
y 
66
%
 in
 
A
us
tr
al
ia
. 
M
an
n 
et
 a
l. 
-7
02
9 
pa
rt
ic
ip
an
ts
. 
T
he
 
-U
nd
er
 a
ge
 2
0 
ye
ar
s.
 
-S
iz
e 
o
f c
oh
or
t 
-O
nl
y 
on
e 
o
f e
ac
h 
o
ft
h
e 
U
se
 o
fH
b
A
lc
 l
ev
el
s 
da
ta
 is
 f
ro
m
 t
he
 
-K
no
w
n 
or
 f
ou
nd
 t
o 
be
 d
ia
be
ti
c 
at
 
-U
se
 o
fH
b
A
 I c
 to
 r
ev
ie
w
 s
am
e 
te
st
 F
P
G
, 
O
G
T
T
 a
nd
 
be
tw
ee
n 
5.
7-
-6
.4
%
 f
or
 
(2
01
0)
 
N
H
A
N
E
S
 1
99
9-
20
06
. 
ba
se
li
ne
 te
st
in
g.
 
pe
op
le
 p
re
vi
ou
sl
y 
di
ag
no
se
d 
or
 
H
B
A
 I 
c 
do
ne
: n
o 
di
ag
no
si
s 
o
fi
F
G
 w
ou
ld
 
T
hi
s 
is
 a
 s
er
ia
l 
cr
os
s 
no
t w
it
h 
gl
uc
os
e 
ab
no
rm
al
it
ie
s 
co
nf
ir
m
at
or
y 
te
st
in
g 
re
cl
as
si
fY
 3
7.
6 
m
il
li
on
 
se
ct
io
na
l 
su
rv
ey
 
w
hi
ch
 d
o 
no
t 
in
cl
ud
e 
di
ab
et
es
 
-N
o 
ap
pa
re
nt
 e
xc
lu
si
on
 
A
m
er
ic
an
s 
pr
ev
io
us
ly
 
in
cl
ud
in
g 
na
ti
on
al
ly
 
ba
se
d 
on
 c
on
di
ti
on
s 
th
at
 
di
ag
no
se
d 
w
it
h 
IF
G
 a
s 
no
t 
re
pr
es
en
ta
ti
ve
 s
am
pl
es
 o
f 
m
ig
ht
 a
ff
ec
t 
H
bA
 I 
c 
ha
vi
ng
 it
 a
nd
 w
ou
ld
 i
de
nt
ifY
 
no
n-
in
st
it
ut
io
na
li
ze
d 
8.
9 
m
il
li
on
 a
s 
ha
vi
ng
 p
re
-
ci
vi
li
an
 U
S 
po
pu
la
ti
on
 
di
ab
et
es
 w
ho
 w
er
e 
no
t 
id
en
ti
fi
ed
 t
hr
ou
gh
 
pr
ev
io
us
 d
ia
gn
os
ed
 a
s 
us
in
g 
st
ra
ti
fi
ed
 m
ul
ti
st
ag
e 
F
P
G
 o
r 
O
G
T
T
. 
T
hi
s 
w
ou
ld
 
pr
ob
ab
il
it
y 
sa
m
pl
in
g 
be
 a
 r
ec
la
ss
if
ic
at
io
n 
o
f 4
6.
5 
de
si
gn
. 
m
il
li
on
 p
eo
pl
e.
 
O
nl
y 
7.
7%
 
ov
er
la
p 
be
tw
ee
n 
FP
G
 5
.5
4-
6.
94
 m
m
ol
/1
 an
d 
H
b
A
lc
 5
.7
-
6.
4%
. 
C
li
ni
ci
an
s 
ne
ed
 t
o 
un
de
rs
ta
nd
 t
he
 d
if
fe
re
nc
es
 i
n 
po
pu
la
ti
on
 r
es
ul
ts
 u
si
ng
 e
ac
h 
te
st
. 
H
bA
 I 
c 
al
on
e 
fo
r 
pr
ed
ia
be
te
s 
sh
ou
ld
 b
e 
us
ed
 
w
it
h 
ca
ut
io
n.
 
M
os
ta
fa
 e
t 
al
. 
-8
69
6 
fr
om
 t
w
o 
gr
ou
ps
: 
-K
no
w
n 
di
ab
et
ic
s 
-L
ar
ge
 s
iz
e 
o
f c
oh
or
t 
-M
ix
ed
 
-O
nl
y 
th
os
e 
w
it
h 
F
P
G
 o
r 
T
he
re
 w
as
 d
is
co
rd
an
ce
 
th
is
 w
as
 a
n 
an
al
ys
is
 o
f 
-L
es
s 
th
an
 4
0 
ye
ar
s 
o
f a
ge
 
et
hn
ic
it
y:
 7
4 
7%
 w
hi
te
 
O
G
T
T
 h
ad
 a
 c
on
fi
rm
at
or
y 
be
tw
ee
n 
th
e 
O
F
T
T
 a
nd
 
(2
01
0)
 
tw
o 
pr
ev
io
us
 p
ro
sp
ec
ti
ve
 
-M
is
si
ng
 re
su
lt
s 
E
ur
op
ea
ns
, a
nd
 2
2 
8%
 A
si
an
s 
O
G
T
T
: 
no
t t
ho
se
 w
it
hi
n 
H
bA
 I c
. 
O
G
T
T
 g
av
e 
a 
re
su
lt
 
sy
st
em
at
ic
 s
cr
ee
ni
ng
 
-O
ne
 h
al
fo
ft
h
e 
pa
rt
ic
ip
an
ts
 h
ad
 
-U
se
d 
O
G
T
T
, F
P
G
 a
nd
 H
b
A
ic
 
IF
G
 o
r 
IG
T
 r
an
ge
s 
-S
ta
te
s 
o
f 
14
07
 (
16
.2
%
) 
w
ith
 I
G
R
. 
pr
og
ra
m
m
es
 o
f p
eo
pl
e 
in
 
to
 h
av
e 
at
 l
ea
st
 o
ne
 r
is
k 
fa
ct
or
 f
or
 
an
d 
di
d 
co
nf
ir
m
at
or
y 
te
st
in
g 
if
 
w
hi
te
 E
ur
op
ea
n 
an
d 
A
si
an
 
H
b
A
ic
 6
-6
.4
%
 g
av
e 
16
10
 
pr
im
ar
y 
ca
re
 w
it
ho
ut
 
di
ab
et
es
. 
F
P
G
>
7m
m
ol
ll
 o
r 
2h
r 
O
G
T
T
 
pe
rc
en
ta
ge
s 
bu
t o
nl
y 
ad
ds
 
( 1
8.
5%
) 
o
f!
 G
R
. 
T
hi
s 
w
as
 a
 
1
2
2
 
T
E
S
T
IN
G
 
FO
R
 
G
L
U
C
O
SE
 
M
E
T
A
B
O
L
IS
M
 
D
IS
O
R
D
E
R
S 
kn
ow
n 
di
ab
et
es
. 
O
ne
 
>
II
 l
m
m
ol
/1
 
to
 9
7 
5%
 
1.
1 
fo
ld
 i
nc
re
as
e 
in
 w
hi
te
 
! 
pr
og
ra
m
 w
as
 a
 s
cr
ee
ni
ng
 
-D
oe
s 
no
t 
in
di
ca
te
 w
ho
 t
he
 
E
ur
op
ea
ns
 a
nd
 a
 1
.5
 f
ol
d 
! 
o
f 
pe
op
le
 w
it
h 
at
 l
ea
st
 
ot
he
r 
2 
5%
 (
n2
17
) 
ar
e 
in
cr
ea
se
 i
n 
A
si
an
s.
 T
he
re
 
on
e 
ri
sk
 f
ac
to
r 
fo
r 
-D
oe
s 
no
t 
in
di
ca
te
 t
ha
t 
w
as
 
w
er
e 
on
ly
 4
77
 w
ho
 w
er
e 
I 
di
ab
et
es
, 
an
d 
th
e 
ot
he
r 
an
y 
te
st
in
g 
fo
r 
co
nd
it
io
ns
 
de
te
ct
ed
 b
y 
bo
th
 t
es
ts
. 
U
si
ng
 
w
as
 a
n 
un
se
le
ct
ed
 
th
at
 m
ig
ht
 a
ff
ec
t 
H
b
A
ic
 
A
D
A
 H
b
A
ic
 o
f5
.7
-6
.4
%
, 
po
pu
la
ti
on
 b
as
ed
 c
oh
or
t. 
39
04
 w
er
e 
de
te
ct
ed
 w
it
h 
IG
R
, w
hi
ch
 w
as
 a
 2
.8
 f
ol
d 
E
ng
la
nd
. 
in
cr
ea
se
 i
n 
w
hi
te
s 
E
ur
op
ea
ns
 
an
d 
3 
fo
ld
 i
n 
A
si
an
s.
 
In
 t
hi
s 
gr
ou
p
, o
nl
y 
87
3 
w
er
e 
IG
R
 
by
 b
ot
h 
O
G
T
T
 a
nd
 H
bA
 I c
. 
M
ay
 n
ee
d 
di
ff
er
en
t 
cu
t-
po
in
ts
 f
or
 d
if
fe
re
nt
 
po
pu
la
ti
on
s.
 
M
uk
ai
 e
t 
al
. 
-1
98
2 
su
bj
ec
ts
 w
ho
 h
ad
 
-K
no
w
n 
di
ab
et
ic
s,
 u
nd
er
 4
0 
or
 
-L
en
gt
h 
o
f s
tu
dy
: p
ar
ti
ci
pa
nt
s 
-D
oe
s 
no
t 
in
di
ca
te
 t
es
ti
ng
 
F
ou
nd
 t
ha
t 
cu
t-
of
f f
or
 
be
en
 p
ar
t o
f a
 
ab
ov
e 
79
 y
ea
rs
 o
f a
ge
. 
w
er
e 
fo
ll
ow
ed
 u
p 
fo
r 
14
 y
ea
rs
 
fo
r 
co
nd
it
io
ns
 t
ha
t c
ou
ld
 
di
ag
no
si
s 
o
f t
ho
se
 a
t h
ig
he
r 
(2
01
2)
 
po
pu
la
ti
on
-b
as
ed
 
-O
n 
m
ed
ic
at
io
n 
th
at
 c
ha
ng
ed
 
-D
id
 O
G
T
T
, F
PG
, H
b
A
ic
 a
nd
 
af
fe
ct
 H
bA
 I 
c 
re
su
lt
s 
ri
sk
 o
f d
ia
be
te
s 
in
 J
ap
an
es
e 
pr
os
pe
ct
iv
e 
st
ud
y 
o
f 
le
ve
ls
 o
f g
ly
ca
em
ia
. 
in
su
li
n 
le
ve
ls
 a
s 
le
ve
l 
as
 
-A
t b
as
el
in
e 
on
ly
 o
ne
 te
st
 
po
pu
la
ti
on
 i
s 
si
m
il
ar
 to
 w
ha
t 
ca
rd
io
va
sc
ul
ar
 h
ea
lt
h 
ch
ol
es
te
ro
l 
le
ve
ls
 
fo
r 
gl
uc
os
e 
an
d 
H
b
A
ic
: n
o 
ot
he
r 
st
ud
ie
s 
ha
ve
 f
ou
nd
 f
or
 
si
nc
e 
19
61
 
-D
id
 p
ro
ce
ss
 g
lu
co
se
 s
am
pl
es
 
co
nf
ir
m
at
or
y 
te
st
in
g 
A
si
an
 p
op
ul
at
io
n.
 
F
P
G
 is
 
-P
ar
ti
ci
pa
nt
s 
w
er
e 
se
lf
-
w
it
hi
n 
30
 m
in
ut
es
 o
f d
ra
w
in
g 
sa
m
e 
a
s 
A
D
A
 g
ui
de
li
ne
s 
o
f 
se
le
ct
ed
 a
s 
ev
er
yo
ne
 in
 
to
 r
ed
uc
e 
in
 t
ub
e 
gl
yc
at
io
n 
5.
6 
m
m
ol
/1
 b
ut
 5
.5
%
 f
or
 
th
e 
ag
e 
gr
ou
p 
w
as
 
H
bA
 I c
 , 
an
d 
si
gn
if
ic
an
tl
y 
in
vi
te
d;
 t
ho
se
 w
ho
 
lo
w
er
 f
or
 2
 h
ou
r 
po
st
 lo
ad
 
re
sp
on
de
d 
w
er
e 
in
cl
ud
ed
 
gl
uc
os
e 
6.
9 
m
m
ol
/1
. 
if
 th
ey
 m
et
 th
e 
cr
it
er
ia
. 
S
en
si
ti
vi
ty
 a
nd
 s
pe
ci
fi
ci
ty
 
-U
rb
an
 J
ap
an
 
fo
r 
th
es
e 
cu
t-
of
fs
 w
er
e 
67
.5
, 
65
.6
%
 f
or
 F
P
G
, 
66
.1
, 5
7.
4%
 
fo
r 
H
b
A
ic
, a
nd
 6
5.
1
, 6
4.
2 
fo
r 
2h
 p
os
t 
lo
ad
. 
N
ak
ag
am
i 
et
 a
l. 
-1
90
4 
pa
rt
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D
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 r
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 o
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re
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 b
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 d
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f r
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w
er
e 
de
fi
ne
d 
di
ab
et
ic
s 
re
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b
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b
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 m
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 b
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at
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 o
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 t
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 d
id
 
no
t o
ne
 o
ft
h
e 
m
ea
su
re
s 
o
f9
3
%
, a
nd
 i
n 
w
om
en
, 
a 
no
t 
de
ve
lo
p 
di
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ed
 (
in
 a
 p
re
vi
ou
s 
po
pu
la
ti
on
 
di
ff
er
en
ce
s.
 
H
b
A
lc
 o
f &
5 
in
 
S
tr
ai
t 
Is
la
nd
er
s 
( 1
54
 ),
 
st
ud
y)
 u
se
 o
fF
P
G
 in
 t
hi
s 
-A
na
em
ia
 is
 w
id
es
pr
ea
d 
in
 
A
us
tr
al
ia
n 
ab
or
ig
in
al
 
an
d 
C
an
ad
ia
n 
W
es
t 
po
pu
la
ti
on
 to
 d
et
er
m
in
e 
in
di
ge
no
us
 p
op
ul
at
io
n 
an
d 
po
pu
la
ti
on
 g
av
e 
se
ns
it
iv
it
y 
C
oa
st
 F
ir
st
 N
at
io
ns
 
di
ab
et
es
 w
it
h 
hi
gh
 s
en
si
ti
vi
ty
 
no
 e
vi
de
nc
e 
o
f t
es
ti
ng
 
o
f8
8
.9
%
 a
nd
 s
pe
ci
fi
ci
ty
 o
f 
(1
70
).
 
an
d 
sp
ec
if
ic
it
y 
w
hi
ch
 i
f i
ro
n 
de
fi
ci
en
cy
 
96
.9
%
; T
or
re
s 
Is
la
nd
er
s 
-I
nd
iv
id
ua
ls
 w
er
e 
co
ul
d 
ha
ve
 r
ai
se
d 
H
B
A
 I 
c 
se
ns
it
iv
it
y 
o
f7
6
.2
%
 a
nd
 
re
cr
ui
te
d 
th
ro
ug
h 
sp
ec
if
ic
it
y 
o
f 
I 0
0%
; 
an
d 
co
m
m
un
it
y 
m
ee
ti
ng
s 
an
d 
F
ir
st
 N
at
io
ns
 7
3%
 a
nd
 
fl
ye
rs
. 
97
.7
%
, r
es
pe
ct
iv
el
y.
 
U
se
 o
f 
-A
us
tr
al
ia
, T
or
re
s 
S
tr
ai
t 
H
b
A
lc
 o
f7
%
 h
as
 u
til
ity
 i
n 
Is
la
nd
s,
 C
an
ad
a 
sc
re
en
in
g 
fo
r 
di
ab
et
es
 i
n 
th
is
 
hi
gh
-r
is
k 
po
pu
la
ti
on
. 
T
an
ko
va
, 
-2
23
 I
 i
n 
a 
re
pr
es
en
ta
ti
ve
 
N
ot
 h
av
in
g 
at
 le
as
t o
ne
 r
is
k 
fa
ct
or
 
-H
ig
h 
ri
sk
 g
ro
up
s 
-H
ig
h 
ri
sk
 g
ro
up
 
H
b
A
ic
 c
ut
-o
ff
of
6.
1 
ga
ve
 
sa
m
pl
e 
o
f h
ig
h 
ri
sk
 
fo
r 
di
ab
et
es
, 
su
ch
 a
s 
fi
rs
t 
de
gr
ee
 
-S
iz
e 
o
f c
oh
or
t A
ll 
pa
rt
ic
ip
an
ts
 
-N
o 
ap
pa
re
nt
 te
st
in
g 
fo
r 
op
ti
m
al
 s
en
si
ti
vi
ty
 8
6%
 a
nd
 
C
ha
ka
ro
va
, 
B
ul
ga
ri
an
s 
in
 a
 c
ro
ss
 
re
la
ti
ve
 w
ith
 T
2D
m
; o
ve
rw
ei
gh
t 
ha
d 
H
B
A
 I c
, O
G
T
T
 a
nd
 F
PG
 
co
nd
it
io
ns
 th
at
 a
ff
ec
t 
sp
ec
if
ic
it
y 
92
%
 fo
r 
se
ct
io
na
l 
se
tt
in
g.
 
or
 h
av
in
g 
ce
nt
ra
l 
ob
es
it
y;
 h
is
to
ry
 
-A
ls
o 
di
d 
F
IN
D
R
IS
C
 8
 p
oi
nt
 
H
b
A
lc
 
di
ag
no
si
ng
 d
ia
be
te
s.
 A
nd
 
D
ak
ov
sk
a,
 a
nd
 
-R
ec
ru
it
ed
 th
ro
ug
h 
o
f g
es
ta
ti
on
al
 d
ia
be
te
s;
 h
av
in
g 
qu
es
ti
on
na
ir
e 
on
 a
ll 
-O
nl
y 
on
e 
te
st
 o
f e
ac
h 
ki
nd
 
H
b
A
ic
 o
f5
.5
%
 g
av
e 
ad
ve
rt
is
in
g 
an
d 
re
fe
rr
al
s 
ba
by
 o
ve
r 4
kg
; 
hi
st
or
y 
o
f I
FG
 o
r 
pa
rt
ic
ip
an
ts
 
ca
rr
ie
d 
ou
t;
 n
o 
se
ns
it
iv
it
y 
o
f7
1
%
 a
nd
 
A
ta
na
ss
ov
a 
fr
om
 p
hy
si
ci
an
s 
IG
T
; a
rt
er
ia
l 
hy
pe
rt
en
si
on
; 
li
pi
d 
co
nf
ir
m
at
or
y 
te
st
in
g 
sp
ec
if
ic
it
y 
o
f6
4
%
 fo
r 
-B
ul
ga
ri
a 
ab
no
rm
al
it
ie
s;
 c
li
ni
ca
ll
y 
pr
ed
ia
be
te
s.
 A
pp
ly
in
gj
us
t 
(2
0 
12
) 
es
ta
bl
is
he
d 
at
he
ro
sc
le
ro
ti
c 
H
bA
 I 
c 
w
ill
 m
is
s 
25
%
 o
f 
di
se
as
e.
 
th
os
e 
w
it
h 
IF
G
 a
nd
 I
G
T
 a
nd
 
12
%
 o
f t
ho
se
 w
ith
 d
ia
be
te
s.
 
S
tr
on
g 
co
rr
el
at
io
n 
fo
un
d 
1
2
6
 
T
E
S
T
IN
G
 
FO
R
 
G
L
U
C
O
SE
 
M
E
T
A
B
O
L
IS
M
 
D
IS
O
R
D
E
R
S 
be
tw
ee
n 
F
IN
D
R
IS
C
, 
H
B
A
ic
, 
S
ys
to
li
c 
B
lo
od
 
P
re
ss
ur
e,
 a
nd
 tr
ig
ly
ce
ri
de
 
le
ve
l. 
H
bA
 I 
c 
is
 a
 u
se
fu
l 
an
d 
pr
ac
ti
ca
l 
to
ol
 f
or
 i
de
nt
if
Y
in
g 
di
ab
et
es
 a
nd
 p
re
di
ab
et
es
 
am
on
gs
t t
hi
s 
hi
gh
-r
is
k 
gr
ou
p.
 
va
n 
'T
 R
ie
t 
et
 
-2
75
3 
re
cr
ui
te
d 
fr
om
 a
 
-Y
ou
ng
er
 th
an
 4
0 
ol
de
r 
th
an
 6
5 
-S
iz
e 
o
f s
tu
dy
 a
nd
 r
an
do
m
ly
 
-N
o 
ap
pa
re
nt
 e
xc
lu
si
on
 f
or
 
H
b
A
ic
 in
 g
en
er
al
 p
op
ul
at
io
n 
pa
rt
ic
ul
ar
 g
eo
gr
ap
hi
ca
l 
ye
ar
s 
o
f a
ge
 
ch
os
en
 
an
y 
co
nd
it
io
n,
 a
nd
 n
o 
ha
d 
on
ly
 m
od
er
at
e 
al
. 
(2
01
0)
 
ar
ea
. 
-R
an
do
m
 s
am
pl
e.
 
-M
is
si
ng
 v
al
ue
s 
te
st
in
g 
fo
r 
an
y 
co
nd
it
io
n 
co
rr
el
at
io
ns
 w
it
h 
FP
G
 a
nd
 
-U
rb
an
 N
et
he
rl
an
ds
 
kn
ow
n 
to
 a
ff
ec
t 
H
bA
 I 
c 
O
G
T
T
, 
w
hi
le
 i
t 
ha
d 
hi
gh
er
 
-W
hi
le
 t
he
 a
rt
ic
le
 i
nd
ic
at
es
 
co
rr
el
at
io
ns
 w
it
h 
F
P
G
 a
nd
 
th
at
 I
 0 
8%
 o
f t
he
 s
tu
dy
 
O
G
T
T
 in
 d
ia
be
ti
cs
. 
M
os
t 
gr
ou
p 
w
er
e 
no
t o
f D
ut
ch
 
cu
t o
ff
 p
oi
nt
 w
it
h 
th
e 
hi
gh
es
t 
or
ig
in
 th
ey
 d
o 
no
t 
in
di
ca
te
 
se
ns
it
iv
it
y 
fo
r 
sc
re
en
in
g 
fo
r 
o
f w
ha
t o
ri
gi
n 
th
ey
 w
er
e 
di
ab
et
es
 i
s 
5.
8%
. 
T
hi
s 
cu
t-
o
ff
 w
ou
ld
 d
et
ec
t 
72
%
 o
f 
I 
pa
ti
en
ts
 w
it
h 
ne
w
ly
 
di
ag
no
se
d 
di
ab
et
es
 b
y 
O
G
T
T
 a
nd
 3
0%
 o
f t
ho
se
 
w
it
h 
ot
he
r 
gl
uc
os
e 
ab
no
rm
al
it
ie
s 
at
 h
ig
he
r 
ri
sk
 
fo
r 
de
ve
lo
pi
ng
 d
ia
be
te
s.
 
W
an
g
et
 a
l. 
-4
54
9 
A
bo
ri
gi
na
l 
-K
no
w
n 
di
ab
et
ic
, r
ec
ei
vi
ng
 
-S
iz
e 
o
f s
tu
dy
, a
nd
 in
 a
 v
er
y 
-N
o 
te
st
in
g 
fo
r 
co
nd
it
io
n 
H
b
A
ic
 i
de
nt
if
ie
d 
on
ly
 
A
m
er
ic
an
s 
fr
om
 
di
ab
et
es
 m
ed
ic
at
io
n,
 o
n 
re
na
l 
hi
gh
 r
is
k 
po
pu
la
ti
on
 
su
ch
 a
s 
an
ae
m
ia
 th
at
 m
ig
ht
 
5
4
%
o
ft
h
o
se
 id
en
ti
fi
ed
 b
y 
(2
01
1)
 
co
m
m
un
it
ie
s 
in
 
di
al
ys
is
, h
av
in
g 
ha
d 
a 
ki
dn
ey
 
-L
on
gi
tu
di
n
al
 s
tu
dy
 d
on
e 
ov
er
 
af
fe
ct
 H
bA
 I 
c,
 w
hi
ch
 i
s 
F
P
G
. 
F
P
G
 i
de
nt
if
ie
d 
89
%
 o
f 
N
or
th
/S
ou
th
 D
ak
ot
a,
 
tr
an
sp
la
nt
 a
t 
ba
se
li
ne
 o
r 
se
co
nd
 
4 
ye
ar
s 
pr
ev
al
en
t 
in
 A
bo
ri
gi
na
l 
th
os
e 
id
en
ti
fi
ed
 b
y 
H
bA
 I c
. 
O
kl
ah
om
a,
 a
nd
 A
ri
zo
na
. 
ex
am
. 
C
om
m
un
it
ie
s 
E
it
he
r 
on
e 
al
on
e 
on
ly
 
id
en
ti
fi
ed
 6
3%
 o
f i
nd
ec
en
t 
-R
ur
al
 a
nd
 U
rb
an
 U
ni
te
d 
T
2D
m
 c
as
es
. 
T
he
 tw
o 
S
ta
te
s.
 
to
ge
th
er
 w
or
ke
d 
be
tt
er
. 
S
ug
ge
st
s 
th
at
 H
bA
 I c
 b
e 
do
ne
 a
s 
ro
ut
in
e 
sc
re
en
 a
nd
 
al
l 
th
os
e 
w
it
h 
va
lu
es
 b
et
w
ee
n 
1
2
7
 
T
E
S
T
IN
G
 
FO
R
 
G
L
U
C
O
SE
 
M
E
T
A
B
O
L
IS
M
 
D
IS
O
R
D
E
R
S 
4.
75
%
-6
.5
%
 th
en
 h
av
e 
an
 
I 
F
P
G
. 
Z
ho
u 
et
 a
l. 
-9
03
 p
ar
ti
ci
pa
nt
s 
cr
os
s 
K
no
w
n 
di
ab
et
ic
s,
 u
nd
er
 a
ge
 2
1 
or
 
-A
ll
 p
ar
ti
ci
pa
nt
s 
ha
d 
O
G
T
T
, 
-S
iz
e 
o
f s
tu
dy
 
H
bA
 I 
c 
as
 a
 t
es
t 
fo
r 
de
te
ct
in
g 
I 
se
ct
io
na
l 
st
ud
y.
 
ov
er
 7
9 
ye
ar
s 
o
f a
ge
. 
H
B
A
 I 
c 
an
d 
F
P
G
 
-N
o 
ap
pa
re
nt
 t
es
ti
ng
 f
or
 
ne
w
 d
ia
be
te
s 
w
as
 a
de
qu
at
e 
(2
00
9)
 
P
ar
ti
ci
pa
nt
s 
se
lf
-s
el
ec
te
d 
-T
he
re
 w
er
e 
a 
nu
m
be
r 
o
f a
t 
co
nd
it
io
ns
 t
ha
t 
m
ig
ht
 a
ff
ec
t 
bu
t 
no
t 
fo
r 
de
te
ct
in
g 
by
 a
dv
er
ti
si
ng
 o
n 
th
e 
ri
sk
 p
ar
ti
ci
pa
nt
s 
w
it
h 
63
 8
%
 
H
bA
 I 
c 
m
ea
su
re
s 
pr
ed
ia
be
te
s.
 
H
bA
 I c
 o
f>
6
%
 
im
pa
ct
 o
f D
ia
be
te
s.
 
ha
vi
ng
 B
M
I>
25
kg
/m
2 ,
 
an
d 
52
 
-O
nl
y 
on
e 
te
st
 o
f e
ac
h 
ki
nd
: 
cl
as
si
fi
ed
 8
0%
 o
f t
ho
se
 w
it
h 
-U
rb
an
 C
hi
na
 
8%
 h
yp
er
te
ns
io
n 
no
 c
on
fi
rm
at
or
y 
te
st
in
g 
di
ab
et
es
. 
H
bA
 I 
c 
al
so
 
id
en
ti
fi
ed
 2
5%
 o
f t
ho
se
 w
it
h 
pr
ed
ia
be
te
s.
 
Z
ie
m
er
 e
t 
al
. 
-3
54
8 
to
ta
l 
pa
rt
ic
ip
an
ts
: 
-K
no
w
n 
di
ab
et
ic
s,
 u
si
ng
 
-O
nl
y 
th
os
e 
th
at
 h
ad
 O
G
T
T
 in
 
-D
id
 n
ot
 t
es
t 
fo
r 
al
l 
A
fr
ic
an
 A
m
er
ic
an
 a
cr
os
s 
al
l 
15
81
 c
am
e 
fr
om
 t
he
 
gl
uc
oc
or
ti
co
id
s,
 p
re
gn
an
cy
 o
r 
N
H
A
N
E
S
 w
er
e 
in
cl
ud
ed
 
he
am
og
lo
bi
no
pa
th
ie
s 
no
r 
gl
yc
ae
m
ic
 r
an
ge
s 
ha
d 
hi
gh
er
 
(2
01
0)
 
S
cr
ee
ni
ng
 f
or
 I
m
pa
ir
ed
 
la
ct
at
io
n 
-D
id
 s
cr
ee
n 
fo
r 
va
ri
an
t 
al
l 
co
nd
it
io
ns
 t
ha
t c
ou
ld
 
H
bA
 I c
 t
ha
n 
no
n-
H
is
pa
ni
c 
G
lu
co
se
 T
ol
er
an
ce
 s
tu
dy
 
-O
nl
y 
us
ed
 d
at
a 
fo
rm
 s
el
f-
he
m
og
lo
bi
n
's
 
ha
ve
 e
ff
ec
te
d 
H
b
A
lc
 
w
hi
te
. 
T
he
 d
if
fe
re
nc
e 
gr
ew
 
(a
 s
el
f-
se
le
ct
ed
 s
tu
dy
) 
re
po
rt
ed
 A
fr
ic
an
 A
m
er
ic
an
s 
no
n-
-S
iz
e 
o
f t
he
 c
oh
or
t 
as
 t
he
 g
lu
co
se
 i
nt
ol
er
an
ce
 
an
d 
19
67
 f
ro
m
 t
he
 
H
is
pa
ni
c 
an
d 
no
n-
H
is
pa
ni
c 
w
hi
te
s 
-T
ha
t a
ll 
th
os
e 
w
it
h 
kn
ow
n 
w
or
se
ne
d.
 
T
hi
s 
su
gg
es
te
d 
N
H
A
N
E
S
 I
II
 s
tu
dy
, 
-U
nd
er
 4
0 
in
 t
he
 N
H
A
N
E
S
 I
II
 
gl
yc
ae
m
ia
 w
er
e 
ex
cl
ud
ed
 
th
at
 p
hy
si
ol
og
ic
 o
r 
ge
ne
ti
c 
w
hi
ch
 i
s 
a 
ra
nd
om
is
ed
 
tr
ia
l 
as
 o
nl
y 
th
os
e 
ov
er
 4
0 
ha
d 
an
 
-T
he
 u
se
 o
f t
w
o 
st
ud
ie
s 
w
ith
 
di
ff
er
en
ce
s 
m
ay
 c
on
tr
ib
ut
e 
to
 
cr
os
s 
se
ct
io
na
l 
st
ud
y.
 
O
G
T
T
. 
so
m
ew
ha
t d
if
fe
re
nt
 
th
e 
di
ff
er
en
ce
s 
an
d 
th
at
 
-T
he
se
 s
tu
di
es
 w
er
e 
do
ne
 
po
pu
la
ti
on
s 
ta
ke
n 
a 
de
ca
de
 
as
se
ss
m
en
ts
 o
f g
lu
co
se
 
a 
de
ca
de
 a
pa
rt
. 
ap
ar
t s
pe
ak
 to
 t
he
 m
ai
nt
en
an
ce
 
co
nt
ro
l 
sh
ou
ld
 b
e 
m
ad
e 
w
ith
 
-U
ni
te
d 
S
ta
te
s 
o
f t
he
 d
if
fe
re
nc
es
 b
et
w
ee
n 
ca
ut
io
n 
in
 c
er
ta
in
 
ra
ci
al
 g
ro
up
s 
po
pu
la
ti
on
s.
 S
ug
ge
st
 th
at
 
ad
di
ti
on
al
 g
lu
co
se
 m
ea
su
re
s 
sh
ou
ld
 b
e 
in
cl
ud
ed
 i
n 
cl
in
ic
al
 
ju
dg
m
en
t m
ak
in
g.
 
1
2
8
 
T
E
S
T
I
N
G
 
FO
R
 
G
L
U
C
O
S
E
 
M
E
T
A
B
O
L
IS
M
 
D
IS
O
R
D
E
R
S 
O
th
e
r 
in
fo
rm
a
ti
o
n 
is
 r
e
q
u
ir
ed
 i
n
 o
rd
e
r 
to
 h
e
lp
 i
n
te
rp
re
t 
y
o
u
r 
ri
sk
 o
f 
d
e
,•
el
o
p
in
2 
ty
p
e 
2 
d
ia
b
e
te
s 
C
E
R
T
A
IN
 F
A
C
T
O
R
S
 A
R
E
 R
E
L
A
T
E
D
 T
O
 A
 H
IG
H
E
R
 R
IS
K
 O
F
 D
E
V
E
L
O
P
IN
G
 D
IA
B
E
T
E
S
. 
P
le
a
se
 c
h
e
c
k
 o
ff
 w
h
ic
h
 O
f 
th
e
 f
O
ll
o
w
in
g
 e
th
n
ic
 g
ro
u
p
s
 y
o
u
r 
b
io
lo
g
ic
a
l 
lb
lo
o
d
l 
p
a
re
n
ts
 b
e
lo
n
g
 t
o
: 
9
. 
M
o
th
e
r 
["
"]
 
D
 
L
J 
D
 
D
 
[~
] 
D
 
1
0
. 
F
a
th
e
r 
[ 
J 
W
h
it
e
 r
ca
uc
as
la
m
 
D
 
A
b
o
ri
g
in
a
l (
F
ir
st
 N
a
tio
n
s 
p
e
rs
o
n
, M
e
ti
s,
 l
n
u
lt
l 
L
J
 
B
la
ck
 
D
 
La
ti
n
 A
m
e
ri
ca
n 
D
 
s
o
u
th
 A
si
an
 l
E
as
t I
n
d
ia
n
, P
ak
is
ta
ni
, s
ri
 L
an
ka
n
, e
tc
.l 
D
 
E
as
t A
si
a
n 
<C
hi
n
es
e
, V
ie
tn
a
m
e
se
, F
ili
pi
n
o
, K
or
ea
n
. e
tc
 .I 
D
 
O
th
e
r 
1
1
. 
W
h
a
t 
Is
 t
h
e
 h
ig
h
e
s
t 
le
v
e
l 
o
f 
e
d
u
c
a
ti
o
n
 t
h
a
t 
y
o
u
 h
a
v
e
 c
o
m
p
le
te
d
?
 
D
 
so
m
e
 h
ig
h
 s
ch
o
o
l o
r 
le
ss
 
D
 
H
ig
h
 s
ch
o
o
l 
d
ip
lo
m
a
 
D
 
So
m
e
 c
o
lle
g
e 
o
r 
u
n
iv
e
rs
it
y 
D
 
U
n
iv
e
rs
it
y 
d
e
g
re
e
 
1
2
. 
In
 g
e
n
e
ra
l,
 w
o
u
ld
 y
o
u
 s
a
y 
y
o
u
r 
h
e
a
lt
h
 I
s .
..
 
D
 
E
xc
el
le
n
t 
D
 
v
e
ry
g
o
o
d
 
D
 
G
o
o
d
 
D
 
Fa
ir
 
D
 
Po
o
r 
1
5
. 
A
t 
th
e
 p
re
s
e
n
t 
ti
m
e
, 
d
o
 y
o
u
 s
m
o
ke
 c
ig
a
re
tt
e
s
?
 
0
D
al
ly
 
D
 
O
cc
as
io
n
a
lly
 
D
 
N
o
t
a
ta
ll
 
1
4
. 
o
v
e
r 
y
o
u
r 
e
n
ti
re
 l
if
e
ti
m
e
, 
a
b
o
u
t 
h
o
w
 m
a
n
y
 y
e
a
rs
 I
n
 t
o
ta
l 
d
id
 y
o
u
 s
m
o
k
e
? 
S
O
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Appendix E 
Glossary of Acronyms 
ADA: American Diabetes Association 
AUC: Area Under the Curve 
BMI: Body Mass Index 
CBG: Capillary Blood Glucose 
FBG: Fasting Blood Glucose 
GCT: Glucose Challenge Test 
GDM: Gestational Diabetes Mellitus 
HbAlc: Glycated Haemoglobin Ale 
HR: Hazard Ratio 
IDF: International Diabetes Foundation 
IFG: Impaired Fasting Glucose 
IGT: Impaired Glucose Tolerance 
NP: Nurse Practitioner 
NPV: Negative Predictive Value 
OGTT: Oral Glucose Tolerance Test 
OR: Odds Ratio 
PCOS: Polycystic Ovary Disease 
POC: Point Of Care 
PPV: Positive Predictive Value 
RBG: Random Blood Glucose 
RCT: Randomised Controlled Trial 
ROC: Receiver Operator Characteristics 
RPG: Random Blood Glucose 
WHO: World Health Organisation 
WHR Waist to Hip Ratio 
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Glossary of Terms 
Adipose tissue/fatty tissue: a connective tissue consisting mainly of fat cells 
(adipocytes). It is specialized to synthesize and contain large globules of fat within a 
network of fibres. It is found mainly under the skin but also in deposits around the 
muscles and organs. 
a cells/alpha cells: the alpha cells of the islets of Langerhans produce a hormone that 
inhibits expression of insulin called glucagon, which releases glucose from the liver and 
fatty acids from fat tissue. The presence of glucose and free fatty acids stimulate 
insulin release and inhibit glucagon release. 
Anabolic hormone: primarily responsible for protein synthesis resulting in the 
promotion of muscle growth and the growth of other complex living tissues in the body 
(e.g., insulin). 
Area under the curve: also referred to as receiver operating characteristics (ROC). 
Accuracy is measured by the area under the ROC curve. An area of 1 represents a 
perfect test; an area of .5 represents a worthless test. A rough guide for classifying 
the accuracy of a diagnostic test is the traditional academic point system: 
• .90-1 =excellent (A) 
• .80-.90 =good (B) 
• .70-.80 =fair (C) 
• .60-.70 =poor (D) 
• .50-.60=fail (F) 
Beta cell: the most common islet cell, it produces insulin. 
Biochemistry: the study of the chemical substances and processes that occur in plants, 
animals, and microorganisms and the changes they undergo during development and 
life. 
Catabolic hormone: a substance that promotes the metabolic breakdown of complex 
molecules into simpler ones, often resulting in a release of energy (e.g. , glucagon). 
Cephalic insulin reaction: the cephalic phase of insulin secretion is evoked by the 
sight, smell, and taste of food (before the gut absorbs any nutrient) and is mediated by 
pancreatic innervation. 
Cardiovascular disease: any diseases, either congenital or acquired, of the heart or 
blood vessels. 
Concentration gradient: A gradient that results from an unequal distribution of ions 
across the cell membrane. 
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c) cells/delta cells: these form 5% of the Islets ofLangerhans. Delta cell granules 
contain somatostatin, whose effects inhibit the release of glucagon and insulin. 
Disulfide bond: a strong covalent bond, important in linking polypeptide chains in 
proteins. It is a single bond between two sulfur molecules; specifically, the -S-S-
link binding two peptide chains (or different parts of one peptide chain) . It also occurs 
as part of the molecule of the amino acid, cystine, and is important as a structural 
determinant in many peptide and protein molecules, such as keratin, insulin, and 
oxytocin. 
Endocrine: the endocrine system is a collection of glands, each of which secretes 
different types of hormones directly into the bloodstream. The system's effects are 
slow to start and prolonged in effect, lasting from a few hours up to weeks. The 
hormones secreted by the endocrine system have a variety of functions, including 
regulation of growth, metabolism, sexual development, and function. 
Endogenous: something that has an internal cause or origin (i.e., it has grown or 
originated from within the organism). 
End Stage Renal Failure (ESRD): a permanent condition in which the kidneys are no 
longer able to filter waste from the blood. As the wastes build up, the nephrons 
increasingly lose the ability to filter. ESRD is generally diagnosed when kidney 
function drops to 10% of normal levels. 
Enzyme: a substance that acts as a catalyst in living organisms, regulating the rate at 
which chemical reactions proceed without itself being altered in the process. 
Exocrine: there is no actual exocrine system; however, there are a number of 
exocrine glands. Exocrine glands secrete substances through a duct opening in a gland 
onto an external or internal body surface. 
Facilitated diffusion: a transport system that uses carrier molecules but does not 
require energy to function. A chemical first binds to the carrier protein in the cell 
membrane and then diffuses through the membrane. Because no energy is used, 
facilitated transport into the cell cannot proceed if the concentration of that chemical is 
greater inside the cell membrane than outside. 
Family Nurse Practitioner: a registered nurse, who has acquired an expert 
knowledge base, complex decision-making skills and clinical competencies for 
expanded practice. The specializations of such nurses are determined by the contexts 
in which they are credentialed to practice. Family NPs provide care to the entire age 
continuum. 
Fenestrated capillaries: capillaries that have pores in the endothelial cells that are 
spanned by a diaphragm of radially oriented small slender fibers that allow small 
molecules and limited amounts of protein to diffuse. 
Insulin: a hormone used in the regulation of carbohydrate, fat, and protein 
metabolism. 
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Gap junctions: specialized intercellular connections between cells. They directly 
connect the cytoplasm of two cells, which allows various molecules and ions to pass 
freely between the two cells. 
Glucagon: a 29-amino acid peptide hormone released by the alpha cells of the 
pancreas. It causes the liver to convert stored glycogen into glucose, which is 
released into the bloodstream. 
Glucose metabolism disorders: a group of pathological conditions in which blood 
glucose cannot be maintained within the normal range. In the context of the present 
project, it will refer to those that cause primarily hyperglycemia. 
Gluconeogenisis: the synthesis of glucose from molecules that are not carbohydrates, 
such as amino and fatty acids. 
Glycogenolysis: the breakdown of glycogen to release glucose. 
Glycolysis: the breakdown of glucose by enzymes, releasing energy and pyruvic acid. 
Hepatocytes: a cell ofthe liver. 
Homeostasis: a state of equilibrium or balance. 
Hydrophilic: having an affinity for water. A hydrophilic substance dissolves, mixes, 
or is absorbed easily in water. 
Hyperglycaemic state: Having a higher-than-normallevel of glucose in the blood. 
Hypertriglyceridema: An elevated triglyceride concentration in the blood. 
Hypothalamus: A region of the brain between the thalamus and the midbrain that 
functions as the main control center for the autonomic nervous system. It also acts as 
an endocrine gland by producing hormones including the releasing factors that control 
pituitary gland secretion of hormones. 
Impaired fasting glucose (IFG): is used to describe an elevated blood sugar in the 
fasting state. The blood glucose level is higher than normal but not high enough to be 
classified as diabetes. This is also referred to as pre-diabetes. 
Impaired glucose tolerance: is a condition that occurs after a person develops a 
raised blood glucose level after eating or after a glucose load of 75g. The level is 
raised but not sufficiently to be classified as a diabetic. It is considered a pre-diabetic 
state of intermittent hyperglycemia and is associated with insulin resistance. It is also 
referred to as pre-diabetes. 
Incretins: are a group of gastrointestinal hormones that cause an increase in the 
amount of insulin released from the beta cells of the pancreas after eating. This 
occurs before blood glucose levels rise. They also have the effect of slowing gastric 
emptying. 
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Inflammatory/proinflammatory cytokines: cytokines are small cell signaling protein 
molecules that are secreted by numerous cells and are used in intercellular 
communication. They cause certain changes in cells and blood vessels. 
Proinflammatory cytokines exist to cause changes that allow the immune system to gain 
access to tissues. Because the cells of the immune system are usually trapped in the 
circulation, proinflammatory cytokines help these immune cells escape the blood 
circulation and get to the tissues where they are needed, either by causing the blood 
vessels to leak or by helping white blood cells to leave the blood vessels. 
Insulin resistance: is a state in which the body' s tissues have a lowered level of 
response to insulin. As a result, the body must produce larger amounts of insulin to 
maintain normal levels of glucose in the blood. 
Insulin signal transduction pathways: signal transduction is a chain of events that 
converts the message that a certain kind of molecule is present into a physiological 
response. The insulin transduction pathway is one that occurs when insulin binds to the 
cellular insulin receptor; this leads to a cascade of processes that promote the usage or 
storage of glucose in cells. The insulin signal transduction pathway is composed of a 
number of trigger mechanisms made up of functions that occur in the cells that serve as 
signals. 
Innervation: the supply of an organ or body part with nerves. It can also mean the 
stimulation of that nerve to cause an effect. 
Intracellular: within a cell or cells. 
Lipogenesis: the formation of fatty acids and other lipids within the body. 
Lumen: a cavity or channel within a tube or tubular organ. 
Mitochondria: small spherical or rod-shaped cytoplasmic organelles, enclosed by two 
membranes separated by an intermembranous space; the inner membrane is infolded, 
forming a series of projections. Mitochondria are the principal sites of ATP synthesis; 
they contain enzymes of the tricarboxylic acid cycle and for fatty acid oxidation, 
oxidative phosphorylation, and many other biochemical pathways. 
Myocytes: muscle cells. 
Negative predictive value (NPV): The number that test negative for a condition that 
truly do not have the condition 
Nephropathy: a disease of the kidney caused by damage to the small blood vessels or 
to the glomerular filtration network. 
Non-esterfied fatty acids: (or free or unsaturated fatty acids): the major 
component of triglycerides. Triglycerides are the most common form of fat stored in 
the body, consisting of three fatty acids linked to a glycerol. High levels of 
triglycerides in the bloodstream have been linked to atherosclerosis. 
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Normoglyceamic: having the normal amount of glucose in the blood. 
Paracrine action: a type of hormone function in which hormones that are released 
from endocrine cells bind to receptors on nearby cells and affect their function. It is 
also the secretion of a hormone by an organ rather than by an endocrinal gland. 
Parasympathetic fibers : The cell bodies of the parasympathetic preganglionic fibers 
are in the brain stem nuclei and in the sacral spinal cord (S2, S3, and S4) and the third, 
seventh, ninth, and tenth cranial nerves. They synapse in cranial autonomic ganglia or 
in terminal ganglia near target organs. They generally act to conserve resources and 
restore homeostasis. These fibers use acetylcholine as transmitters in the 
postganglionic fibers ; they may also release co-transmitters. 
Pathophysiology: disordered physiological process (es) associated with disease or 
mJury. 
Phosphorylation: the process of attaching a phosphate group to a protein, sugar, or 
other compound. 
Physiology: The way in which a living organism or bodily part functions, and its 
study. 
Portal blood system: This system is responsible for directing blood flow from parts 
of the gastrointestinal tract to the liver. Substances absorbed in the small intestine 
first travel to the liver for processing before going to the heart. The system includes 
the lower portion of the oesophagus to the upper part of the anal canal; it also includes 
venous drainage form the spleen and pancreas. 
Positive predictive value (PPV): the number of those that test positive for the 
condition that truly have the condition. 
Postganglionic fibers: these are fibers that go from the ganglion to the effector or 
target organ. 
Pre-diabetes: Is the state between normal glucose levels and diabetes. It can take the 
form of either impaired glucose tolerance of impaired fasting glucose. It can precede 
diabetes by as much as a decade. 
Receptor: in biochemistry, a molecular structure or site on the surface or interior of a 
cell that binds with substances such as hormones, antigens, drugs, or neurotransmitters. 
Retinopathy: a disease of the eye. It can be caused by chronic persistent or acute 
damage to the retina of the eye. Ongoing inflammation and vascular remodeling may 
occur over a period of time without the individual being aware. It can lead to 
blindness. 
Sensitivity: the ability of the screening test to identify patients as having either a 
glucose metabolism disorder or diabetes 
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Simple sugars/monosaccharides: sugars like glucose or fructose that cannot be broken 
down to another form of sugar. 
Specificity: the ability of the screening test to idenitify patients who are not suffering 
from a glucose metabolism disorder or diabetes. 
Translocation: transportation of a dissolved substance within an organism actively 
across a cell membrane. Active transport requires the use of energy. 
Vitreous haemorrhage: Vitreous haemorrhage is the leaking of blood into one of the 
several potential spaces formed within and around the vitreous body of the eye, which 
may then obscure a patient's vision. The vitreous humour is a clear, gel-like 
substance that comprises the back of the eye and prevents light from directly reaching 
the retina. A mild vitreous haemorrhage may result in a patient being able to see only 
a few dark spots, while a severe event may block out all vision, only permitting 
perception of light. 
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